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Abstract  
The progression of regenerative medicine and advanced cell banking technology provide 
the hope of using perinatal tissue-derived autologous MSCs for personalised medicine. 
Mesenchymal stem cells (MSCs) derived from placenta, with the advantages of being non-
invasive and having fewer ethical issues, are a promising source for cell therapy. The 
hyperglycaemic intrauterine environment in pregnancies affected by gestational diabetes 
mellitus (GDM) alters the development of the placenta and may have impacts on placental 
MSCs behaviours and functions. Therefore, we aimed to investigate the influence of the 
GDM on placental MSCs and further explore their therapeutic potential. 
Placental MSCs were isolated from amniotic membrane (AMSCs) and chorionic membrane 
(CMSCs). The biological, functional, and immunological characteristics of healthy- and 
GDM- AMSCs/CMSCs were examined. Compared with healthy MSCs, the GDM-MSCs 
displayed some levels of alteration in adipogenic capacities and macrophage 
immunoregulatory properties while comparable immunophenotypes, osteogenesis, 
chondrogenesis, and T-cell regulation ability were observed in GDM-MSCs.  
As the major adverse consequence of GDM is an increased risk of developing diabetes, 
these women may benefit from cell therapy for diabetes in the future. We developed a 
step-wise differentiation approach to generating functional insulin-producing cells through 
a short-term glucose priming period combined with a 16-day serial stimulation of 
compounds and growth factors, such as activin A, retinoic acid, EGF, GLP1 across different 
differentiation stages. This approach successfully generated insulin-producing cells from 
GDM- and healthy- CMSCs which displayed pancreatic beta-cell properties and functions. 
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Moreover, with more promising potential of CMSCs in regenerative medicine, DNA 
microarray was performed to examine their transcriptional profiles. Comprehensive 
investigation of gene expression by microarray and validation of differences between 
healthy- and GDM- CMSCs via real-time PCR and functional assays revealed enhanced 
capacities of GDM-CMSCs in wound healing and cardiogenesis compared to healthy-CMSCs. 
However, significantly reduced expression in detoxification enzymes belonging to the 
aldehyde dehydrogenase gene families (ALDH1A1/1A2, ALDH2, ALDH3) accounted for 
downregulation across several metabolic pathways and oxidative stress dysregulation in 
GDM-CMSCs.  
Taken together, understanding these placental stem cell behaviours provides an insight to 
developing therapeutic applications of GDM-MSCs and heathy-MSCs for future autologous 
stem cell therapies. 
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1.1 Gestational diabetes mellitus (GDM) 
1.1.1 Clinical manifestation 
Pathogenesis 
Pregnancy is normally accompanied with progressive insulin resistance beginning at mid-
pregnancy and progressing through the third trimester, as the result of maternal 
hyperglycaemia which is thought to facilitate nutrient flux from the mother to fetus1. 
Placental hormones are the major factors that contribute to the disruption of 
glucose/insulin balance and lead to insulin resistance owing to the fact that insulin 
resistance rapidly abates following delivery. The secretion of human placental lactogen, 
human placental growth hormone, oestrogen, and cortisol during pregnancy attenuates the 
ability of maternal organs that respond to insulin2. Insulin-desensitising effects along with 
increased maternal adiposity leading to insulin resistance, the need for maternal insulin is, 
therefore, increased during pregnancy. Pancreatic beta-cells increase their insulin secretion; 
however, when insulin secretion is inadequate to compensate for the insulin resistance of 
pregnancy, the development of gestational diabetes mellitus (GDM) occurs3. 
Diagnosis 
GDM is defined as glucose intolerance with onset or first diagnosed during pregnancy, 
usually beginning at the second trimester.4 The diagnostic thresholds of glucose intolerance 
for GDM vary from country to country. The criteria recommended by World Health 
Organization (WHO) are a 75g oral glucose tolerance test (OGTT) with fasting plasma 
glucose ≥ 5.1 mmol/l, OGTT 1 h ≥ 10.0 mmol/l and OGTT 2 h ≥ 8.5 mmol/l5. In the UK, the 
National Institute for Health and Care Excellence (NICE) has published updated guidance 
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for the diagnosis of GDM in 2015, involving a fasting plasma glucose concentration above 
5.6 mmol/l and 7.8 mmol/l after administration of a 2-hour 75g OGTT6. Women with risk 
factors for GDM, such as obesity, family history of diabetes, glucose intolerance, and past 
GDM, are provided with OGTT at their first antenatal appointment7.  
Prevalence 
The incidence of GDM is increasing worldwide and varies among ethnic groups, which has 
been reported to be higher among Asian and Hispanic women8. The increasing prevalence 
is positively associated with the growth of advanced maternal age, obesity, and inactivity. 
Globally, the recently prevalence has increased to approximately 15% compared to the 
previous 8% in 19989, while in Europe, the prevalence is around 12.6% reported in 201310, 
11. GDM accounts for the majority of pregnancies complicated by diabetes, 87.5%, with the 
remaining being due to type 1 diabetes (7.5%) and type 2 diabetes (5%)12. Type 1 diabetes 
is an autoimmune disease resulting in the destruction of beta-cells and where lifetime 
insulin replacement is normally required while type 2 diabetes has a pathophysiological 
similarity with GDM; hyperglycaemia, insufficient insulin production, and insulin 
resistance13. Approximately 3.5% of pregnancy was complicated by GDM in the UK in 200814; 
however, the number is likely to rise with the growing trend in obesity15. A cohort study 
published in 2012 measured the frequency of GDM based on various locations, with 2,376 
participants in Manchester and 1,671 participants in Belfast indicating that 22.5% and 
10.2% of those screened having GDM, respectively16. A recent report published in 2014 
suggested that 7 million women were obese in the UK17, which is a major risk factor 
contributing to GDM with a 3 to 5-fold increased likelihood vs. non-obese women18, 19.  
Treatment 
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Diet control and lifestyle modification are generally provided as first-line treatments. 
Metformin, a common oral hypoglycaemic agent, is also widely prescribed to reduce 
hyperglycaemia in GDM and T2DM patients. Metformin can exert its function by reducing 
hepatic glucose production and enhancing insulin sensitivity20. However, some concerns 
exist regarding the potential adverse effects on fetus due to its ability to pass the placenta 
have been raised21. Alternatively, insulin therapy has been shown to reverse insulin 
resistance and improve perinatal outcomes where disadvantages include the need for 
injection, weight gain, and hypoglycaemia22, 23. The combination of insulin and metformin 
was proved to have superior glycaemic control and less insulin requirement or weight gain24.  
1.1.2 Morbidity and mortality for mother and infant 
The risk of antepartum morbidity in women with GDM can be increased when combined 
with maternal hypertensive disorders, such as gestational hypertension, preeclampsia, and 
eclampsia25, 26. The biological connection between GDM and hypertension is not fully 
understood; however, studies have suggested that excessive circulating glucose stimulated 
intracellular changes in stress signalling pathways and vascular remodelling which might 
result in the elevated risk of hypertension27-29. It is worth noting that the frequency of 
stillbirth is higher in GDM than healthy pregnancies, especially when it is complicated by 
hypertension. Therefore, screening for GDM and careful blood pressure monitoring are 
important during pregnancy and urinary protein excretion is recommended for GDM 
women at the second half of gestation3. 
Apart from antepartum morbidity, there are many short and long term health concerns 
rising from GDM pregnancies. Fetuses in GDM pregnancies often have an accelerated 
growth pattern owing to the maternal hyperglycaemia. When an estimated fetal weight is 
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in excess of 4000-4500 g, it is considered as macrosomia. Infants with macrosomia have an 
abnormally low head circumference/abdominal circumference ratio due to the increased 
adiposity in the body30. The excessive growth of fetus also leads to adverse perinatal 
outcomes, including birth trauma, shoulder dystocia, bone fractures, and nerve palsies. 
Caesarean section is usually recommended to reduce the risk of birth trauma31. Long-term 
outcomes result from metabolic disorders caused during pregnancy, leaving both mother 
and infant abnormal glucose tolerance, subsequent obesity, and strong risks for future 
metabolic syndrome, cardiovascular disease, and diabetes32, 33.  
1.1.3 Gestational diabetes and future risk of diabetes 
Prevalence 
Although the symptoms of GDM are usually resolved after delivery, GDM is associated with 
a long-term risk of developing type 2 diabetes mellitus (T2DM) later in life among both 
mother and their offspring. GDM represents the single largest risk factor for future 
development of diabetes, where 40-60% women with a GDM history develop T2DM over 
subsequent decades and approximately 5-10% are found to have T2DM immediately after 
pregnancy34, 35. A population-based cohort study of approximately 9,000 women with GDM 
from 1990 to 2016 in the UK, indicated that women diagnosed with GDM were 20 times 
more likely to develop T2DM and an over 2.8 times increased incidence of ischemic heart 
disease later in life36. The highest incidence of developing T2DM in women with a previous 
GDM occurs in the first 5 years after pregnancy37. Therefore, postpartum follow-up glucose 
testing (typically performed 6-12 weeks after delivery) and an annual test are usually 
encouraged. Moreover, children born from GDM pregnancy have a high tendency of being 
overweight, obese and displaying abnormal glucose tolerance, resulting in T2DM in their 
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early adulthood38. Exposure to hyperglycaemia in the uterus has adverse effects on fetal 
outcomes, from epigenetic modification to physical fetal programming, leading to the 
development of T2DM39. A study conducted among Caucasian pregnant women, indicated 
that offspring from GDM women had a higher frequency of impaired glucose tolerance with 
a prevalence of 11.1% at 1-4 years and 20.0% at 5-9 years of age40. 
Implication for the pathogenesis 
The underlying mechanisms of developing T2DM in GDM women have been investigated in 
various aspects. Physiologically, insulin resistance progresses during pregnancy and the 
level of insulin resistance almost reach T2DM levels in late pregnancy. Insufficient 
compensatory insulin secretion by beta-cells in GDM women reveals a deficiency in beta-
cell function. The insulin requirement reduces after the delivery and GDM symptoms 
resolve; however, beta-cell dysfunction remains unsolved. The long-term deterioration of 
beta-cell function increases the likelihood of T2DM development41. As illustrated in Figure 
1-1, insulin secretion is approximately 50% lower in GDM than healthy pregnancy at 3rd 
trimester. 
At the molecular level; reduced insulin receptors, abnormal localisation of GLUT4 
transporters, and impaired glucose transport caused by GDM may have an irreversible 
impact on insulin sensitivity42, 43. Dysregulation of cytokines, such as increased circulating 
leptin, inflammatory cytokine tumor necrosis factor-α (TNF-α), and reduced levels of 
adiponectin all play a role in obesity and the progression to T2DM44-46. 
GDM is known for its maternal inheritance transmitting to the next generation a genetic 
predisposition and permanently impaired glucose homeostasis during fetal growth caused 
by hyperglycaemic environment. Genetic studies indicated that GDM women carried T2DM 
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susceptibility genes which were transmitted to their offspring47-49. The increasing interest 
in epigenetic alternations in fetus where DNA methylation and histone modification of 
metabolic-associated genes is affected by hyperglycaemia50. Non-genetic evidence has 
been demonstrated in several in vivo models, where, for example, the offspring from 
diabetic rats were observed to have decreased pancreatic weight, low pancreatic insulin 
content, and low beta-cell mass51, 52. 
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Figure 1-1. Insulin sensitivity-secretion relationship  
The correlation between insulin sensitivity and secretion in GDM and healthy women. 
Insulin sensitivity index was calculated as the ratio of glucose disposal rate to steady-state 
plasma insulin concentration. Prehepatic insulin secretion rates were assessed from steady-
state plasma insulin and C-peptide concentration. FFM, fat-free mass. Reprinted from 
Buchanan, 200153 
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1.2 Placenta 
1.2.1 Placental structure and function 
Placentation 
The development of the placenta begins following on from fertilisation and once the 
fertilised ovum enters the uterus and becomes blastocyst. Immediately after attachment to 
the uterine lining, the blastocyst starts to enlarge while cells proliferate and differentiate. 
The outer layer of the blastocyst (trophoblast) becomes the cytotrophoblast and 
syncytiotrophoblast which will further develop into the placenta and fetal membranes 
while the inner cell masses will develop into embryo. The cytotrophoblast is the stem cell 
source of the placenta, which gives rise to most of the placental cell types while the 
syncytiotrophoblast is a specialised epithelium, which invades the endometrium (uterine 
mucosa) and establishes contact with maternal vessels forming a lacunar network. Lacunae 
is then surrounded by syncytial cells and filled with maternal blood and tissues54, 55 (Figure 
1-2). Meanwhile, cytotrophoblastic stem cells penetrate into the syncytiotrophoblast layer 
and differentiate into the villous cytotrophoblast constituting primary chorionic villi, 
endovascular cytotrophoblast remodelling maternal spiral arteries, and interstitial 
cytotrophoblast invading the endometrium and eventually becoming placental-bed giant 
cells to anchor the growing fetus56, 57.  
Primary villi are formed of syncytiotrophoblast underlying cytotrophoblast and following 
the growth of extraembryonic mesodermal cells to the primary villi core turns them into 
secondary villi. Secondary villi expand and invade the maternal decidua while soon after 
vasculogenesis occurs, blood vessels begin to grow, and then differentiate rapidly to form 
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functional tertiary villi. Maternal and fetal vessels are connected at this stage and the 
placenta evolves to form a highly branched structure55. Fetal and maternal vascularisation 
is complete by the 17th to 20th day and the thickness and circumference of placenta 
continues to increase until the fourth month. There is no obvious increase in thickness after 
the fourth month while circumference usually continues to grow. 
 
 
Figure 1-2. Formation of the placenta 
(a) Implantation of blastocyst in the endometrium. Apoptotic maternal uterine cells are 
phagocytised by syncytiotrophoblast cells for proper implantation. (b) Maternal tissue fluid, 
uterine secretions, and blood from the erosion of the maternal capillaries are forming the 
lacunae. (c) Formation of primary germ layers and chorionic villi. Reproduced from Pearson 
Education Inc., publishing as Benjamin Cummings, 2004. 
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Structure 
An average term placenta is approximately 22 cm in diameter, 2.5 cm central thickness, and 
a weight of 400-500 g, with a round disc-like appearance and an inserted umbilical cord55. 
Figure 1-3 demonstrates the schematic structure of a full-term placenta. The chorionic plate 
and intervillous space are on the fetal side of placenta which is bathed in maternal blood. 
Umbilical vessels branch into the chorionic plate and supply the capillaries of chorionic villi 
forming a highly vascularised central core. Between the chorionic and basal plates is a large 
cavernous intervillous space, where the villi are in direct contact with maternal blood58. The 
basal plate is on the maternal side of placenta, composed of fetal trophoblasts and maternal 
uterine decidua. Maternal arteries penetrate the myometrium (middle layer of the uterine 
wall) and divide into endometrial spiral arteries, highly coiled within the decidua basalis. 
The cytotrophoblastic shell is formed on the maternal surface of placenta, attaching firmly 
to endometrial tissues. A gap in the cytotrophoblast shell allows maternal endometrial 
arteries to reach the intervillous space and bath the chorionic villi in maternal blood59, 60. 
Function 
Placenta, the interface between maternal and fetus circulation, plays an important role 
during fetal development by regulating gas exchange, nutrient transport, and waste 
elimination as well as the secretion of hormones during pregnancy. The fetal lung is filled 
with fluid in the uterus; therefore, the placenta is responsible for the gas exchange during 
the entire pregnant period. Oxygen and carbon dioxide can pass through the placenta by 
passive diffusion61. Nutrient transport is critical for fetal growth and includes, glucose, 
amino acids, fatty acids, ions, vitamins, and water. Glucose, functioning as the main source 
of energy, crosses the placenta through passive infusion and several types of glucose 
transporters. Amino acids and fatty acids are important for fetal proteins, essential fatty 
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acid, and lipids synthesis which can be transferred to fetus by active transport through 
various transporter proteins and fatty acid binding proteins. Sodium and chloride are 
transferred by passive transport while calcium ion, iron, and vitamins are transferred by 
active carrier-mediated transport59, 62.  
 
Figure 1-3. Schematic drawing of the placenta  
Transverse section through a placenta illustrating the structure and feto-maternal 
circulation at term. Reprinted from Moore et al., 200460 and Griffiths et al., 201559 
 
Besides gas exchange and nutrient transport, another important function of the placenta is 
endocrine regulation which is involved in mediating placental growth, immune function, 
and fetal development. The placenta produces steroid hormones – oestrogen, 
progesterone and several protein hormones. The two major protein hormones secreted by 
placental trophoblast are human placental lactogen (HPL) and human chorionic 
gonadotrophin (HCG). The production of HCG peaks at the 10th week of gestation and slowly 
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decreases until the end of pregnancy, which plays a role in placental angiogenesis, 
immunotolerance, endometrial receptivity, and embryo implantation63. HPL has both 
insulin-like and anti-insulin effects, which regulates maternal lipolysis, carbohydrate 
metabolism, and glucose homeostasis. Through the reduction of maternal insulin sensitivity, 
HPL promotes maternal body to use fatty acid and induces maternal insulin resistance in 
order to facilitate the mobilisation of nutrients and glucose for the fetus64. In transgenic 
mice overexpressing HPL, the proliferation of pancreatic beta-cells showed significantly 
enhanced leading to an increased in insulin production. The enhanced secretion of HPL 
during pregnancy is associated with insulin resistance and contributing to the 
hyperglycaemia and hyperinsulinaemia in the maternal body65. Steroid hormones are 
produced by ovaries until the 8th week of gestation and the placenta then takes over 
production of oestrogen and progesterone producing an increasing amount until before 
labour. Major functions of oestrogen and progesterone include stimulating uterine growth, 
promoting mammary gland development, preventing uterine contractions, and the onset 
of labour59, 65. 
1.2.2 Anatomy of placental membranes 
The placental membrane is a bilayer structure composed of amniotic and chorionic 
membranes. During placental development, the amnion and chorion fuse early in the 
second trimester66. The bilayer membrane migrates outwards from the placenta and 
encloses the amniotic cavity, where the fetus is growing and protected within the amniotic 
fluid67.  
The amnion is an avascular membrane, consisting of an epithelial monolayer, basement 
membrane, and amniotic mesoderm layer68, 69 (Figure 1-4). Nutrients and gas diffuse freely 
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from amniotic fluid and underlining decidua. The epithelial monolayer, also called amniotic 
epithelium, is a single layer of epithelial cells directly in contact with amniotic fluid and 
uniformly resting on the basement membrane. The basal membrane is composed of 
collagens secreted by mesenchymal cells situated beneath the basement membrane in the 
amniotic mesoderm. Interstitial collagens (type I and III) form parallel bundles for 
maintaining the mechanical integrity of the amnion. Filamentous connections between 
interstitial collagens and the epithelial membrane are formed by collagens type V and VI69. 
Connecting between the amnion and chorion are formed via a spongy layer (intermediate 
layer) of loosely arranged glycoproteins and collagen fibres, mostly type III collagen70. 
The chorion is composed of a chorionic mesoderm and trophoblastic region (Figure 1-4). 
The former has a similar composition to the amniotic mesoderm, containing collagens and 
mesenchymal cells; the latter contains extravillous trophoblast cells. In between the 
chorionic mesoderm and trophoblast region is a basal membrane68, 71. 
 
Figure 1-4. Cross-section of placental membrane 
(A) Schematic presentation of the amniotic and chorionic membrane structure. (B) Layers 
of human placental membrane visualised by histology. AE, amniotic epithelium; AM, 
amniotic mesoderm; CM, chorionic mesoderm; CT, chorionic trophoblast. Reproduced from 
Baergen et al., 200572 and Parolini et al., 200868 
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1.2.3 Placental pathology complicated by GDM 
Structure and morphology 
The composition of a healthy term placenta is 80-88% water, 10% protein, and 1% fat while 
diabetic placentas are found to have increased mass, DNA, glycogen, and lipids. The 
increase of glycogen and fat exceeds the relative amount of placental DNA, suggesting that 
each placental cell contains a higher level of glycogen and fat than a normal glucose-
tolerant placenta73. Increased placental weight happens in both GDM women with and 
without glycaemic control during pregnancy and also shows a positive correlation with fetal 
weight and fat mass74, 75. Two common features of GDM placenta, hyperproliferation and 
hypervascularisation, lead to an enlarged placental surface and exchange area. 
Hyperglycaemia in early gestation induces trophoblast proliferation and structure 
modification. The thickening of the trophoblastic basement membrane results in increased 
diffusion distances between the maternal and fetal systemic circulations and which may be 
the consequence of trophoblast hyperproliferation at early gestation76, 77. High incidences 
of abnormal villous development and branching in GDM placenta are observed where the 
cause and mechanism are still unclear. Low oxygen levels in the diabetic environment are 
suggested to have a profound influence on the upregulation of proangiogenic factors such 
as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)-2 in GDM 
placenta hence stimulating placental vascularisation76, 78. Furthermore, the villous regions 
are likely to have accumulation of the placental resident macrophages promoting the 
release of leptin, TNF-α, and interleukins leading to alterations of placental metabolic and 
endocrine functions79. 
Nutrient transport 
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Maternal overweight, obesity, or GDM status all alter maternal circulating levels of glucose, 
fatty acids/cholesterol, and amino acids to the fetal circulation and ultimately, influence 
fetal growth and development. Glucose, the principal energy substance for both fetus and 
placenta, is supplied from the maternal circulation. It is reported that placental explants 
from GDM pregnancies exhibit 2- to 3- fold higher glucose uptake and a 40-50% reduction 
in fatty acid oxidation80. Increased glucose transporter, GLUT-1, expression and activity 
affects the amount of glucose transport across the placenta81. Some studies indicate that 
the major mechanism affecting maternal-fetal glucose transport depends on glucose 
concentration gradient instead of glucose transporter expression82, 83. The increased 
steepness of the glucose concentration gradient results in a higher glucose flux across the 
placenta. When fetal hyperinsulinaemia happens, glucose gradient will favour a persistently 
high glucose flux even though maternal blood glucose is under control by GDM treatment84. 
Insulin sensitive glucose transporter, GLUT-4, which promotes glucose utilisation within 
cells, shows a reduction in activity in GDM women skeletal muscle cells85, 86. Since fetal 
glucose consumption can be modified by maternal glucose concentration, the reduced 
glucose metabolism in the maternal body and increased uptake of glucose in placenta 
enhance the risk of excessive glucose transfer to the fetus in GDM pregnancies.   
Amino acids are important for the formation of proteins and nucleic acids in the fetus. Most 
amino acids are transported in both directions between the maternal and fetal circulation. 
Upregulation of the placental syncytiotrophoblast amino acid transporters has been 
observed in GDM. These are responsible for alanine, glutamine, and serine transport and 
are associated with macrosomia87. Increased lipid transport has also been noted in GDM 
pregnancies with the expression of receptors and regulators for fatty acid and cholesterol 
transport88. Maternal lipoprotein transporting fatty acids and cholesterol requires 
lipoprotein receptors, lipases which are highly expressed in GDM placentas89. Moreover, 
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maternal adipose tissues also play a role in regulating lipid transport and insulin resistance 
by secreting elevated levels of adipocytokines, such as leptin, adiponectin, and TNF-α90.  
Studies on the pathophysiology of GDM between maternal and fetus are based on the 
hypothesis by Pedersen91 who stated that maternal hyperglycaemia leads to fetal 
hyperinsulinaemia and increased glucose utilisation, which is responsible for macrosomia 
and neonatal morbidity. The key features of the hypothesis are showed in Figure 1-5.  
 
Figure 1-5. Effect of maternal nutrients on fetal development 
The Pedersen’s hypothesis91 of hyperglycaemia-hyperinsulinemia has been modified and 
indicated the contribution of maternal nutrients on fetal growth and development. 
Reproduced from Clinicalgate (https://clinicalgate.com/). 
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1.3 Mesenchymal stem cells (MSC) 
1.3.1 Stem cells in birth-associated tissues 
Stem cell population 
Mesenchymal stem cells (MSCs) are defined as multipotent cells capable of differentiating 
into a variety of cell types. Originally, the MSC was referred to solely in respect of 
mesenchymal cell lineages differentiation ability; however, increasing studies have 
indicated a trans-differentiation potential in adult tissue-derived MSCs92, 93. MSCs can be 
isolated from different parts of human placenta, which are thought to have a more primitive 
property due to their originating from inner cell mass of blastocyst giving them more 
potential in the three cell germ layer differentiation94.  
Haematopoietic stem cells (HSCs) are involved in haematopoiesis and give rise to many 
types of blood cells and generate the haematopoietic system. Being a highly vascularised 
organ mediating fetal-maternal exchanges the placenta and umbilical cord blood contain a 
large numbers of HSCs95. 
Umbilical cord and cord blood 
The umbilical cord contains a gelatinous connective tissue used to protect umbilical vessels, 
which is known as Wharton’s jelly. Several types of progenitor cells can be isolated from 
different regions of Wharton’s jelly although whether these progenitor populations are 
equivalent is not yet clear96, 97. Functioning as the connection between the placenta and 
fetus, when haematopoietic cells and MSCs circulate through the umbilical cord, these cells 
are likely to migrate and rest in Wharton’s jelly. Migratory perivascular cells may also be 
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one of the MSC cell types in Wharton's jelly perivascular region96, 98. 
Fetal haematopoiesis starts at about 2 weeks after fertilisation in the yolk sac and gradually 
moves to the liver before moving to the bones and taking place in the bone marrow. 
Umbilical cord blood is a rich source of HSCs, which are more primitive than bone marrow 
derived HSCs or their counterparts in peripheral blood. Umbilical cord blood is considered 
as an effective alternative to bone marrow transplantation99. 
Amniotic fluid 
Fetus is allowed to move freely in amniotic fluid, which acts in a protective and nourishing 
role during pregnancy. Amniotic fluid starts to appear immediately after the formation of 
the amniotic cavity and increases in volume through gestation. It contains proteins, 
carbohydrates, fats, and hormones to support nutrient and waste exchanges. Due to the 
direct contact with embryonic components, a variety of embryonic cells from three germ 
layers are present in the amniotic fluid100. Multipotent MSC-like cells have been described 
within amniotic fluid; however, the characteristics may be various based on gestational 
ages101, 102.  
Placental membrane 
Soon after the implantation of blastocyst, the inner cells mass (embryoblast) transforms 
into two distinct layers, epiblast and hypoblast, which is also known as bilaminar embryonic 
disc. The epiblast constitutes the amniotic epithelium between the outer layer (trophoblast) 
and embryonic disc. Subsequently, bilaminar embryonic disc develops into three germ 
layers (ectoderm, mesoderm, and endoderm) and the extraembryonic mesoderm 
surrounding the amniotic cavity gives rise to amniotic and chorionic mesoderm (Figure 1-
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2). Given that the cells constituting amniotic and chorionic membranes are evolved from 
the embryoblast, it has been suggested that these cells retain a pluripotent phenotype. 
Studies have shown that these fibroblast-like cells derived from amnion and chorion have 
MSCs characteristics103, 104. 
Decidua and chorionic villi 
The decidua is the maternal part of the placenta, essential for implantation, placenta 
formation and maintenance of pregnancy. During pregnancy, the placenta undergoes 
regeneration, differentiation, and shedding while stromal cells in decidua are thought to be 
responsible for the dynamic remodelling and thus found to have stem cell characteristics105, 
106. Chorionic villi are composed of syncytiotrophoblast, underlying cytotrophoblast, and a 
mesenchymal cell-filled central core. Therefore, some studies have successfully isolated 
MSCs from chorionic villi107. However, extravillous trophoblasts invade into decidual tissue 
during villi formation. The characterisation of villi-derived MSCs and isolation process need 
to be further elucidated.  
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1.3.2 Characterisation of MSCs in placenta 
MSCs derived from placenta share common criteria with bone-marrow MSCs and most of 
the MSCs derived from adult tissues (adipocytes, skin, lung). Most adult organs contain 
tissue-resident MSCs that contribute to tissue maintenance and repair of trauma, ageing, 
or disease. Although MSCs phenotypes can be altered due to different MSC 
niche/microenvironment, some general characteristics have been used to define human 
MSCs. Placenta-derived MSCs are plastic adherent, form fibroblast colony-forming units, 
undergo mesenchymal differentiation potential (bone, fat and cartilage), and display an 
appropriate range of surface antigen expression108. Due to the lack of unique markers for 
the identification of the MSCs, there is an agreed specific panel of surface antigen – cluster 
of differentiation (CD)-90, CD73, and CD105 concurrent with the absence of CD45, CD34, 
CD14, and human leukocyte antigen (HLA)-DR109 (Table 1-1).  
 
Table 1-1. Recommended markers for placenta-derived MSCs 
The signs (+) or (-) indicate the presence or absence of markers respectively. 
  Marker Description Expression 
CD90 (+) Thy-1 cell surface antigen MSC marker 
CD73 (+) Ecto-5’-nucleotidase MSC marker 
CD105 (+) Endoglin, TGFβ receptor III MSC marker 
CD45 (-) Protein tyrosine phosphatase, receptor type, C Hematopoietic cells 
CD34 (-) Transmembrane phosphoglycoprotein Hematopoietic stem cells 
CD14 (-) Myeloid cell-specific leucine-rich glycoprotein Monocytes/Macrophages 
HLA-DR HLA Class II/MHC II receptor Antigen presenting cells 
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1.3.3 Amnion-derived stem cells 
There are two cell types can be isolated from amniotic membrane – amniotic epithelial cells 
(AECs) from the innermost layer of the amnion and amniotic mesenchymal stem cells 
(AMSCs) from mesoderm layer (Figure 1-6). AECs are developed at very early stage of 
gestation (8 days after fertilisation) and capable of secreting growth factors, such as basic 
fibroblast growth factor, epidermal growth factor110, keratinocyte growth factor, and 
hepatocyte growth factor. The epithelial nature of AECs is demonstrated by their ability to 
undergo epithelisation, their expression of several epithelial markers, and their secretion 
of growth factors. AECs are also able to regulate angiogenesis, fibroblast activation, and 
immunosuppression111, 112. Moreover, research has reported stem cell characteristics of 
AECs, indicated by the expression of stem cell markers and possession of a differentiation 
ability. Pluripotency of AECs has been suggested following demonstration of pluripotent 
marker expression and evidence of three germ layers differentiation in mouse models113, 
114.  
Similarly, AMSCs from the mesoderm layer have MSC characteristics and the capacity to 
differentiate beyond mesodermal lineages. In addition to skeletal, muscle, and 
cardiomyocytic differentiation (mesoderm), AMSCs also differentiate into neurogenic 
lineages115 (ectoderm), hepatocytes116 (endoderm), and endothelial cells117. Moreover, 
despite the pluripotent marker expression of AMSCs, including octamer-binding 
transcription factor 4 (OCT4), nanog homeobox (NANOG), protein antigens – T cell receptor 
alpha locus (TRA)-1-60 and TRA-1-81, AMSCs do not display any evidence of teratoma114, 
115.  
Isolation and separation of AECs and AMSCs can be performed by trypsin digestion. AECs 
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can be released from the amnion and suspended in trypsin solution while AMSCs need 
further digestion of the collagen matrix to be isolated from mesoderm layer. Moreover, the 
cell surface markers are somehow different between AECs and AMSCs, where AECs display 
epithelial markers which are lacking in AMSCs118 (Table 1-2). The yield of AMSCs is 
approximately 1 million per gram of the placental membrame119. 
 
 
Figure 1-6. Stem cells derived from placental membranes 
(A) Human placenta and manual separation of amniotic/chorionic membrane (B) Schematic 
representation of the placental membrane structure and MSCs from different membrane 
layers. AECs, amniotic epithelial cells; AMSCs, amniotic mesenchymal stem cells, CMSCs, 
chorionic mesenchymal stem cells.  
Reproduced from Tabatabaei et al., 2014120, Parry et al., 199870, and Humpath 
(http://www.humpath.com/). 
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1.3.4 Chorion-derived stem cells. 
Chorionic MSCs (CMSCs) are derived from the chorionic mesoderm layer and share 
common characteristics with AMSCs (Figure 1-6). They both display plastic adherence, a 
mesodermal differentiation ability, and display MSCs markers (Table 1-2). In an in vivo study, 
CMSCs engrafted in neonatal swine and rats and did not induce a xenogeneic response 
indicating the immunoprivileged status of CMSCs121, 122. CMSCs can be induced to neuron-
like cells that showed comparable or even greater potential than AMSCs123, 124. A studied 
comparing CMSCs from early and late gestation found similar phenotypes and the 
expression of pluripotent markers in both stage derived CMSCs. It might indicate the 
retained pluripotency of CMSCs during gestation but when applying to an in vivo skin 
wound, early gestation-derived CMSCs accelerated the wound repair compared to late 
gestation-derived CMSCs125. However, the literature on CMSCs is insufficient and limited 
characterisation of multi-lineage differentiation potential. 
In addition, as the outermost layer of highly vascularised placenta lying adjacent to the 
decidual cells, the chorionic membrane was recently found to contain HSCs which are 
absent in the amnion. HSCs were observed in chorion at all gestational ages after 5-weeks 
of pregnancy and HSCs derived from mid-gestation showed superior engraftment potential 
in an in vivo model126. However, if mechanical dissection of decidual tissues is insufficient, 
cross-contamination with maternal cells, blood cells, and decidual cells may be observed in 
CMSCs culture127. 
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Table 1-2. Surface markers of AECs, AMSCs, and CMSC 
Cell 
surface antigens expressed on AEC, human amniotic epithelial cells; AMSCs, human 
amniotic mesenchymal stem cells; CMSCs, human chorionic mesenchymal stem cells. 
Reproduced from Kmiecik et al., 2013124 
  
Cell type Phenotype 
AECs 
Epithelial markers: E-cadherin, CK7, CD49f, EpCAM 
Mesenchymal and embryonic markers: CD90+, CD105+, CD73+, CD44+, 
CD166+, CD29+, HLA-A,B,C+/-, CD13+, CD24+, SSEA-3+, SSEA-4+, TRA-
1-60+, TRA-1-81+, NANOG+, SOX2+, SSEA-1-, CD117+/-, CD49e- 
Haematopoietic markers: CD34-, CD45-, CD14-, CD11-, HLA-DR-, CD31- 
Others: CD324+, CD349- 
AMSCs 
Mesenchymal and embryonic markers: CD90+, CD105+, CD73+, CD44+, 
CD166+, CD29+, HLA-A,B,C+/-, CD13+, CD49d+, CD49e+, CD54+, Oct-
3/4+ 
Haematopoietic markers: CD34-, CD45-, CD14-, CD31-, HLA-DR-, 
CD133-, CD3- 
Others: CD349+, CD140b+, CD324- 
CMSCs 
Mesenchymal and embryonic markers: CD90+, CD105+, CD73+, CD44+, 
CD166+, CD29+, HLA-A,B,C+/-, CD13+, CD10+, CD49e+, CD54+, SSEA-4-
/+, NANOG+, SOX+, CD117- 
Haematopoietic markers: CD34-, CD45-, CD14-, CD31-, HLA-DR-, CD3-, 
CD133- 
Others: CD349+, CD140b+, CD324- 
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1.3.5 Immunomodulation of amnion-/chorion- derived stem cells 
MSC-modulated immune function can be categorised into immunosuppression and 
immunoprivilege. The former is defined as the ability to supress immune cell (T-cells, B-cells, 
natural killer cells) function, such as proliferation and cytokine secretion while the latter 
describes that MSCs are able to protect themselves from immunological defence 
mechanisms.  
AECs, AMSCs, and CMSCs lack or present very low expression levels of major 
histocompatibility complex (MHC) class I antigens (HLA-A, HLA-B, HLA-C) and an absence of 
MHC class II (HLA-DP, HLA-DQ and HLA-DR)128, 129 in order to avoid immune responses 
caused by T cells. Hence, placental membrane-derived stem cells (PM-SCs) have the ability 
to engraft and survive in immunocompetent neonatal swine, rats and rabbits, without a 
xenogenic response122, 130. In an in vitro immune assay of AECs and allogeneic lymphocytes, 
no cytotoxic responses were observed whereas inhibition of lymphocyte proliferation was 
observed131. Placental membrane expresses high level of HLA-G, which is important for 
maternal-fetal tolerance, preventing rejection from the maternal immune system at 
implantation stage132. One unique characteristics of PM-SCs is the presence of HLA-G129, 133 
which is mainly expressed in immunoprivileged organs (testis, ovary, and embryonic cells) 
and shows significantly higher levels in birth-associated MSCs than in adult tissue-derived 
MSCs134, 135. HLA-G interacts with inhibitory receptors present on all immune cells and 
exerts its function by inducing apoptosis or arresting immune cells at the G0/G1 phase136. 
This immunopriviledged status of AECs, AMSCs, and CMSCs may reflect their embryonic 
origin. 
The immunosuppression of placental tissue-derived MSCs involves direct cell-cell contact 
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and secretory effects. In the presence of PM-SCs, the maturation of monocytes into 
dendritic cells is supressed by preventing the expression of CD1a and reducing 
costimulatory molecules CD40, CD40 ligand, CD80 and CD86 expression for T cell activation 
137. Without direct contact with PM-SCs in a trans-membrane co-culture system, PM-SCs 
are able to secrete soluble inhibitors to regulate immune cells138 as well as the increased 
amount of prostaglandin 2 supressing T cells proliferation139. PM-SCs also secrete cytokines 
involved in angiogenesis, tissue repair or immune modulation, including VEGF, interleukin 
(IL)-6, IL-11, macrophage colony-stimulating factor (M-CSF)124. In addition, AMSCs are found 
to supress the production of C-X-C motif chemokine (CXCL)-10, CXCL9, and C-C motif 
chemokine (CCL)-5, demonstrating a significant anti-inflammation capacity111. 
Immunomodulatory effects of AMSCs have been investigated on various in vitro 
experiments of natural killer, B cells, CD4+ T cells, CD8+ T cells regulatory T cells, and 
dendritic cells111 while the understanding of CMSCs immunology is still limited.  
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1.4 Regenerative medicine 
1.4.1 Placental membranes in clinical application 
Historical background 
Human amniotic membrane has been used for skin transplantation for over a hundred years. 
The first reported medical use of amniotic membrane dates back to 1910 with its use as a 
skin graft140. Descriptions of amniotic membrane applied to burned and ulcerated skin 
surfaced was introduced appeared shortly after. They found that the amniotic membrane 
accelerated epithelialisation and reduced the pain on burned or ulcerated sites141. In the 
1930s, amniotic membrane was applied in surgical reconstruction of vaginas142. The first 
report of using both amnion and chorion as a biological dressing material for conjunctival 
defects was described in 1940143. Kim et al. further used amniotic membrane for corneal 
surface reconstruction in a rabbit model144. Thereafter, more advanced studies on the 
clinical applications of placental membrane had begun and biological mechanisms were 
investigated. 
Current application 
Currently, placental membrane is used in a broad range of clinical applications due to its 
ability to reduce scarring and its immunomodulatory effect in suppressing inflammation in 
the healing process. There are numerous cytokines and growth factors found in the 
placental membrane making it an advantageous biomaterial for wound healing and 
regeneration145-147. Epidermal growth factor (EGF), vascular EGF (VEGF), basic fibroblast 
growth factor (bFGF), transforming growth factors (TGFs), keratinocyte growth factor (KGF), 
and many chemokines are important for the healing process and are contained within the 
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placental membrane. The chorion contributes 75% of the growth factor content in a 
amnion/chorion graft148, 149. The amniotic and chorionic membrane products are 
commercially available via dehydration or cryopreservation techniques for their 
preservation and used in clinical practice, including cardiothoracic surgery (mainly for 
surgical closure)150, 151, ocular surface reconstruction152, wound repair and management, 
especially for severe burns and chronic skin ulcers153, 154. It is also suggested that stem cells 
derived from placental membrane retain their wound healing properties155. 
In recent years, using amniotic membrane in tissue engineering as a biological supporting 
matrix (scaffold) has gained increasing interest. It is described as improving cell proliferation, 
migration, differentiation, and as possessing antimicrobial properties, making amniotic 
membrane a good prospective scaffolding material69, 156. 
1.4.2 Placenta-derived MSCs in preclinical/clinical studies 
MSC are a promising source for cell tissue engineering and cell-based therapies due to their 
ability to proliferate and differentiate into various functional cell types. The placenta is a 
reservoir of stem cells and due to its low immunogenicity, easy acquisition without invasive 
procedures and ethical concerns make placenta-derived MSCs an attractive source for 
regenerative medicine. 
Cardiovascular repair 
Myocardial infarction leads to irreversible damage to myocardial calls and is associated with 
high morbidity and mortality; therefore, cardiac regeneration has been widely investigated 
via gene therapy, cell therapy, and growth factors157. MSCs have the ability to differentiate 
and regulate secretion of multiple growth factors as well as angiogenesis factors 
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demonstrating great therapeutic potential. AMSCs were induced to differentiate into 
cardiomyocytes and expressed cardiac-related genes as well as proteins in in vitro 
experiments158. Human AMSCs labelled with a fluorescent marker and transplanted into 
rats were found to integrate into the myocardial infarct tissue region and differentiate into 
cardiomyocyte-like cells. Surprisingly, AMSCs survived for more than 2 months in the rat 
models, improving ventricular functions and enhancing capillary density159. Another in vivo 
study evidenced the ability of AMSCs to transdifferentiate into cardiomyocytes in infarcted 
myocardium rats and indicated a strong association with the expression of HLA-G, IL-10, 
and progesterone that regulated fetal-maternal tolerance during pregnancy playing an 
important role in cardiac regeneration160. A mixture of AMSCs and CMSCs expressed 
increased levels of cardiac-related genes and proteins than bone-marrow MSCs when 
treated with cardiogenic differentiation inducers161. In a chronic heart failure mouse model, 
placental MSCs enhanced cardiomyocyte proliferation and improved cardiac 
performance162. In addition, placental MSCs reduced apoptosis of cardiomyocytes at the 
infarcted border area and enhanced vascularity in pig models163. 
AMSCs and CMSCs are known to secrete angiogenic factors and modulate angiogenesis. 
Their secretion of HGF, IGF-1, and VEGF promoted blood flow and capillary density in mouse 
ischemia model164. In particular, the VCAM-1+ subpopulation of CMSCs was suggested to 
have superior angiogenic potential in vitro and in vivo165.  
Neurological disorders 
Owing to their stem cell characteristics, AECs have been studied in many neurological 
diseases, where AECs have demonstrated neuroprotective and neuroregenerative effects. 
Through the expression of neural markers - nestin, glial fibrillary acidic protein, and 
microtubule-associated protein 2 (MAP-2), AECs are inclined towards neuronal lineages166. 
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Using AECs to treat peripheral nerve injuries in monkeys showed enhanced growth of host 
neurons and guided regenerative sprouting167. AECs were differentiated into neuronal 
progenitors and transplanted to traumatic brain injury in rat models, which showed 
improved neurological function, brain tissue morphology, and elevated levels of 
neurotrophic factors, such as brain-derived neurotrophic factor and nerve growth factor168.  
Parkinson's disease is associated with the progressive loss of dopaminergic neurons in the 
brain. In a Parkinson’s disease mice model, AMSCs were transplanted into the brain and the 
results indicated that AMSCs differentiated into neural progenitor cells and promoted 
endogenous neurogenesis169. In vitro differentiation of placental MSCs into neural 
precursor cells was followed by transplantation into in vivo models. These placental MSC-
derived neural precursor cells improved neuronal functions170. Placental MSCs have been 
investigated for their therapeutic potential in multiple sclerosis and neurodegeneration of 
the central nervous system171, 172. 
Musculoskeletal diseases 
Myogenic potential has been demonstrated with AECs, AMSCs, CMSCs, umbilical cord-
derived MSCs, and placental tissue-derived MSCs. These MSCs differentiated into myogenic 
lineages in vitro and following in vivo implantation, showed positive results of treating 
skeletal muscle degeneration173. Kawamichi et al., (2010) demonstrated the intrinsic 
differentiation potential of placental MSCs into myotubes improving the efficiency of 
dystrophin delivery in muscle fibres upon implantation into mice174. 
CMSCs displayed therapeutic potential with osteogenesis imperfecta which is characterised 
by brittle bones in response to abnormal collagen composition and currently has no curable 
treatment. The intraperitoneal injection of CMSCs in osteogenesis imperfecta mice models 
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reduced fractures, increased bone ductility and bone volume along with the upregulation 
of endogenous genes involved in endochondral and intramembranous osteogenesis175. 
Placental MSCs were used in bone tissue engineering, by inducing osteogenic 
differentiation, seeding on a scaffold, and transplanting to injured radius segmental bone 
in rabbits, while the results showed markedly enhanced bone repair176. 
Hepatic and pulmonary regeneration 
AECs, AMSCs, and placental MSCs are capable of inducing liver regeneration and regulating 
cytokine expression to decrease inflammation, fibrosis, and hepatocyte apoptosis. AECs 
have been successfully differentiated to hepatocytes in several studies. The expression of 
hepatic-specific transcription factors, genes involved in drug metabolism, and functional 
enzymatic activities for drug degradation (Cytochrome P450 1A and 3A) were detected in 
AEC-derived hepatic-like cells177, 178. It suggested the promising potential of using AEC-
derived hepatocytes transplantation for liver disease therapy. 
Apart from their differentiation ability, the cytokine regulatory effect of AECs, AMSCs, 
CMSCs plays a major role in suppressing fibrosis. Fibrosis is normally caused by a 
progressive accumulation of extracellular matrix (ECM) components resulting in the 
thickening and scarring of connective tissue and chronic tissue inflammation179. The 
transplanted AECs in a carbon tetrachloride-4-induced liver fibrosis mouse displayed an 
ability to supress MMPs that instigated fibrinolysis and to increase IL-10 concentrations180. 
Infusing AMSCs in a carbon tetrachloride-4-treated mouse liver protected it from fibrosis 
and apoptosis181. Amniotic membrane also displayed anti-fibrotic properties with a 
reduction of ductular reaction and ECM deposition182. 
Likewise, immune regulatory effect was demonstrated in a lung fibrosis model where AECs, 
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AMSCs, and CMSCs supressed bleomycin-induced lung fibrosis with significant reductions 
in neutrophil infiltration183, 184. Moreover, the application extended to cigarette-induced 
obstructive pulmonary disease. Intravenous injection of AMSCs was associated with a delay 
of the emphysema progression and alleviated lung damage185. However, the inflammation 
was not entirely repressed and AMSCs were observed in heart, liver, and kidney. The 
homing efficiency of AMSCs to the target tissue needs to be further assessed.  
Clinical trials 
Currently, most of the clinical trials using birth-associated tissues are dedicated to cord 
blood HSCs. The first cord blood HSCs transplant was in 1988; thereafter, over 35,000 
transplants have been performed worldwide186. However, since MSCs have been found in 
various birth-associated tissues, the cell therapy using perinatal MSCs has become a 
growing field. Figure 1-7 shows the numbers of clinical trials registered worldwide per year 
by cell type, indicating the significantly increasing numbers in perinatal MSCs vs. cord blood 
cells transplantation187. Some recent clinical applications using placental MSCs in phase 2 
trials include severe aplastic anaemia, haemorrhagic cystitis, hypoxic ischaemic 
encephalopathy, stroke, rheumatoid arthritis, and graft-versus-host disease. Many clinical 
studies with placenta- or placental membrane- derived MSCs are still in phase 1 trial with 
small groups of participants. However, with great differentiation potential and 
immunomodulatory ability, there has been an increasing interest in regenerative medicine 
of birth-associated MSCs. Some challenges such as mixed cell populations upon 
differentiation, insufficient amount and purity of specialised cells, and route and timing of 
cell administration still need to be overcome to achieve therapeutic outcomes. 
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Figure 1-7. Numbers of clinical trials using perinatal cells per year 
Numbers of cell therapy using perinatal MSCs/HSCs in clinical trials registered per year 
divided by the type of the cells: cord blood cells/HSCs that are unmanipulated or 
manipulated (specific cell type), perinatal MSC (Wharton's jelly, fetal membrane, amniotic 
fluid, placenta), other perinatal cells, multiple sources. MSC, mesenchymal stem cell; HSCs, 
haematopoietic stem cells. Reproduced from Couto et al., 2017187  
 
1.4.3 Banking of neonatal tissues and stem cells 
Cord blood banking has been a popular option since 1993 when the first cord blood bank 
established188. Banked cord blood has been successfully applied to clinical research and 
disease treatments while many biobanks have introduced a new type of service – the 
storage of birth-associated MSCs and new companies specialised in placental component 
banking have appeared. Pregnant women can choose to donate their placenta and 
placenta-derived cells to public banks such as UK Transplant Living Amniotic 
Membrane/Placenta Donation Programme for research purpose or privately store their 
own placental cells in commercial biobanks. Biobanking processes are required to follow 
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the principles and guidelines of good manufacturing practice (GMP) for medicinal products 
for human use189. Although advancements in isolation and characterisation techniques 
allow scientists to obtain abundant MSCs from the placenta, the lack of specialised medical 
trainees in hospitals to ensure the quality and integrity of placenta and high costs ensuing 
from the import of biobanks using quality assurance system controls (such as International 
Organization for Standardization (ISO)) remain challenging for placental cell banking190, 191. 
The storage of placental cells or components is also beneficial for discovery and screening 
of new drugs192. The establishment of placental cell biobanks shows exciting promise for 
future regenerative medicine and stem cell transplantation therapies.  
1.4.4 MSC therapy in type 2 diabetes  
Type 2 diabetes is characterised by a combination of a defect in beta-cell function resulting 
in insulin deficiency and insulin resistance. The frequency of diabetic comorbidities and 
complications, including cardiovascular disease, neuropathy, infections, and impaired 
wound healing are high when hyperglycaemia is uncontrolled193. Although diabetes is a 
treatable disease, the existing therapeutic strategy can neither reverse insulin resistance 
nor the progression of beta-cell dysfunction194. Lifelong monitoring of glucose level and 
treatment poses a burden on diabetic patients. Therefore, research is searching for new 
potentially curative therapies for diabetes.  
The whole-pancreas transplant was first performed in 1966195 while with the improvement 
in surgical techniques and immunosuppressive therapy in modern medicine, transplant 
obviates the need for lifelong insulin treatments and prevents diabetic complications196. 
The necessity of major surgery and shortage of donors limit the availability of this 
therapeutic approach. In 1999, the transplantation of islet cells with minimally invasive 
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procedure was introduced197. Transplanted islet cells successfully enhance insulin 
production, control blood glucose levels, and reduce the requirement of insulin. However, 
xenotransplantation of islets can introduce risk of zoonotic infections198 while human 
allotransplantation is limited due to increased recipient demand greater than donor tissue 
supplies and the complications of immunosuppressive drugs199. 
MSCs, possessing immunosuppressive capacity and differentiation potential have 
generated a great interest in light of diabetic therapy. MSCs transplantation offers several 
advantages, such as lower risks, less complicated procedures, and abolishing the need for 
immunosuppressive therapy. Figure 1-8 summarises the potential of MSC-mediated type 2 
diabetes therapy. 
Regeneration and protection of islets 
MSCs have been suggested to have the ability to promote pancreatic islet regeneration and 
to protect endogenous beta-cells from apoptosis. In streptozocin-induced diabetic mice, 
MSCs homed to and promoted the repair of pancreatic islets through enhancing 
endogenous cells to proliferate and regain their function200. MSCs express a set of 
chemokine receptors (CXCR4, CXCR6, CCR1, CCR7) in response to islet-secreted chemokines 
and allow them to migrate towards the damaged islet site201. Through their paracrine 
mechanisms, MSC transplantation can modify the pancreatic microenvironment and 
thereby allow endogenous beta-cell regeneration. 
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Figure 1-8. MSC therapeutic effects on type 2 diabetes 
MSCs demonstrate beneficial effects through IPCs differentiation while undifferentiated 
MSCs promote islet cell regeneration, protect endogenous islet cells, and ameliorate insulin 
resistance. IPCs, insulin-producing cells; IGF-1, insulin-like growth factor-1; VEGF, vascular 
endothelial growth factor; PDGF, platelet-derived growth factor; IRS-1, insulin receptor 
substrate-1; PI3K, phosphoinositide 3-kinase. Reprinted from Zang et al., 2017202 
 
Following MSCs intravenous injection, diabetic mice showed increased EGF expression in 
plasma and pancreas203. The secretion of EGF, insulin-like growth factor (IGF)-1, and 
platelet-derived growth factor (PDGF) are thought to be beta-cell mitogenic factors and 
other cytokines such as VEGF-α and angiopoietin-1 play a role in vascularisation202. 
Additionally, different MSC subtypes may have different levels of therapeutic effect. Cell 
sorting based on aldehyde dehydrogenase (ALDH) activity reveals that bone-marrow MSCs 
with high ALDH expression have greater potential in improving hyperglycaemia and insulin 
secretion by increasing islet size, beta-cell mass, and vascularisation. The secretory activity 
of MSCs induces Wnt signal activation, the expression of matrix metalloproteases and 
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EGFR-activating ligands, contributing to islet regeneration204. 
Increased oxidative stress and hypoxia are strongly associated with the diabetic 
environment leading to islet apoptosis. MSCs support islet survival and protect islets from 
oxidative stress-induced injury in order to maintain their normal functions. The increased 
viability through downregulation of apoptotic regulators (caspase 3, caspase 8, p53) and 
upregulation of anti-apoptotic genes enhance resistance to oxidative stress-induced 
apoptosis and dysfunction in islets205. Proinflammatory states of diabetes are characterised 
by increased levels of proinflammatory cytokines such as TNF-α, IL-6, interferon-γ206. Co-
culture of MSCs with pancreatic islets prevents beta-cell apoptosis induced by treatment 
with proinflammatory cytokines, suggesting the islet-protected role of MSC in inflammatory 
environment207.  
Insulin-producing cell generation 
Although MSC transplant has the aforementioned advantages, whether residual beta-cells 
and the remaining endogenous precursors could have enough numbers for regeneration to 
cope with hyperglycaemia and their regenerative efficiency remains unclear. Therefore, 
replacing damaged beta-cells by inducing MSC differentiation into insulin-producing cells 
(IPCs) may be a direct way to restore islet function. 
Knowing that pancreatic cells derived from endodermal lineages, many studies have shown 
the capacity of MSCs to differentiate beyond mesenchymal lineage. Since MSCs do not 
spontaneously differentiate into pancreatic lineage in vitro, delicate reprogramming 
processes are required208. Particularly as, unlike embryonic stem cells, adult tissue-derived 
MSCs usually express low levels of pluripotent markers; therefore, MSCs reprogramming, 
examination of pancreatic markers, and evaluation of functions are important for IPC 
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differentiation. The differentiation approach for IPC generation can involve treatment with 
many molecules to induce MSC transdifferentiation into endocrine lineages and maturation 
of functional insulin-secreting cells. Table 1-3 lists the compounds commonly used in 
current IPC differentiation protocols. Three major stages of IPC differentiation described – 
definitive endoderm, pancreatic endoderm, and mature beta-cells are each characterised 
by lineage-specific gene expression; however, differentiation protocols depend on different 
MSC types and range from one step to multiple steps209.  
The functions of MSC-generated IPCs have been investigated in many in vivo diabetic 
models. When transplanting IPCs into diabetic mice, hyperglycaemia was under control 
within two weeks and restored normal glycaemic condition as well as the co-expression of 
insulin, glucagon, and somatostatin in IPC-treated diabetic mice210. The transplanted IPCs 
sustainably expressed insulin, c-peptide, and pancreatic-specific markers without apparent 
apoptosis in vivo for at least three weeks211. Longer survival time of transplanted IPCs was 
also reported, which maintained glucose regulatory function up to 5 weeks212.  
However, the challenges are the percentage of mature IPCs is low and in most animal 
models, IPCs are implanted into the renal capsular space. The homing ability of 
differentiated MSCs to the injured organ will ease the cell transplant process in clinical 
practice.  
Table 1-3. Factors involved in IPC differentiation 
Compounds Function in IPC differentiation 
High glucose Increases beta-cell replication 
Activin A 
Promotes beta-cell regeneration  
Increases insulin content 
N2 and B27  Serum supplements in serum-free medium 
FGF 
Early stage differentiation 
Cluster formation 
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EGF 
Accelerates beta-cell proliferation  
Increases insulin expression 
HGF Induces beta-cell cluster formation 
Retinoic acid 
Induces endocrine and ductal differentiation  
Induces insulin-positive differentiation 
Nicotinamide 
Induces insulin gene  
Enhances insulin content, DNA content  
β-mercaptoethanol Increases the potency of nicotinamide 
Betacellulin 
Promotes beta-cell regeneration  
Increases cell mass and maturation 
 GLP-1 
Accelerates maturation of beta-cells towards glucose 
responsive insulin secretion 
Exendin-4 
Accelerates maturation of beta-cells towards glucose 
responsive insulin secretion 
Pentagastrin 
Expands beta-cell mass in combination with other 
factors 
FGF, fibroblast growth factor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; 
GLP-1, glucagon-like peptide-1 
 
 
Amelioration of insulin resistance 
In addition to beta-cell dysfunction, insulin resistance usually co-exists in type 2 diabetes 
which occurs when cells fail to respond normally to insulin and have impaired glucose 
uptake. MSCs were found to alleviate hyperglycaemia in high-fat diet-induced diabetic rats 
by activating insulin receptor substrate (IRS)-1 signal and Akt (protein kinase B) 
phosphorylation213. Adipose tissue macrophage-induced chronic low-grade inflammation is 
also thought to play a role in exacerbating insulin resistance. MSCs infusion promoted 
insulin sensitivity in diabetic rat through converting inflammatory phenotype macrophages, 
M1 into anti-inflammatory phenotype M2. The study indicated that MSCs upregulated IL-
4R expression and promoted phosphorylation of STAT6 (signal transducer and activator of 
transcription 6) in macrophage leading to polarisation of macrophage into M2 phenotype214. 
However, the underlying mechanisms of MSC-mediated insulin sensitivity are not yet clear. 
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1.5 Introduction to microarray 
1.5.1 Microarray technology 
In the past, researchers used to discover genes based on one gene per experiment principle 
via mutations, selections, and cloning schemes. In the late 90’s, tens of thousands of human 
cDNA sequences represented previously unseen genes215 and brought us to think about the 
unexplored world of human genome. Thereafter, DNA microarray technology has 
progressed rapidly and introduced a new tool for genetic study with a slide or chip 
containing thousands of genes arrayed within a small surface area. Microarray technology 
provides a systematic and comprehensive way to explore the gene expression on genome-
wide level216. It has revolutionised biological science research in recent times, for instance, 
large numbers of publications describing data from microarrays, academia or industrial 
disease and drug discovery, clinical application for evaluating dosages of drugs217. 
The principle of microarray technology is based on DNA hybridization, a process in which 
the DNA strand binds to its unique complementary sequence (Figure 1-9A). The arrayed 
material (DNA strand) has generally been termed as probe. For DNA array, RNA isolated 
from two different samples, is converted to complementary DNA (cDNA) and labelled with 
two distinct fluorescent dyes (such as Cy5 and Cy3). Both samples are mixed in hybridization 
buffer and hybridized to a microarray chip that carries the probes of each specific gene. Two 
samples result in competitive binding of differentially labelled cDNA to its corresponding 
probe and through high-resolution confocal fluorescence scanning, relative signal intensity 
measured at each probe indicates the expression level of genes on the array218 (Figure 1-
9B). Based on this basic concept of microarray, today’s technology has developed a wide 
range of DNA microarray platforms including one- and two-channel formats, cDNA and 
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oligonucleotide microarrays, spotted and in-situ synthesised microarrays, and commercially 
developed microarrays219. 
 
Figure 1-9. Overview of DNA microarray 
(A) Hybridization with gene elements on a microarray. (B) Schematic overview of probe 
microarray with two samples. Fluorescent dye Cy3 (green) and dye Cy5 (red) having the 
fluorescence emission wavelength of approximately 570 nm and 670 nm, respectively. 
Reprinted from Quackenbush, 2006220. 
1.5.2 Applications of microarrays 
The predominate application of DNA microarrays has been to measure gene expression 
levels based on the abundances of RNAs in different tissues. Gene expression provides a 
key clue to a given alteration in phenotype and by looking at overall patterns of gene 
expression, helps to understand the genetic regulatory networks in order to identify co-
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regulated genes with related functions. One of analytical methodologies to identify 
functionally related genes is cluster analysis which partitions genes into groups and clusters 
based on the similarity of expression patterns. By clustering, it is useful for elucidating the 
role of certain genes that appear in the same cluster and the relation of differentially 
expressed gene clusters in a particular phenotype221.  
Microarray technology has also been applied to transcription factor binding analysis and 
genotyping. The former is combined with chromatin immunoprecipitation to determine 
binding sites of transcription factors that regulate the activation or inhibition of gene 
expression219. The latter usually refers to single-nucleotide polymorphism (SNP) genotyping, 
commonly used in discovering variation in a single nucleotide that occurs at a specific 
position in whole genome222. Moreover, SNP genotyping is widely used in cancer research. 
Knowing that tumour formation involves simultaneous changes in cells and genes, SNP 
genotyping can identify single gene mutation, cancer biomarkers, target genes of tumour 
suppressors as well as the identification of genes associated with chemoresistance to 
provide information for drug discovery223. 
Microarray has provided scientists with a convenient and useful tool for genome-wide 
analysis; however, with recent advancements and radical decline costs in next generation 
sequencing technologies, it offers another attractive option for genome-wide studies and 
may supersede many applications of microarray in the future. 
1.6 Hypothesis and aims 
Given that the placental environment is affected by pregnant complications, it would be 
important to investigate whether the biological properties of MSCs derived from GDM 
placenta were altered. On the other hand, the high risk of developing diabetes of women 
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with a GDM history and their offspring, placental MSCs come to be a valuable source for 
their future cell therapy. Therefore, we aim to characterise AMSC-/CMSC- derived from 
GDM and healthy placenta and investigate their differentiation potential for insulin-
producing cell generation. Furthermore, we used DNA microarray technology to 
comprehensively understand the biological properties between healthy- and GDM- MSCs. 
The aims of this study can be divided into three main objectives: 
 Characterise AMSCs and CMSCs from GDM and healthy women via biological 
(morphology and immunophenotypes), functional (growth and tri-lineage 
differentiation), and immunological (T-cell and macrophage modulation) 
characterisation. 
 Develop a feasible approach to generating insulin-producing cells from Healthy-/GDM- 
CMSCs and AMSCs in an attempt to explore their therapeutic potential in diabetes 
therapy.  
 Perform DNA microarray to identify gene profiles and investigate benefits and 
disadvantages of using CMSCs from healthy and GDM women in future regenerative 
medicine.  
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Materials and methods 
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2.1 Materials  
Table 2-1. List of materials 
 Catalogue 
number 
Supplier 
2-mercaptoethanol (Gibco) 21985023 ThermoFisher Scientific 
2',7'-dichlorofluorescin diacetate 
(DCFDA) 
ab113851 Abcam 
3-(4,5-dimethylthiazol-2yl)-
2,5diphenyltetrazolium bromide 
(MTT) 
M6494 ThermoFisher Scientific 
3-isobutyl-1-methylxanthine (IBMX) I7018 Sigma-Aldrich 
4',6-Diamidino-2-phenylindole 
(DAPI) 
D9542 Sigma-Aldrich 
ABTS Liquid Substrate Solution A3219 Sigma-Aldrich 
Acetic acid A6283 ThermoFisher Scientific 
Aldehyde dehydrogenase (ALDH) 
activity colorimetric assay kit 
MAK082 Sigma-Aldrich 
Alcian blue A3157 Sigma-Aldrich 
Alizarin red S A5533 Sigma-Aldrich 
Ascorbic acid phosphate A8960 Sigma-Aldrich 
Beta-glycerophosphate disodium salt 
hydrate 
G5422 Sigma-Aldrich 
Bicinchoninic acid (BCA) protein 
assays 
23227 ThermoFisher Scientific 
Bovine serum albumin (BSA) fatty 
acid free powder 
11433164 ThermoFisher Scientific 
Cellular senescence assay kit KAA002 Merck Millipore 
Chloroform C/4960/17 ThermoFisher Scientific 
Collagenase type IV 10780004 ThermoFisher Scientific 
Corning Transwell polyester 
membrane cell culture inserts 
CLS3460-48EA Sigma-Aldrich 
Crystal violet  C6158 Sigma-Aldrich 
Dexamethasone D2915 Sigma-Aldrich 
Dimethylsulphoxide (DMSO) D2650 Sigma-Aldrich 
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Dulbecco’s Modified Eagle Medium 
(DMEM)- 4.5 g/L glucose 
BE12-709F Lonza 
Dulbecco’s Modified Eagle Medium 
(DMEM)- 1g/L glucose 
LZBE12-707F Lonza 
DMEM, no glucose, no glutamine, no 
phenol red 
A1443001 ThermoFisher Scientific 
DMEM F12 1:1 mixture  BE04-687Q Lonza 
Exendin-4 E7144 Sigma-Aldrich 
Ethanol (absolute) E0650/17 ThermoFisher Scientific 
Ethylene diamine tetra-acetic acid 
(EDTA) 
BP2482-1 ThermoFisher Scientific 
Foetal bovine serum (FBS) FB-1001G/500 Biosera 
Glycerol  G6279 Sigma-Aldrich 
Glucose G7021 Sigma-Aldrich 
Human Betacellulin 100-50 PeproTech 
Human EGF  AF-100-15  PeproTech 
Human GLP-1 (7-36a.a) 130-08 PeproTech 
Human/Murine/Rat Activin A (E.coli) 120-14E  PeproTech 
High-Capacity cDNA Reverse 
Transcription Kit 
4368814 ThermoFisher Scientific 
Human IL-2 Mini ABTS ELISA 
Development Kit 
900-M12 PeproTech 
Human IL-10 Mini ABTS ELISA 
Development Kit 
900-M21 PeproTech 
Human TNF-α Mini ABTS ELISA 
Development Kit 
900-M25 PeproTech 
Human Insulin ELISA Kit  ab200011 Abcam 
Human C-Peptide ELISA 
80-CPTHU-
E01.1-ALP 
Stratech 
Human TGF-beta 3 (E.coli) 100-36E PeproTech 
Hydrogen peroxide solution (H2O2) 216763 Sigma-Aldrich 
Indomethacin I7378 Sigma-Aldrich 
Insulin Antibody sc-9168 Santa Cruz 
Insulin, Transferrin, Selenium (ITS) I3146 Sigma-Aldrich 
Isopropanol 11398461 ThermoFisher Scientific 
L-Glutamine BE17-605E Lonza 
LIVE/DEAD Viability/Cytotoxicity Kit L3224 ThermoFisher Scientific 
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L-Proline P5607 Sigma-Aldrich 
MEM Eagle NEAA (100X) LZBE13-114E Lonza 
Methanol 10141720 ThermoFisher Scientific 
Mouse anti-rabbit IgG-Texas Red sc-3917 Santa Cruz 
Nicotinamide N0636  Sigma-Aldrich 
Oil Red O O0625 Sigma-Aldrich 
PDX-1 Antibody (B-11) Alexa Fluor 
488 
sc-390792 
AF488 
Santa Cruz 
Penicillin-Streptomycin DE17-603E Lonza 
Phorbol 12-myristate 13-acetate 
(PMA) 
P8139-5MG Sigma-Aldrich 
Phycoerythrin conjugated antibodies 
CD105 
130-098-845 Miltenyi Biotec 
Phycoerythrin conjugated antibody 
CD73 
130-097-932 Miltenyi Biotec 
Phycoerythrin conjugated antibody 
CD90 
130-098-906 Miltenyi Biotec 
Phycoerythrin conjugated antibody 
CD14 
130-098-167 Miltenyi Biotec 
Phycoerythrin conjugated antibody 
CD19 
130-098-168 Miltenyi Biotec 
Phycoerythrin conjugated antibody 
CD34 
130-098-140 Miltenyi Biotec 
Phycoerythrin conjugated antibody 
CD45 
130-098-141 Miltenyi Biotec 
Phycoerythrin conjugated antibody 
HLA-DR 
130-098-177 Miltenyi Biotec 
Phycoerythrin conjugated antibodies 
IgG1isotype 
130-098-849 Miltenyi Biotec 
Phycoerythrin conjugated antibodies 
IgG2a isotype 
130-098-849 Miltenyi Biotec 
Phytohaemaglutinin (PHA) L166 Sigma-Aldrich 
Phosphate buffered saline (PBS) BE17-516F Lonza 
Radioimmunoprecipitation assay 
(RIPA) buffer 
R0278-50ML Sigma-Aldrich 
Retinoic acid R2625 Sigma-Aldrich 
Rosewell Park Memorial Institute 
(RPMI1640) 
12-918F Lonza 
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RNAlater R0901 Sigma-Aldrich 
Sodium butyrate B5887 Sigma-Aldrich 
Sodium pyruvate S8636 Sigma-Aldrich 
Taurine T8691 Sigma-Aldrich 
TRIzol Reagent 15596026 ThermoFisher Scientific 
Trypsin/Versene(EDTA) BE02-007E Lonza 
Trypan blue T8154 Sigma-Aldrich 
Tween-20 P7949-100ML Sigma-Aldrich 
QuantiFast SYBR Green PCR Kit 204054 Qiagen 
UltraPure DNase/RNase-Free 
Distilled Water 
10977049 ThermoFisher Scientific 
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2.2 Placental samples collection 
All placentas in our research were collected from Royal Stoke University Hospital, UK, after 
obtaining Research Ethics Committee and Health Research Authority approvals (Reference 
15/WM/0342). Women undergoing Caesarean sections were consented to donate their 
placenta. Term placentas were collected from healthy donors (n=10) and donors with GDM 
(n=11). Individuals were classified as GDM after clinical diagnosis using an OGTT between 
24 and 28 weeks pregnant. The OGTT was carried out by the measurement of fasting plasma 
glucose (FPG) concentration, and 2 hours after a 75 g solution of glucose was consumed, 
plasma glucose was measured again. If the patients exceeded the NICE clinical guidelines 
for glucose concentration thresholds (section 1.1.1) were diagnosed with GDM. The cell 
isolation process was performed within an hour of collecting the placenta from Caesarean 
section. Maternal and fetal details of the samples used in this study were listed in Table 2-
2.  
For each placenta, both amniotic mesenchymal stem cell (AMSCs) and chorionic 
mesenchymal stem cells (CMSCs) were isolated from the same placental membrane. 
Independent samples were grouped into Healthy-CMSCs, Healthy-AMSCs, GDM-CMSCs, 
and GDM-AMSCs for all the comparisons and statistical analysis in this thesis.  
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Table 2-2. Placenta sample details 
Samples Ethnicity Age Weeks BMI Infant/Weight  
Healthy01 Nigerian 46 38 38 Girl / 3380 Hypertension / GDM in last pregnancy 
Healthy02 Caucasian 26 39 22 Girl / 3400 Hepatitis B 
Healthy03 Caucasian 33 37 24 Girl / 3280 - 
Healthy04 Caucasian 33 39 30 Girl / 3440 - 
Healthy05 Caucasian 29 39 37 Girl / 3280 Previous smoker 
Healthy06 Caucasian 41 39 22 Girl / 3720 - 
Healthy07 Caucasian 30 39 20 Girl / 3095 Current smoker 
Healthy08 Caucasian 24 39 21 Girl / 3540 Previous smoker 
Healthy09 Caucasian 30 39 27 Girl / 3780 GDM in last pregnancy 
Healthy10 Caucasian 26 39 29 Girl / 3100 - 
Healthy11 Caucasian 32 39 25 Girl / 3630 - 
GDM01 Chinese 35 38 25 Boy / 3740 - 
GDM02 Caucasian 31 39 22 Girl / 4660 Addison's disease / received hydrocortisone before delivery 
GDM03 Caucasian 31 37 42 Boy / 3120 & Boy / 3600 Non identical twins 
GDM04 Caucasian 24 37 40 Boy / 3468 - 
GDM05 Caucasian 23 37 34 Girl / 2920 Previous smoker 
GDM06 Caucasian 43 39 44 Girl / 3860 GDM on metformin 
GDM07 Caucasian 35 39 25 Boy / 3580 GDM on insulin 
GDM08 Caucasian 32 36 29 Boy / 3581 GDM on insulin and metformin 
GDM09 Caucasian 20 39 20 Boy / 3940 GDM on metformin 
GDM10 Caucasian 32 39 36 Girl / 3380 - 
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2.3 Isolation and culture of AMSCs and CMSCs  
The placenta dissection and cell isolation were conducted in a class II microbiological safety 
cabinet. All materials used in isolation process were sterile. The CMSCs/AMSCs isolation 
process was performed within an hour of collecting the placenta from Caesarean section, 
using the protocol described by Marongiu et al., (2010)224. The placenta dissection process 
was demonstrated in Figure 2-1. 
Umbilical cord was trimmed and cut an X-shaped incision onto the placental surface. 
Amniotic membrane was manually peeled from the underlying chorionic membrane and 
immediately washed with PBS for several times to remove blood clots. As chorionic 
membrane is attached to maternal tissues, a removal of decidual tissue was required. 
Decidual tissue and blood clots on chorionic membrane were carefully removed by forceps 
and washed with PBS. Following wash steps, membranes were placed in 20 ml prewarmed 
0.05% trypsin/EDTA solution in 50 ml centrifuge tubes and incubated at 37°C for 1 hour. 
Membranes were then washed with PBS for 3-5 times to remove any residual trypsin 
solution. To release the cells, membranes were placed in freshly prepared digestion media 
containing 1 mg/ml collagenase type IV and 25 µg/ml DNase I in serum free Dulbecco’s 
Modified Eagle Medium (DMEM) in 50 ml centrifuge tubes. Digestion media was filtered 
through a 0.2 μm filter and prewarmed before use. Membranes were digested at 37°C 
incubator for 1-1.5 h and during the digestion process, the membranes were checked every 
15 minutes. Incubating on a rotator or shaking the tubes every 15 minutes was sometimes 
required to enhance the digestion process. The incubation stopped once the membranes 
were completely dissolved. Equal volume of PBS was added to the centrifuge tubes 
containing digestion media and dissolved membranes. The mobilised cells were pelleted by 
centrifugation at 200g for 5 minutes and then supernatant was discarded, the pellet was 
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washed with PBS, and pelleted again at 200 g for 5 minutes. Cell pellet was then re-
suspended in growth media consisting of 10% FBS, 1% L-glutamine, 1% Penicillin-
Streptomycin, and 1% non-essential amino acids (NEAA) in DMEM and seeded at the 
density of 1 x 105 cells/cm2.  
 
Figure 2-1. MSC isolation from placental membranes. 
AMSCs and CMSCs were isolated from amniotic and chorionic membrane, respectively. 
Following trimming the umbilical cord and cutting an X-shaped incision on placental surface, 
amnion was peeled from the underlying chorion and washed with PBS. Blood clots and 
decidual tissue attached to chorion were removed by forceps and chorion was washed with 
PBS. After the washing step, both amnion and chorion were digested with trypsin and 
digestion media containing 1 mg/ml collagenase type IV and 25 μg/ml DNase I in serum 
free DMEM to release the AMSCs and CMSCs from the membranes. Reproduced from 
Marongiu et al., 2010224 and Koo et al.,2012225 
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2.4 Cell culture techniques  
All cell cultured procedures were performing using disposable sterile consumables in a class 
II microbiological safety cabinet. Cells were cultured in standard tissue culture T25, T75 
flasks or multi-well culture plates and maintained in 5% CO₂ at 37 °C incubators. 
2.4.1 Cell passage, cryopreservation, and recovery  
For adherent cell lines, cells were sub-cultured when its growth reached 80-90% confluence. 
Media were aspirated, monolayer cells were rinsed with PBS, and sufficient amount of 
trypsin/EDT (0.05% trypsin/0.02% ethylenediaminetetraacetic acid (EDTA) diluted 1 in 10 in 
PBS) was added to cover cells. Cells were then incubated at 37 °C for about 10 minutes until 
detached. Cell maintenance media added to halt the trypsin activity in an equivalent 
volume of trypsin/EDTA solution and cell suspensions were transferred to a centrifuge tube 
for pelleting at 1,000 rpm for 5 minutes. Cell pellet was re-suspended in fresh maintenance 
media for seeding. 
To cryopreserve the cells for future use, cells were detached using trypsin/EDTA and re-
suspended in freezing media (10% FBS DMEM supplemented with 10% DMSO). 1 ml of 
freezing media containing approximately 2 x 106 cells was transferred into a cryovial and 
placed in Mr. Frosty for slowly cooling to -80 °C before transferred to liquid nitrogen for 
further storage.  
To recover frozen cells, cryovials taken out from liquid nitrogen were immediately placed 
into a 37 °C water bath. Thawed the cells by gently swirling the cryovials and transferred 
thawed cells to the desired amount of growth media in a centrifuge tube. Cells were 
pelleted at 1,000 rpm for 5 minutes, supernatant was aspirated, and pellets were re-
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suspended in growth media for seeding. 
2.4.2 Morphological observation and measurement 
Changes in cell morphology were detected by a light microscope and images were 
processed with ImageJ software to analysis cell length and surface area. For analysis, 5 
images were taken from each sample from passage 0-2. The images were open by ImageJ 
and to calibrate the images, scale was set based on a known distance. Images were adjusted 
by modifying the contrast and sharpening the images until the shapes of cells clearly 
appeared. To measure cell lengths, line tool in ImageJ was used to draw a line based on the 
longest axis from cell periphery and length of the line was measured to represent each cell 
length. At least 100 single cells were measured in each image. Cell surface area was 
measured by ImageJ through automatically circling the outline of cells and the edged cells 
were excluded (Figure 2-2). 
 
Figure 2-2. Cell morphology analysis 
(A) Original image (B) Contract and brightness adjustment (C) Cell length measurement (D) 
Cell surface area measurement. All images were analysed by ImageJ.  
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2.4.3 Cell counting and doubling time  
Cells were suspended and diluted in culture media, if trypan blue was used, a small amount 
of cell suspension was mixed with the equal volume of trypan blue. 10 µl of the cell 
suspension was loaded into a haemocytometer adhered with a coverslip. Cells were 
counted from 4, 1 mm2 corner squares under a microscope and each square represents a 
volume of 0.1 µl. To determine the number of cells/ml, the mean number of each square 
was multiplied by 104 while if cell suspension was diluted 1:1 with trypan blue, the dilution 
factor was also taken into account by multiplying 2 in the calculation. 
Cell numbers were counted every 2 days and the doubling time was calculated at passage 
3. Equation for doubling time = (T2-T1) × log 2/ (log N2 – log N1), where: T1, final time 
(hours); T2, initial time; N1, initial cell numbers; and N2, final cell numbers. 
2.4.4 MTT assay  
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, ThermoFisher) 
assay has been widely used to determine cell viability and proliferation since its 
development by Mosmann in the 1980’s226. The measurement of MTT is based on 
mitochondrial function of cells by measuring activity of mitochondrial enzymes such as 
succinate dehydrogenase227. The increased measurement of MTT represents enhanced 
metabolic activity, which can be affected by cell proliferation, different conditions, chemical 
treatments, and cell death228. Therefore, MTT assay can only indirectly reflect the viable cell 
numbers and proliferation. Viable cells with active metabolism can convert soluble yellow-
coloured MTT into an insoluble purple-coloured formazan product through NAD(P)H-
dependent cellular oxidoreductase enzymatic activity, indicating mitochondrial activity229. 
The MTT compound was prepared in PBS at a concentration of 5 mg/mL, filtered through a 
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0.2 μm filter, and stored at -20 °C. Cells were seeded at 3,000 cells/well in a 96-well plate in 
triplicate and performed MTT assay every 2 days for a 12-day period. When performing 
MTT assay, media was aspirated and added 90 µl serum-free media plus 10 µl MTT solution 
into each well. Following incubating the plates at 37 °C for 4 hours, 100 µl DMSO was added 
and incubated at 37 °C for 30 minutes to dissolve purple formazan crystals. Plates were 
wrapped in foil and shaken on an orbital shaker for 5 minutes before reading the 
absorbance at wavelengths of 570 nm using a plate reader. As phenol red present in the 
media can generate background, wells without cells contained same proportion of serum 
free media, MTT solution, and DMSO was used as a blank. The results are presented as 
mean ± SD of triplicates, taking time as the horizontal axis and optical density (OD) as the 
longitudinal axis. 
2.4.5 Production of conditioned media  
Cells at passage 3 were seeded in T75 flasks and when reaching 80–90% confluence, cells 
were washed with PBS and then 15 ml of fresh media without FBS was added. After 
incubating for 48 hours, conditioned media was collected by transferring supernatant to a 
centrifuge tube and filtering through a 0.2 μm filter to remove cell debris. Supernatant was 
stored at −80 °C until further use.  
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2.5 Flow cytometry 
Flow cytometry is a technique to investigate cell populations at the single-cell level through 
labelling cells with fluorescent antibodies and suspending cells in dynamic fluidics to pass 
through the flow cytometer. As the cells traverse the laser beam, fluorescent light emission 
from the cells is detected and converted to electronic signals, subsequently processed and 
visualised on a monitor for analysis (Figure 2-3).  
Flow cytometry was used to investigate the cluster of differentiation (CD) surface antigens 
for MSC characterisation. Cells were obtained from a T75 flask at 90% confluence, 
trypsinised using trypsin/EDTA, and re-suspended in flow cytometry buffer (0.5% BSA and 
2 mM EDTA in PBS). Suspension cells were equally divided into 10 Eppendorf tubes and 
centrifuged at 300 g for 10 minutes in preparation for antibody conjugation. Phycoerythrin 
conjugated antibodies (CD14, CD19, CD34, CD45, CD73, CD90, CD105, HLA-DR, and isotype 
controls IgG1 and IgG2a) were diluted in flow cytometry buffer. The diluted concentration of 
each antibody was based on manufacturer’s suggestion (Miltenyi Biotec). After centrifuging 
cell suspension, supernatant was discarded and cell pellets were re-suspended in 50 μl 
diluted antibody followed by incubation in the dark at 4 °C for 15 minutes. 1 ml of flow 
cytometry buffer was added to each tube and cells centrifuged at 300 g for 10 minutes, 
removed supernatant, re-suspended in 300 μl buffer for flow cytometry analysis. Flow 
cytometry was carried out using Beckton Dickinson FC500 and at least 50,000 events were 
acquired for each assessment. Data were analysed using Flowing Software to produce 
colour dot plots, histogram plots and set gates for analysing percentage of positive events. 
Isotype control IgG1 was used for CD19, CD73, CD90, CD105; IgG2a was for CD14, CD34, 
CD45, HLA-DR analysis. 
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Figure 2-3. Flow cytometry technique 
The sheath fluid mobilises cell suspension and directs it through laser beam as a single 
event per time. Forward scatter, associated with the size of the particle, and side scatter, 
reflecting the granulosity of the cell can be detected without the requirement of specific 
labelling. The appropriate lasers should be assigned for the corresponding excitation and 
emission spectra which can identify the positive staining of fluorescent markers. 
Reproduced from Menon et al.230 
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2.6 Tri-lineage differentiation and assessment  
Cells at passage 3 were seeded in a 24-well plate in complete growth media (DMEM with 
10% FBS, 1% L-glutamine, and 1% NEAA) overnight to allow attachment. Following cell 
adherence, the medium was replaced with a differentiation medium, which was changed 
every 3 days during the 21-day culture. All images of differentiation were monitored with 
an inverted optical microscope (Olympus). 
2.6.1 Osteogenesis 
To induce osteogenic differentiation, 2 × 104 cells/well were seeded in a 24-well plate and 
cultured in differentiation media consisting of 50 µM ascorbic acid, 10 mM β-glycerol 
phosphate, and 0.1 µM dexamethasone in complete growth media231. 
Osteogenesis was evaluated by the stain of mineral deposition in differentiated osteoblasts 
with alizarin red S. Following removing the differentiated media, cells were fixed by 500 
μl/well of 10% formalin for 20 minutes, washed with PBS, and incubated in 2% alizarin red 
S solution for 10 minutes. Alizarin red S was prepared in distilled water (dH2O) and paper 
filtered. Stained wells were then washed gently using tap water and allowed to dry for 
imaging.  
2.6.2 Adipogenesis 
For adipogenesis, 2 × 104 cells/well were seeded and cultured in complete growth media 
supplemented with 0.5 µM dexamethasone, 0.5 mM 3-Isobutyl-1-methylxanthine (IBMX), 10 
µg/ml insulin, and 100 µM indomethacin232, 233. 
Adipogenesis was assessed by Oil Red O stain for intracellular lipid droplets. Oil Red O stock 
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solution was prepared by dissolving 350 mg of Oil Red O in 100 mL isopropanol and shaking 
overnight on a rotator. Oil Red O working solution was prepared freshly prior to staining by 
mixing 6 parts of Oil Red O stock solution with 4 parts of dH2O and filtered through a 0.2 μm 
filter. For staining, cells were washed, fixed with 10% formalin as descried in osteogenesis 
assessment, and rapidly washed with 60% isopropanol. Filtered Oil Red O working solution 
was added and incubated for 10 min, which was then washed 3 times with dH2O and 
imaged immediately. 
For quantitative analysis of positive staining, 500 μl of 100% isopropanol was added to each 
well and incubated for 10 minutes with gently shaking to ensure all the Oil Red O staining 
was eluted. 100 μl of the solution was transferred to each well in a 96-well plate and 
measured the absorbance at 500 nm. 100% isopropanol was used as blank. 
2.6.3 Chondrogenesis 
To induce chondrogenic differentiation, 1 x 105 cells were re-suspended in 8 μl of medium 
and dropped in the centre of the well as a micromass. After 1-hour incubation in the 
standard culture condition to allow cells to attach to the culture surface, micromass was 
then replenished with chondrogenic differentiation media, supplemented with 1% ITS, 0.1 
µM dexamethasone, 50 µM ascorbic acid, 40 μg/mL L-proline, 1% sodium pyruvate, and 10 
ng/mL TGF-β3 in complete growth media with reduced FBS to 1%234, 235. 
After 21-day differentiation period, cells were fixed and proteoglycan-rich matrix 
accumulation was detected by Alcian blue for chondrogenesis evaluation. 1% Alcian blue 
solution was prepared by dissolving 0.5 g Alcian Blue 8GX in 50ml of 3% acetic acid (pH 1.5) 
and paper filtered. Fixed cells were incubated with 1% Alcian blue solution overnight, 
washed gently with tap water, and images were captured immediately. 
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2.7 RNA extraction and reverse transcription 
Total RNA was extracted by TRIzol reagent, a monophasic solution of phenol, guanidine 
isothiocyanate, and proprietary components for supressing RNase activity and isolating 
RNA from large or small numbers of cells and tissue samples. 
RNA isolation process was conducted in a biosafety cabinet. Cell monolayer was rinsed with 
PBS and 1 ml of TRIzol reagent (ThermoFisher) per well in a 6-well plate was added to lyse 
the cells. Cell lysate was transferred to a 1.5 ml Eppendorf tube, vortexed thoroughly and 
incubated for 10 minutes to permit complete dissociation of the nucleoproteins complex. 
0.2 ml of chloroform was added and samples were vortexed for 15 seconds repeating for 2-
3 times. Following centrifuging at 12,000 g for 15 minutes at 4 °C, the mixture separated 
into a lower red phenol-chloroform, an interphase, and an upper aqueous phase where 
RNA remained exclusively. The upper aqueous phase was then transferred to a new 
Eppendorf tube containing 0.5 ml of isopropanol, mixed and incubated for 10 minutes 
before centrifuging at 12,000 g for 10 minutes at 4 °C to allow RNA precipitation. A white 
small pellet at the bottom of the tube was washed with 1 ml 75% ethanol twice by briefly 
vortexing and pelleting at 7,500 g for 5 minutes at 4 °C. Supernatant was discarded and air 
dried the RNA pellet for 10 minutes, followed by re-suspending the pellet in 20 µl of RNase-
free water. To solubilise the pellet, Eppendorf tubes were incubated in a 55 °C water bath 
for 10–15 minutes. RNA was stored at -80 °C for further applications. 
RNA concentration and purity was determined by Nanodrop spectrophotometer (ND-2000). 
1 µl of RNA was used for measurement and the ratio of A260/A280 was around 1.8-2.2 which 
is generally accepted as good RNA quality. For microarray experiments, in order to obtain 
high purity of RNA, 1 x 107 cells were pelleted at 1,000 rpm for 5 minutes and stored in 1 ml 
of RNAlater solution (Sigma) at 4 °C. Samples were sent to Welgene Biotech Company for 
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RAN extraction and microarray analysis (section 5.3).  
Complementary DNA (cDNA) was prepared from 1 μg of total RNA using High-Capacity 
cDNA Reverse Transcription Kit (ThermoFisher). RNA was diluted to a desired concentration 
in RNase-free water with a total volume of 10 μl. Equal volume of reverse transcription 
master mix was prepared based on manufacturer’s instruction and mixed with diluted RNA 
samples. Samples were briefly centrifuged and loaded to a thermal cycler (MJ Research 
PTC-200). The program for reverse transcription: 25 °C for 10 minutes, 37 °C for 2 hours, 85 
°C for 5 minutes, and cooling down to 4 °C before removing the samples from thermal cycler. 
The cDNA samples were stored in -20 °C for further applications. 
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2.8 Real-time polymerase chain reaction (qPCR) 
Gene expression analysis was evaluated by real-time PCR using QuantiFast SYBR Green PCR 
Kit (Qiagen). All cDNA was diluted 1:4 in RNase-free water and used to perform real-time 
PCR. 2 μl of diluted cDNA was mixed with an appropriate amount of SYBR Green master mix 
based on manufacturer’s instruction alongside 250 nM of respective forward and reverse 
primers. Primers were designed to be fully complementary to template DNA sequences 
using NCBI Primer-BLAST online tool. Primers were 18 - 25 nucleotides in length, containing 
40 - 60% GC content, and lacking lack significant secondary structures, and primer pairs 
were approximately the same length. Regions of complementarity at the 3’ end of primers 
were minimised to reduce the potential for the formation of primer dimer236. 
SYBR Green generates a fluorescent signal when bound to double stranded DNA during the 
course of amplification. The fluorescent signal represents the relative abundance of product 
determined by the comparison of the cycle number that each sample has accumulated 
sufficient fluorescence to cross an arbitrary threshold value. The threshold level is set in the 
exponential phase of product amplification and above background levels for all samples 
(Figure 2-4A). A melting curve (dissociation curve) analysis shows the change in 
fluorescence observed when double-stranded DNA with incorporated dye molecules (SYBR 
Green) dissociates into single-stranded DNA as the temperature of the reaction is raised237. 
Primer-dimers, non-specific or mismatched sequences generally have a lower melting 
temperature than the specific PCR product of the reaction (Figure 2-4B). Therefore, melting 
curves analysis was used to check real-time PCR reactions for primer-dimers and to ensure 
reaction specificity during assay optimisation. Real-time PCR used in this study depended 
on relative quantification and was unaffected by the lack of quantitative DNA standards, as 
the ratio of two targets was assessed within the same assay and many of the sources of 
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measurement uncertainty similarly affected both determinations, and thus did not 
influence the final result238.  
 
Figure 2-4. Real-time PCR amplification and dissociation curve 
(A) The three phases of fluorescence accumulation across cycles during a real-time PCR 
amplification – initiation phase (early exponential), exponential phase (log-linear), and 
plateau phase. A threshold is set on the log-linear phase of amplification curve. (B) The 
post-amplification melting curve (dissociation curve) analysis to differentiate specific PCR 
products from primer dimers. 
 
The cycle at which the threshold is passed (CT) was normalised for all samples using the CT 
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value for the housekeeping reference gene GAPDH (glyceraldehyde 3-phaosphate 
dehydrogenase). The choice of GAPDH as the reference gene was validated for every sample 
and confirmed that it remained constant in all samples being compared at all points of the 
experiment. All runs included a no-template control (NTC) which contained all reaction 
components except the cDNA sample. If an amplification curve appears in NTC, it indicates 
the existence of primer-dimers or contamination with completed PCR reaction product, 
which can lead to inaccurate expression levels. Every pair of primers used in this study was 
optimised for its ideal melting temperature (Tm, Table 2-3), which results in the lowest 
variation in replicates, a negative NTC, a melting curve analysis revealing detection of a 
specific product and high reproducibility between replicate reactions (Figure 2-4B). All 
primers were optimised via a test run, including three experimental samples in triplicates 
and a NTC control.  
The total volume of each reaction mixture was 15 μl and real-time PCR was carried out in 
real-time PCR system (Agilent Stratagene Mx3000P). Primer sequences for each gene are 
shown in Table 2-3. All samples were amplified at 95 °C for 10 minutes followed by 40 cycles 
of a denaturation step at 95⁰C for 10 seconds, and a 30-second annealing step at the 
optimised temperature for the primers (Table 2-3). The expression levels of genes were 
normalised to the reference gene, GAPDH (ΔCt= Ct(target)−Ct(reference)), and compared with 
controls to generate the 2-ΔΔCt (ΔΔCt= ΔCt(experimental)− ΔCt(control)) for calculating relatively fold 
changes. 
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Table 2-3. Primer sequences 
Gene ID Forward sequence Reverse sequence Tm 
ADIPOQ  AGGCCGTGATGGCAGAGATG CTTCTCCAGGTTCTCCTTTCCTGC 60 
ALDH1A1  TCAAACCAGCAGAGCAAACT TAGGCCCATAACCAGGAACA 60 
ALDH2 CTGCTGACCGTGGTTACTT CTCCCAACAACCTCCTCTATG 60 
ALDH3B1 GCTGAAGCCATCGGAGATTAG GCTCCCTGTGAAGAAGATGTAG 60 
AQP1 CTGCATGGTCAAGCCTCTTA TCAAGGGAGTGGGTGAATTG 60 
CCL-17 CGGGACTACCTGGGACCTC CCTCACTGTGGCTCTTCTTCG 60 
CD24 CTCCTACCCACGCAGATTTATTC AGAGTGAGACCACGAAGAGAC 60 
CELSR1 TACTTCTGCGGTGCTGGTTT GTCCGTAAACCGTCCCTTCC 58 
CTCF GCCTGTTCCAAGACCTGTG GGCGGCTCTGCTTCTCTA 60 
CXCL8 CTGGCCGTGGCTCTCTTG CCTTGGCAAAACTGCACCTT 60 
CXCL12 ATGAACGCCAAGGTCG GGGCTACAATCTGAAGGG 60 
EDN1 CCATGAGAAACAGCGTCAAATC CGAAGGTCTGTCACCAATGT 60 
FLNB TGATCTATGTGCGCTTCGGT GACATGCATTTACCGGTGCC 60 
GAPDH ACTTCAACAGCACACCCACT GCCAAATTCGTTGTCATACCAG 58 
GLUT2 ACTTCAACAGCACACCCACT GCCAAATTCGTTGTCATACCAG 58 
HBEGF AATCTGGCTTAGTGCCACCC GCACTCTGACCACGGAAGAT 60 
HMOX1 TCTTGGCTGGCTTCCTTACC GGATGTGCTTTTCGTTGGGG 60 
IL-1β ATTCTCTTCAGCCAATCTTCA TATCCCATGTGTCGAAGAAG 60 
IL-10 TCAGCAGAGTGAAGACTTTC CCTTGCTCTTGTTTTCACAG 60 
IL-12 AAAGGACATCTGCGAGGAAAGTTC CGAGGTGAGGTGCGTTTATGC 60 
INS TGCCCACAATCTCATACTCAA TACAGACAGGGACCAGAGCAT 58 
ISL1 GCAGCCTTTGTGAACCAACA TTCCCCGCACACTAGGTAGAGA 58 
MET TGGTGCAGAGGAGCAATGG CATTCTGGATGGGTGTTTCCG 60 
MRC1 ACCTCACAAGTATCCACACCATC CTTTCATCACCACACAATCCTC 58 
NANOG  CAACTGGTCAATTTTTCAGAAGGA TTGAGAGGACATTGATGCTACTTCAC 55 
NEUROG3 CCCAGCCTTTACTCTTCCTACCAC GATTCCTCTCCACAGTTATAGAAGGGA 60 
NKX2.5 CAACATGACCCTGAGTCCCC TAATCGCCGCCACAAACTCT 60 
NOG CATGCCGAGCGAGATCAAA CAGCCACATCTGTAACTTCCTC 60 
NPPB TGGAAACGTCCGGGTTACAG GACTTCCAGACACCTGTGGG 60 
NQO1 GGGATGAGACACCACTGTATTT AGTGATGGCCCACAGAAAG 60 
OCT4 CTATTCTTTTGCGCCGGTAGA CTCACGGGTCACTTGGACAGT 55 
PAX6 GTCCGAGTGTGGTTCTGTA CTCAGTTTGAATGCATGGGA 58 
PDGFA GGAACGCACCGAGGAAGA GCCAGGAGGAGGAGAAACAG 58 
PDX1 TGTCCAACGGATGTGTGAGTA TCCCGCTTATACTGGGCTATT 60 
PPARG GCAGGAGATCTACAAGGACTTG CCCTCAGAATAGTGCAACTGG 58 
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RASIP1 CGTCTCCTTGAGAACCAATACC CATTCCACGCGGGATAAGAA 60 
RSPO3 CACCTTTATCTGAGCCAATGGA ATGCAGGGGGATCTGACATA 60 
SOD2 GGACAAACCTCAGCCCTAAC GCCGTCAGCTTCTCCTTAAA 60 
SOX2 TTCCGGAAGAAAAAGAGCCA AAACAGGTCCCAAGGTGGAGT 57 
TGFB2 ATGCGGCCTATTGCTTTAGA ACCCTTTGGGTTCGTGTATC 60 
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2.9 Immunology characterisation 
2.9.1 Culture and stimulation of Jurkat cells 
Jurkat T cells were originally cultured in 10% FBS RPMI 1640 and gradually adapted to 10% 
FBS DMEM through culturing in a mixture of RMPI and DMEM at the ratio of 4:1, 2:1, 1:1, 
0.5:1, and 0:1 with each subculture. For subculture, suspension Jurkat T cells were 
transferred to a centrifuge tube, pelleted at 1,000 rpm for 5 min, removed supernatant, and 
re-suspended in fresh growth media. Cells were seeded at a density of 1x105 cells/ml in 25 
ml growth media in a T75 flask. 
To induce activation of Jurkat T cells, 5x105 cells/ml were stimulated with 5 μg/ml 
phytohaemagglutinin (PHA, stock solution 0.5 mg/ml in PBS) and 50 ng/ml phorbol 12-
myristate 13-acetate (PMA, stock solution 100 µg/ml in DMSO) and control samples 
(without PHA and PMA) were received same amount of DMSO treatment. PHA is a lectin 
that binds to the T cell receptor and leads the stimulation of signal transduction for IL-2 
secretion. Likewise, PMA is a small organic compound, which can diffuse through cell 
membrane into cytoplasm and directly activate protein kinase C leading to IL-2 production. 
The combination of PHA and PMA strongly enhanced Jurkat cells IL-2 production239.  
2.9.2 Supernatant collection 
The secretion of cytokine interleukin 2 (IL-2) is considered as an active state of Jurkat cells. 
Activated Jurkat cells were cultured in conditioned media from CMSCs or AMSCs for 24, 48, 
and 72 hours. Supernatant was collected at each time point for IL-2 ELISA assays, 
centrifuged at 1,500 rpm for 5 minutes to remove cell debris and transferred to a new 
Eppendorf tube for storage in a -80 °C freezer. CMSC and AMSC conditioned media 
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incubated in an empty well without Jurkat cells was used as a blank control.  
2.9.3 Culture and stimulation of THP-1 cells 
Human monocytes THP-1 cells were maintained in DEME containing 10% FBS, 1% L-
glutamine, 1% Penicillin-Streptomycin. As both Jurkat cells and THP-1 monocytes are 
suspension cell lines, the same sub-cultured method described in section 2.9.1 was applied 
to THP-1. 
To simulate THP-1 cells for microphage polarisation, THP-1 cells were treated with 50 ng/ml 
PMA for 24 hours. Roughly 80% of suspension THP-1 attached to flask after 24 hours, 
indicating a differentiated state (M0 macrophage) and the suspension cells were removed 
by media change. M0 macrophages were polarised to M1 macrophages by incubation with 
20 ng/ml of interferon-γ (IFN-γ) and 10 pg/ml of lipopolysaccharide (LPS). Macrophage M2 
polarisation was induced by incubation with 20 ng/ml of interleukin 4 (IL-4). 
2.9.4 Co-culture system  
In co-culture experiments, 5 × 105 THP-1 cells were placed to a well in 12-well plates and 
treated with PMA for 24 hours. Media was gently aspirated and changed to 1.5 ml fresh 
media. The Transwell inserts (membrane pore size of 0.4 μm, Corning) were then placed 
into each well and 5 × 105 CMSCs or AMSCs in 0.5 ml media were added to the Transwell 
insert. Following incubation for 24 hours, supernatant was collected, centrifuged at 1,500 
rpm for 5 minutes, and transferred to a new Eppendorf tube for storage at -80 °C. The 
adherent THP-1 cells at the bottom of the wells were lysed with TRIzol reagent 
(ThermoFisher) for RNA extraction. 
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2.10 ELISA assay 
ELISA (enzyme-linked immunosorbent assay) is designed for detecting and quantifying 
peptides, proteins, and hormones. ELISA assays performed in this study were sandwich 
ELISA, which involved an attachment of a capture antibody to a microplate, binding of target 
protein to the capture antibody, and then the detection of signals via a conjugated antibody 
and an enzymatic substrate. ELISA was performed in a 96-well plate and all samples were 
performed in duplicate.  
2.10.1 IL-2, IL-10, TNF-α 
The human IL-2, IL-10, and TNF-α development kits were purchased from PeproTech 
containing a recombinant protein, standards, capture antibody, detection antibody 
(biotinylated antibody). For ELISA assay, every wash step mentioned in this protocol was 
performed by adding 300 μl wash buffer (0.05% Tween-20 in PBS) per well, flicking the plate 
for aspiration, patting the plate on a paper towel and the entire procedure was done in 3-4 
repeats. 
To coat the plate with capture antibody for targeting the specific antigen in the samples, 
monoclonal capture antibody (IL-10, IL-2, TNF-α) was diluted in PBS to a concentration of 1 
μg/ml and added 100 μl to each well. The plate was sealed and incubated overnight at room 
temperature. Following the wash step, 300 μl blocking buffer (1% BSA in PBS) was added to 
each well and incubated for 1 hour. The plate was then washed and ready for protein 
(antigen) detection from supernatant collected in section 2.9. The standard was serially 
diluted from 0.01 μg/ml to zero in diluent (0.05% Tween-20, 0.1% BSA in PBS). 100 μl of 
standard or samples was added to each well and incubated at room temperature for 2 hours. 
For signal detection, the plate was washed and incubated with 100 μl diluted detection 
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antibody (IL-10, IL-2, TNF-α; 0.5 μg/ml in diluent) recognising a different epitope on the 
target protein for 2 hours, followed by Avidin-HRP conjugate through incubation with 
diluted Avidin-HRP secondary antibody (1:2000 in diluent) for 30 minute. To read the signal 
by plate reader, the plate was washed and 100 μl of ABTS-substrate (2,2’-Azino-bis (3-
ethylbenzothiazoline-6-sulfonic acid)) was added to each well, which changed the colour 
from yellow to green/blue-ish during reaction, indicating the presence of the protein-of-
interest in the samples. The plate was read every 5 minute intervals until desired OD 
readings were obtained for a maximum 40-minute period. The signal was read at 405 nm 
with wavelength correction set at 650 nm by a plate reader. The standard curves used to 
determine the concentration of the samples were shown in Figure 2-5. The best fitting 
trendline and equation was calculated by Excel using a second- or third- degree polynomial 
equation based on the R2 value. R2 evaluates the scatter of the data points around the fitted 
regression line. The R2 value >0.99 was used for standard curve equation. 
 
Figure 2-5. ELISA standard curves for IL-10, TNF-α, and IL-2  
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The mean O.D. values of the standards (X-axis) obtain from duplicate absorbance were 
plotted against the known concentration of the standard (Y-axis). The best fitting standard 
curves and equations were calculated based on the R2 value greater than 0.99.  
2.10.2 Insulin and C-peptide 
The secreted insulin, C-peptide, and intracellular insulin content was measured by 
commercialised specific insulin or C-peptide ELISA with pre-coated plate and highly specific 
capture antibody. To induce insulin/C-peptide release, undifferentiated CMSCs/AMSCs 
(controls) or CMSC/AMSC-derived insulin producing cells were washed with PBS and pre-
incubated for 1 hour in phenol red-free DMEM without glucose and then media was 
switched to phenol red-free DMEM with glucose at different concentration for glucose 
challenge. The media volume for glucose challenge was 1 ml/well in a six well plate. Cells 
were first incubated in 5.5 mM glucose (low glucose) phenol red-free DMEM for 1 hour and 
supernatant was collected by centrifuging at 1,500 rpm for 5 minute to remove cell debris 
and stored in -80 °C for measurement of released insulin/C-peptide with ELISA assays. Cells 
were then incubated in 25 mM glucose (high glucose) phenol red-free DMEM for 2 hours 
and supernatant was collected for ELISA analysis. The phosphodiesterase inhibitor, IBMX 
(0.5 mM) known to stimulate insulin secretion was added together with 5.5 mM or 25 mM 
glucose in phenol red-free DMEM. After subsequently incubating with low and high glucose 
media, cells were trypsinised and lysed in 200 µl RIPA buffer (radioimmunoprecipitation 
assay buffer) for measuring the intracellular insulin content by ELISA. The protein 
concentration was measured using Thermo BCA (bicinchoninic acid) protein assays and 
absorbance was detected by a plate reader against a BSA standard. All samples 
(supernatant and protein) were stored at -80 °C until use. 
The insulin ELISA was performed following the manufacturer’s instructions (Abcam). All the 
solutions were provided with the kit. Briefly, 50 µl of all samples and serially diluted 
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standards was added to each well and incubated with 50 µl antibody cocktail for 2 hours on 
a plate shaker at 400 rpm. Antibody cocktail was prepared by diluting the capture and 
detector antibody in diluent. The plate was washed 3 times and 100 μl of 3,3′,5,5′-
Tetramethylbenzidine substrate (TMB) was added for a 30-minute incubation in the dark on 
a plate shaker. Following the addition of 100 µl stop solution to each well, an endpoint 
reading was recorded at 450 nm using a plate reader. 
The C-peptide ELISA was performed by ALPCO C-peptide ELISA kit, using the test procedure 
for 25 μl sample volume as per the manufacturer’s instructions. 50 μl of assay buffer was 
added to each well and the plate was incubated on a shaker at 800 rpm for 2 hours. 
Following incubation, each well was washed and samples were incubated with 100 μl 
enzyme conjugate solution. For signal detection, the plate was washed, 100 μl TMB was 
added to the well, and incubated for 30 minutes on a plate shaker. 100 μl of stop solution 
was then added to each well and absorbance measured at 450nm by a plate reader. The 
insulin and C-peptide ELISA standard curves were shown in Figure 2-6 and the calculation 
methods were described in section 2.10.1. 
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Figure 2-6. ELISA standard curves for insulin and C-peptide  
The mean O.D. values of the standards (X-axis) obtain from duplicate absorbance were 
plotted against the known concentration of the standard (Y-axis). The best fitting standard 
curves and equations were calculated based on the R2 value greater than 0.99. 
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2.11 Live/dead viability assay 
Cell viability assay was assessed using two-colour fluorescence LIVE/DEAD 
viability/cytotoxicity assay kit (ThermoFisher) and fluorescent images were captured by 
confocal microscope. The calcein-acetoxymethyl (calcein-AM, ThermoFisher) indicates 
intracellular esterase activity while ethidium homodimer-1 (EthD-1, ThermoFisher) 
indicates the loss of membrane integrity. Adherent cells were washed with PBS and 
incubated with calcein-AM (1 µM) and EthD-1 (4 µM) in PBS at 37 °C in the dark for 20 
minutes. Cells were then gently rinsed with PBS to remove residual fluorescent dyes and 
viewed under a confocal microscope. Images were taken immediately and fluorescence 
emission was detected at 530 nm for calcein-AM (live cells) and at 645 nm for EthD-1 (dead 
cells).  
2.12 Beta-galactosidase senescence assay 
Senescence was characterised by the induction of senescence-associated β-galactosidase 
(SA-β-gal) activity, which is present only in senescent cells, not in quiescent or proliferating 
cells. Senescence was confirmed by the catalytic activity of SA-β-gal which catalyses the 
hydrolysis of Xgal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside, Merck) and 
results in the accumulation of blue precipitate. 
To detect SA-β-gal activity, cells were washed with PBS before being fixed using fixation 
solution supplied with the cellular senescence kit (Merck) for 15 minutes at room 
temperature. The SA-β-gal detection solution was prepared following the manufacturer’s 
instruction by diluting the Xgal in staining solution and PBS. After fixation, cells were 
washed with PBS and incubated with the detection solution at 37 °C in the dark for at least 
4 hours or overnight. The detection solution was then removed and cells were washed with 
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PBS. However, sometimes salt crystals were observed when incubating overnight while 
excess amount of salt crystals could be removed by briefly incubating the stained samples 
with DMSO for 10 seconds. Images were obtained under bright-field microscope and blue 
stained cells were counted from several random fields of each samples.  
2.13 Immunofluorescence staining 
The staining was performed on insulin producing cells (IPCs) to confirm the differentiated 
state of CMSCs/AMSCs. Cells were cultured in an 8-well chamber slide for IPC differentiation 
and fixed with 4% paraformaldehyde in PBS for 20 minutes at the end of differentiation 
period to inhibit degradative process of proteins. Fixed cells were either covered in PBS and 
stored in 4 °C up to a week or performed immunostaining straight away.  
Before any antibodies were introduced, cells were permeabilised with 0.3% TritonX-100 in 
PBS for 15 minutes and blocked potential nonspecific binding sites by incubation with 
blocking buffer (1% BSA, 0.1% TritonX-100 in PBS) for 1 hour at room temperature. The 
primary antibody was diluted in 1% BSA in PBS. The appropriate amount of diluted primary 
was added into the samples and incubated overnight at 4 °C. After washing with PBS, the 
samples were then incubated with secondary antibodies diluted in 1% BSA in PBS and 
incubated at room temperature for 2 hours following by counterstained with 4,6-diamidino-
2-phenylindole (DAPI) for 10 minutes. The samples were washed with PBS before taking 
images by confocal microscope.   
The following antibodies and dilutions were used – anti-insulin (1:100, Santa Cruz 
Biotechnology, sc-9168), anti-PDX-1 conjugated to Alexa Fluor 488 (1:100, Santa Cruz 
Biotechnology, sc-390792 AF488), and Alexa Fluor 594 secondary antibody (1:200, 
Invitrogen). 
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2.14 Migration assay 
2.14.1 Transwell assay 
Transwell assay was performed at passage 3. Cells were trypsinised and re-suspended in 
serum free DMEM. Transwell filters with 8 μm pores were placed in a 24-well plate and 2 x 
105 cells in 200 μl serum free media were added to a Transwell chamber. The plate was 
incubated in 37 °C incubator for 10 minutes and then 550 μl of complete growth media 
containing 10% FBS was added to the lower chamber. Cells were allowed to migrate for 8 
or 24 hours at 37 °C.  
To assess the migration, at the end of incubation period, Transwell inserts were carefully 
transferred to a new empty well and cells that did not migrate through the pores remaining 
on the upper side of the filter were removed with a cotton swab. This process was repeated 
3-4 times to completely remove cell debris and every time a clean cotton swab was 
moisturised with dH2O to avoid breaking Transwell membrane when wiping off the cells. 
Cells that migrated through the membrane were fixed by placing Transwell inserts in 100% 
methanol for 15 minute and rinsed with PBS. Cell staining was performed by placing 
Transwell inserts in 0.1% crystal violet dissolved in 20% ethanol/PBS solution for 15 minutes. 
The excess crystal violet was removed by briefly washing with dH2O for few seconds and 
the upper side of the membrane was gently wiped with a cotton swap. The membrane was 
allowed to dry for one hour and images were captured by light microscope. Cell migration 
was quantified by counting migrated cells in five randomly selected fields in each sample. 
2.14.2 Wound healing assay  
A number of 5 x 105 cells was seeded into each well in a 6-well plate and cultured for 2 days 
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until reaching confluence as a monolayer. Wound was created by scratching with a 200-μl 
pipette tip across the surface of the well. After scratching, wells were washed twice with 
media to remove suspension cells and cell debris. In order to obtain the same field during 
image acquisition at different time points, the reference point was made by marking the 
plate with a fine tip marker on the outer bottom of the plate. The plate was then incubated 
at 37 °C for 6 or 12 hours and cell migration towards the gap area was recorded using a light 
microscope. Relative cell migration was calculated by measuring final wound area 
compared to initial area using ImageJ. 
2.15 ALDH activity assay  
Aldehyde dehydrogenase (ALDH) enzymatic activity was quantified by Sigma's ALDH 
Activity Assay Kit. In ALDH activity measurement, acetaldehyde was oxidised by ALDH 
generating nicotinamide adenine dinucleotide (NADH), which reacted with a probe and 
generated a colorimetric (450 nm) coloured product proportional to the ALDH activity 
present. According to manufacturer’s instruction, one unit of ALDH is the amount of 
enzyme that will generate 1.0 μmole of NADH per minute at pH 8.0 at room temperature. 
1 x106 cells were homogenised in 200 μl of ice-cold ALDH assay buffer and centrifuged at 
13,000 g for 10 minutes to remove insoluble cell debris. The supernatant was transferred 
to Eppendorf tubes and kept on ice. Reaction mix was prepared by adding an appropriate 
proportion of ALDH assay buffer, ALDH substrate mix, and acetaldehyde supplied with the 
kit based on manufacturer’s instruction. For background signal correction, a blank was set 
up for each sample by omitting the acetaldehyde from reaction mix. 50 μl of supernatant 
from each sample or serially diluted standard was added into a 96-well plate and then the 
equivalent volume of reaction mix was added to each well. The plate was protected from 
light and incubated on a plate shaker for 5 minutes. Changes in absorbance for ALDH activity 
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were measured at 450 nm every 5 minutes over a 30-minute period. The plate was 
protected from light during the entire incubation period. All samples were performed in 
duplicate. 
The absorbance was corrected to the blank and the activity of ALDH was calculated by the 
following equation: 
ALDH activity = (Tfinal – Tinitial) / (Reaction time(minutes)) x V 
The absorbance at 450 nm at the initial (Tinitial) or final (Tfinal); the amount (nmole) of NADH 
generated between initial and final (Tfinal – Tinitial); duration time between initial and final 
(Reaction time); sample volume added to the well (V). ALDH activity is described as 
nmole/min/mL = milliunit/mL 
2.16 Detection of ROS 
Reactive oxygen species (ROS) was indicated by 2’,7’ - dichlorofluorescin diacetate (DCFDA, 
also known as H2DCFDA, Sigma). After diffusion into cells, DCFDA is deacetylated by 
intracellular esterases and oxidised by ROS converting into 2’, 7’ - dichlorofluorescein (DCF). 
DCF is a highly fluorescent compound which can be detected by fluorescence spectroscopy 
with an excitation and emission spectra of 485 nm and 535 nm, respectively. 
Cells were seeded at 10,000 cells/well in a 96-well plate and allowed attachment for 
overnight incubation at 37 °C. The DCFDA working solution was prepared by diluting 20 mM 
DCFDA/DMSO in assay buffer to a concentration of 25 μM. After attachment, cells were 
washed with PBS and incubated with 25 μM DCFDA solution for 45 min at 37 °C in the dark. 
DCFDA solution was then removed and cells were treated with glucose to induce metabolic 
activity for the desired time period. Tert-Butyl Hydrogen Peroxide (TBHP) solution supplied 
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with the kit was used as positive control. 
For florescent images, ROS detection was observed by confocal microscope. Images were 
taken from randomly selected fields in each sample. The intensity of florescence was 
measured by a fluorescence plate reader (SpectraMax i3x) and signal was read at 
excitation/emission: 485/535 nm. A blank well containing no cells (media only) was used as 
background signal.  
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Characterisation of AMSCs/CMSCs 
from GDM and healthy pregnancies 
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3.1 Introduction  
Cell therapy and tissue engineering using mesenchymal stem cells (MSCs) have emerged as 
an attractive option in disease treatments seeking to maintain, restore, or enhance tissue 
regenerate and function. Safe, effective, and reliable cell sources remain a major issue for 
use in regenerative medicine clinical applications. Bone marrow MSCs have now been 
widely and successfully used in clinical applications for a number of decades240, however 
some limitations have caused concerns, such as their limited expansion capacities, scarcity 
within bone marrow, and the invasive and labour intensive isolation process which can 
associate with an increased risk of infection for the donor233. Thus far, MSC derivation has 
been reported from a wide range of adult tissues including; fat, dental, lung tissue and 
peripheral blood241.  
The human placenta, generally discarded post-partum, is now becoming recognised as a 
plentiful and alternative source of stem cells242. Placental MSCs are phenotypically similar 
to BM-MSCs, in terms of plastic adhesion, immunophenotype, and lineage differentiation 
potential. It has also been suggested that the placental MSC provides a substantial 
expansion potential and delayed senescence243, 244. Moreover, the ease of access, reduced 
ethical conflicts, and reduced age-acquired DNA damage makes them a promising source 
for stem cell therapy245.  
The placenta plays a vital role in fetal development and maternal health by regulating the 
metabolic interaction between the mother and fetus. As the intrauterine environment is 
closely related to placental state, pregnant complications have been associated with 
abnormal placentation246, 247. Gestational diabetes mellitus (GDM), the common pregnancy 
complication, affects both the mother and fetus during pregnancy, where maternal 
hyperglycaemia influences fetal programming and leaves mother and child with high a risk 
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of developing type 2 diabetes later in life33, 34. The GDM environment is also known to have 
an impact on placental pathology, as discussed in section 1.2.3, implying that the 
characteristics of stem cells and progenitor cells in GDM placenta are likely to be affected. 
For example, Hadarits et al. (2003) reported the increased proportion of haematopoietic 
stem cells in cord blood of new-born from GDM pregnancies248; another study showed that 
perivascular stem cells from umbilical cord of GDM pregnancies had lower cell yield and 
proliferative rate when compared to healthy pregnancy249. Environmental factors can cause 
significant effects on cell populations and behaviours; therefore, understanding the 
biological properties of stem cells is important before applying these cells in clinical 
applications. 
In this study, MSCs were isolated from different sides of the placental membrane – amnion 
and chorion in healthy and GDM placenta. Due to the higher risk of developing diabetes in 
women who have had GDM and children from GDM pregnancies, autologous amniotic and 
chorionic MSCs (AMSCs/CMSCs) free of ethical conflicts and immune rejection hold great 
therapeutic potential for diabetes therapy. Recent examples include the transplantation of 
MSC-derived islet cells250 and the use of MSC secretome cytokines to promote the 
regeneration of pancreatic cells251, 252 (section 1.4.4). However, the application of MSC 
therapy to the treatment of human disease requires extensive studies. Establishing 
biological properties is an essential first step to evaluate the therapeutic potential of each 
type of MSCs. 
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3.2 Aim 
Considering that the placental environment is affected by pregnant complications and 
having an impact on placental cells, it would be important to investigate whether the CMSCs 
and AMSCs derived from GDM placenta are an ideal candidate for cell therapy. Therefore, 
we aimed to investigate biological differences between AMSCs and CMSCs obtained from 
GDM and healthy pregnancies for exploring the fundamental differences and 
environmental impacts on AMSCs and CMSCs. 
 
The main objectives of the chapter: 
 Isolate and expand AMSCs/CMSCs from healthy and GDM placental membrane. 
 Characterise MSCs via morphological analysis and surface marker expression. 
 Examine cell proliferation and tri-lineage differentiation ability (osteogenesis, 
adipogenesis, chondrogenesis). 
 Investigate immunomodulatory capacity of MSCs secretome via conditioned media 
and co-culture system. 
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3.3 Methods 
Following informed consent placenta was collected from 10 healthy and 10 GDM women 
undergoing elective caesarean sections, as described in section 2.2. MSCs were isolated 
from amniotic and chorionic membranes processed in sterile conditions (section 2.3) and 
cultured in DMEM supplemented with 10%FBS, 1% L-glutamine, 1% NEAA and 1% Penicillin-
Streptomycin. Morphologically changes were examined at every passage (section 2.4.2) and 
all characterisation was performed at passage 3.  
Experiments performed in this chapter are summarised in Figure 3-1. Cell morphology was 
analysed from passage 0-3 and proliferation capacity was examined via cell count, doubling 
time calculation, and MTT assay during a 12-day period (section 2.4). Surface marker 
characterisation for MSCs was performed via flow cytometry as described in section 2.5. 
Tri-lineage differentiation was performed by inducing osteogenesis, adipogenesis, and 
chondrogenesis in specific differentiation media for 21 days and followed by histological 
staining with alizarin red, Oil Red O, and alcian blue, respectively (section 2.6). Adipogenic 
potential was further assessed through destaining of Oil Red O and marker examination by 
real-time PCR (section 2.6 - 2.8). Immunosuppression of AMSCs/CMSCs was characterised 
by MSC conditioned media via modulation of Jurkat T cell proliferation and cytokine 
secretion. Conditioned media was collected from CMSCs/AMSCs and stored at -80°C until 
further ELISA analysis (section 2.9.2). Co-culture system was used to investigate the 
immunomodulation of MSCs on THP1 monocyte polarisation and cytokine secretion, as 
described in section 2.9. 
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Figure 3-1. Summary of the methodology in chapter 3 
Statistical analysis 
One-way ANOVA and Tukey post-hoc tests or two-way ANOVA where appropriate were used 
to determine the statistical significance of observed differences in the mean values among 
different groups by GraphPad Prism (GraphPad Software). The comparison within two 
groups was analysed by the simple t-test. The data was presented as mean ± SEM. Each 
data point represents the average of at least three independent experiments with three 
repeats in each experiment. A p-value below 0.05 was indicated as statistically significant 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001). 
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3.4 Results 
3.4.1 Morphological analysis 
AMSCs and CMSCs have distinct morphologies independent of disease state  
AMSCs and CMSCs lines derived from healthy (n=10) and GDM (n=10) placenta were used 
in this study. The details of each pregnancy are shown in Table 3-1. Statistical analysis 
demonstrated that there were no significant differences between healthy and GDM groups. 
Table 3-1 Maternal and fetal characteristics 
 Healthy (n=10) GDM (n=10) P value 
Age (years) 30.1 ± 1.68 30.1 ± 2.32 0.38 
BMI (kg/m2) 25.2 ± 1.76 32.4 ± 2.95 0.17 
Gestational age (weeks) 38.7 ± 0.22 38 .0 ± 0.41 0.11 
Infant weight (g) 3425 ± 85.43 3611 ± 151.5 0.09 
Gender (female/male) 10/0 4/7* - 
*Included one non-identical twins placenta.  
Data are presented as mean (± standard deviation) 
 
Morphological observation was performed from passage 0-3 indicating that CMSCs from 
healthy (H-MSCs) and GDM (G-CMSCs) pregnancies exhibited similar fibroblast-like 
morphologies from passage 0 and maintained stable morphological features during 
subsequent culture (Figure 3-2A). Conversely, AMSCs morphology differed between healthy 
(H-AMSCs) and GDM (G-AMSCs) groups where the H-AMSCs displayed a triangular or 
spindle shape post-seeding for 24 hours while the G-AMSCs, which attached more slowly, 
displayed reduced adherence and a more cuboidal shape. Typical MSC morphology of H-
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/G- AMSCs was observed at later passages (Figure 3-2B).  
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Figure 3-2. Observation of cell morphologies 
The morphology of human H-/G- (A) CMSCs and (B) AMSCs from primary culture to passage 
2. Images of passage 0 were taken after seeding for 7 days; images of passage 1 and 2 were 
taken 5 days after subculture. Scale bar = 200 μm. 
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Although human MSCs, derived from many different tissues, are characterised by a 
fibroblast-like morphology, cell length could be various depending on different origins253. 
The CMSC length (the longest axis from the cell periphery) gradually increased and was 
longer than AMSCs between passage 0 to 2. The morphology of AMSCs became elongated 
in the subsequent passages, where more fibroblast-shaped cells were detected. 
Comparison between GDM and healthy pregnancies demonstrated that G-CMSC displayed 
comparable length to H-CMSCs (Figure 3-3A), while G-AMSCs were shorter than H-AMSCs 
(Figure 3-3B). Surface area measurement indicated that AMSCs displayed a larger and 
broader surface area than CMSCs. There was no significant difference in surface area 
between CMSCs or AMSCs taken from healthy and GDM pregnancies (Figure 3-3C). 
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Figure 3-3. Cell length and surface area analysis 
Cell length of H-/G- (A) CMSCs and (B) AMSCs was measured from passage 0-2. Data are 
expressed as the mean ± SEM. One-way ANOVA and post-hoc test were conducted to 
determine the significant differences. (C) Box and whiskers plot of cell surface area 
measured at passage 2 of each group. Whiskers indicate minimum and maximum, box area 
the interquartile range with the median indicated by the mid-point line. Data of cell length 
and area was based on 150 cells per population from 5 independent experiment and 
analysed by Image J. ***p < 0.001, ****p < 0.0001 
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3.4.2 Cell proliferation and doubling time 
CMSCs display a faster proliferative rate than AMSCs while GDM has an opposite impact 
on CMSCs and AMSCs doubling rates 
The proliferation capacity was evaluated every 2 days during a 12-day culture window via 
cell counting and both H-/G- CMSCs and AMSCs were seeded at 10,000 cells/well in a 24-
well plate. H-CMSCs and G-CMSCs both evidenced a short lag-phase at day 0-4, followed by 
an exponential growth curve from days 4-12. The exponential growth kinetics showed a 
more significant increase in H-CMSCs than G-CMSCs (Figure 3-4A). On the other hand, the 
cell numbers of H-AMSCs and G-AMSCs slowly increased for the initial 8 days and gradually 
reached plateau from day 8-12 with more cell numbers in G-AMSCs than H-AMSCs (Figure 
3-4B). Cell doubling time was calculated when H-/G- CMSCs and AMSCs reached 
exponential growth phase at passage 3. A lower proliferation capacity was exhibited in H-
/G- AMSCs with a doubling time of 91.4 hours for H-AMSCs and 81.6 hours for G-AMSCs 
compared to CMSCs from healthy and GDM placenta with doubling times of 37.9 hours and 
44.0 hours, respectively (Figure 3-4C). The data indicated that CMSCs proliferate more 
rapidly than AMSCs and when comparing the healthy and GDM group, G-CMSCs showed a 
lower growth ability than H-CMSCs while AMSCs displayed the converse. 
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Figure 3-4. Growth curves and doubling time 
10,000 cells at passage 3 were plated in 24-well plates and cell numbers were counted every 
2 days. Growth curves of H-/G- (A) CMSCs and (B) AMSCs were shown for a 12-day period. 
Results are presented as mean from three replicates. (C) Cell doubling time for 
CMSCs/AMSCs from healthy and GDM placenta was calculated based on cell counts at 
passage 3. Results represent mean ± SEM. One-way ANOVA was conducted to determine 
the significant differences, **p < 0.01, ***p < 0.001. 
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MTT assay was used to indirectly reflect viable cell numbers based on the measurement of 
mitochondrial metabolic rate228. A reduced metabolic activity in G-CMSCs was observed 
from day 4 when compared to H-CMSC through the detection of cleaved MTT by 
metabolically active cells (Figure 3-5A). This may reflect the reduced cell counts observed 
in the G-CMSCs population (Figure 3-4A). Between H-AMSCs and G-AMSCs the converse 
was noted where G-AMSCs showed a relatively higher metabolic level than H-AMSCs which 
was consistent with both previous cell number and doubling time observations (Figure 3-
5B and 3-4B). However, no obvious increase in the numbers H-/G- AMSCs at day 8-12 was 
observed, but the OD value of MTT results continued to increase with time, which may infer 
that H-/G- AMSCs were still slowing metabolising but not in active cell division phase. 
 
Figure 3-5. Cell proliferation assessed by MTT assay 
Metabolic activity was assessed by measuring the MTT dye absorbance in a 12-day period. 
H-/G- CMSCs and AMSCs were seed at a number of 1,000 cells per well in a 96-well plate 
and performed MTT assay every 2 days. All assays were conducted in triplicate. OD was read 
at wavelength of 570 nm. Results represent mean ± SEM, n=6. One-way ANOVA was 
conducted to determine the significant differences, *p < 0.05, **p < 0.01, ***p < 0.001 
  
 97 
 
3.4.3 Cell immunophenotye  
Healthy- and GDM- CMSCs/AMSCs immunophenotypes are broadly comparable  
Immunophenotypes of AMSCs and CMSCs were characterised by surface marker expression 
according to the International Society for Cellular Therapy minimal definition criteria109. H-
/G- CMSCs and AMSCs were incubated with antibodies to CD19, CD73, CD90, CD105, CD14, 
CD34, CD45, HLA-DR and the recommended non-specific isotype control, either IgG1 or 
IgG2a. Representative histograms of fluorescence intensity for all markers by flow cytometry 
are shown in Figure 3-6A. The immunophenotype of H-/G- CMSCs and AMSCs were 
comparable and displayed high levels of expression of typical MSC markers; CD73, CD90, 
CD105, and low levels of CD14, CD19, CD34, CD45 and HLA-DR. There was no significant 
difference between CMSCs and AMSCs in either GDM or healthy groups. However, CD45 
expression was slightly higher in G-CMSCs/AMSCs when compared to their healthy 
counterparts; 17.5% ± 2.06% in G-CMSCs, 7% ± 2.6% in H-CMSCs (Figure 3-6B) and 19% ± 
1.02% in G-AMSCs, 6.33% ± 1.45% in H-AMSCs (Figure 3-6C). 
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Figure 3-6. Immunophenotype of H-/G- AMSCs and CMSCs 
Immunophenotypic characterisation of H-/G- CMSCs and AMSCs at passage 3 was assessed 
by FACS to examine the expression of typically negative (CD14, CD19, CD34, CD45, HLA-DR) 
and typically positive (CD73, CD90, CD105) MSC markers. (A) Representative histograms of 
MSC markers. Filled histogram, isotype control IgG1 or IgG2a; coloured-line histogram, G-/H- 
CMSCs or AMSCs samples. (B and C) The graph compared the positive percentage of MSCs 
marker expressions between H-CMSCs and G-CMSCs or H-AMSCs and G-AMSCs. Similar 
levels of CD marker expressions were observed in GDM and healthy MSC except for the 
marginally higher CD45 expression. Results represent mean ± SEM, n=6. Two-sample t-test 
was conducted to determine the significant differences, *p < 0.05. 
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3.4.4 Tri-lineage differentiation  
GDM environment promotes MSC lineage commitment toward adipogenesis 
To investigate differentiation potential, H-/G- CMSCs and AMSCs were exposed to specific 
differentiation media to induce tri-lineage differentiation as identified by histological 
staining (Figure 3-7). Following culture in osteogenesis differentiation media, evidence of 
mineralisation in H-/G- CMSCs and AMSCs was evidenced by alizarin red S stained bone 
nodules. CMSCs and AMSCs from both GDM and healthy samples had similar level of 
stained mineralised regions, indicating comparable osteogenic potential.  
For chondrogenesis, Alcian blue was used to stain glycosaminoglycans produced during 
differentiation. H-/G- CMSCs and AMSCs had partly detached from culture plate, formed 
condensations, showing positive Alcian blue staining, although H-/G- CMSCs formed 
condensations to a greater extent than H-/G- AMSCs.  
Adipogenic potential was assessed by Oil-Red-O stain of lipid droplets produced by cells 
undergoing adipogenesis. Following culture in adipogenesis differentiation media, H-
CMSCs and G-CMSCs stained strongly with Oil-Red-O, especially in G-CMSCs with more 
stained lipid vesicles. In contrast, H-AMSCs and G-AMSCs appeared to have reduced staining 
of lipid droplets.  
Overall, CMSCs from healthy and GDM samples both exhibited a tri-lineage differentiation 
capacity while H-AMSCs and G-AMSCs displayed bi-lineage differentiation ability and very 
limited capacity toward adipogenesis. 
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Figure 3-7. Tri-lineage differentiation – osteogenesis, adipogenesis, chondrogenesis 
Representative images of tri-lineage differentiation of H-/G- CMSCs and AMSCs following 
culture in monolayer for 21 days in differentiation media. H-/G- CMSCs/AMSCs were 
induced to differentiate towards osteogenic lineage and stained with Alizarin Red S to 
identify calcified matrix, adipogenic lineage verified by Oil-Red-O for lipid accumulation, 
and chondrogenic lineage detected by Alcian blue for glycosaminoglycans. Scale bar = 200 
µm. 
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The enhanced adipogenic capacity in G-CMSCs was confirmed with other GDM samples 
undergoing 21-day culture in differentiation media and the results of Oil-Red-O stain were 
displayed in Figure 3-8. Abundant Oil-Red-O positive lipid vacuoles were exhibited in both 
H-CMSCs and G-CMSCs while more lipid droplets accumulation could be observed in GDM 
groups (Figure 3-8A). In contrast, only a few or small Oil-Red-O-stained granules were 
detected in H-AMSCs and G-AMSCs (Figure 3-8B).  
To quantify the lipid droplets produced during adipogenesis, positive stain of Oil-Red-O was 
eluted with 100% isopropanol and the absorbance of the elutes was measured at 500 nm 
using a plate reader. H-/G- CMSCs and AMSCs cultured in growth media were used as 
control and adipogenic differentiation was examined on day 14 and day 21 after inducing 
differentiation. Quantitative analysis in Figure 3-8C indicated no significantly increased 
amount of lipid droplet formation in H-/G- CMSCs or AMSCs in the initial 14 days of 
induction. Lipid content significantly increased in H-CMSCs and G-CMSCs on day 21 while 
in H-AMSCs and G-AMSCs, no significant changes was detected by Oil-Red-O elution. 
However, smaller and reduced numbers of stained lipid droplets were observed from 
histological staining (Figure 3-8B). Quantification of Oil-Red-O confirmed the histological 
observations with significantly more intense staining in G-CMSCs after differentiation for 21 
days (Figure 3-8C). 
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Figure 3-8. Oil-Red-O stain and elution 
(A and B) Adipogenic potential in H-/G- CMSCs and AMSCs was examined by Oil-Red-O stain 
after 21 day of differentiation. Scale bar = 100 μm. (C) Quantification of lipid accumulation 
by detecting the absorbance of Oil-Red-O extracts with isopropanol. The mean OD values 
were obtained from 5 independent experiments and expressed as mean ± SEM. One-way 
ANOVA was used to determine statistical significance. ***p < 0.001 indicates G-CMSCs vs. 
H-CMSCs; #p < 0.001 indicates H-/G- CMSCs vs. control. 
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To further investigate enhanced adipogenic potential in MSCs from GDM placenta, the basal 
RNA levels of two major factors involved in adipogenesis, peroxisome proliferator-activated 
receptor (PPAR)-γ and adiponectin (ADIPOQ), were examined. PPARγ is a nuclear receptor 
that functions as a transcription factor regulating adipocyte-specific genes and triggering 
adipogenesis254. ADIPOQ is usually expressed late in adipogenesis and also functions as an 
autocrine factor promoting differentiation and lipid accumulation255. The expression of 
PPARγ and ADIPOQ was examined in H-/G- CMSCs and AMSCs before the induction of 
adipogenesis. G-CMSCs and G-AMSCs both showed a 2 to 3-fold increase in ADIPOQ basal 
expression levels vs. Healthy- CMSCs/AMSCs (Figure 3-9A). Likewise, higher PPARγ 
expression was exhibited in G-CMSCs than H-CMSCs but not in G-AMSCs (Figure 3-9B).  
 
 
Figure 3-9. Basal activity of adipogenesis-regulating genes 
Basal expression levels of (A) ADIPOQ and (B) PPARγ were examined before inducing 
differentiation. The data were normalised to GAPDH and expressed as mean ± SEM of 8 
independent experiments. The fold changes were calculated by comparing the relative 
expression levels in GDM vs. Healthy groups. One-way ANOVA was used to determine 
statistical significance. **p < 0.01, ***p < 0.001. 
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PPARγ and ADIPOQ closely reflect adipogenic progression; therefore, the expression of 
PPARγ and ADIPOQ during adipogenesis at passage 3 were examined at five different time 
points (days 7, 10, 14, 17, 21). The data was normalised to GAPDH and compared with 
undifferentiated H-/G- CMSCs/AMSCs on day 0. PPARγ and ADIPOQ expression in H-/G- 
CMSCs displayed elevation across the differentiation time course, peaking at around day 
10-14 and PPARγ decreasing thereafter while ADIPOQ remaining elevated (Figure 3-10). 
During adipogenic differentiation G-CMSCs expressed significantly higher levels of both 
PPARγ and ADIPOQ than H-CMSCs at almost all time points. PPARγ displayed some 
upregulation in H-/G- AMSCs but not to levels seen with H-/G- CMSCs. The gradual increase 
of PPARγ was observed in H-AMSCs and G-AMSCs from day 0-10 and day 0-14, respectively 
(Figure 3-10A). Notably, ADIPOQ was initially higher in G-AMSCs than H-AMSCs but no 
significant induction during the differentiation period was seen (Figure 3-10B).  
The PPARγ and ADIPOQ RNA levels were determined in adipogenically differentiated H-/G- 
CMSCs/AMSCs and then correlated to lipid accumulation within the cells shown in Figure 
3-8. It suggested that increased expression of PPARγ and ADIPOQ during early stage induced 
adipogenesis initiation and the lipid formation happened at later stage of adipogenesis 
which may be associated with elevated level of ADIPOQ expression. Overall, the results 
once again confirmed that G-CMSCs have enhanced adipogenic capacity whereas H-/G-
AMSCs have a limited adipogenic capacity in spite of G-AMSCs displaying increased basal 
expression levels of adipogenesis-regulating genes.    
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Figure 3-10. Examination of adipogenic progression through marker expression 
Time course of adipogenic marker expressions – (A) PPARγ and (B) ADIPOQ during 
differentiation process were analysed by real-time PCR. The above graph shows the 
comparison between GDM and Healthy groups; the below graph shows the comparison of 
gene expression changes within the same group over 21 days. Relative levels of gene 
expression were normalised to GAPDH and displayed as fold changes over day 0. Each data 
represents mean ± SEM of 5 independent experiments. Two-way ANOVA was used to 
determine statistical significance, continuous variable - days, *p < 0.05, **p < 0.01, 
***p < 0.001, +p < 0.001 differentiated H-/G- CMSCs (day 7, 10 ,14, 17, 21) vs Day 0 
(undifferentiated H-/G- CMSCs), #p < 0.05 differentiated H-/G- AMSCs (day 7, 10 ,14, 17, 21) 
vs Day 0 (undifferentiated H-/G- AMSCs) 
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3.4.5 Effect of conditioned media on Jurkat T cells 
Conditioned media from H-/G- CMSCs and AMSCs has a significant antiproliferative effect 
on T-cells 
MSCs are known to mediate immune cell activity through cell-cell contact and the 
production of paracrine factors. To evaluate the immunoregulatory properties of secreted 
factors from Healthy- and GDM- CMSCs/AMSCs, conditioned media (CM) were collected at 
passage 3 after culturing in serum free media for 48 hours. 10% of FBS were later on added 
to CM when exposure Jurkat T cells to H-/G- CMSCs/AMSCs CM while 10%FBS DMEM 
without H-/G- CMSC/AMSCs CM was used as controls. The proliferation and inflammatory 
cytokines secretion of Jurkat T cells were investigated to compare the immunomodulatory 
effect of H-/G- CMSCs/AMSCs.  
Jurkat T cells cultured in complete growth media (10%FBS) showed a steady increase in 
proliferation and stable growth rate. A significant reduction in Jurkat T cells was noted 
following on from exposure to either H-/G- CMSC or AMSCs CM. In comparison to the 
inhibitory effect of H-/G- AMSCs CM, both Healthy- and GDM- CMSCs CM showed more 
significant reduction in Jurkat T cell proliferation which maintained a consistent inhibitory 
effect for 3 days. The growth of Jurkat T cells cultured in H-/G- CMSCs/AMSCs CM resumed 
on day 4 and day 5 (Figure 3-11A).  
Jurkat T cells were stimulated with phytohemagglutinin (PHA) and phorbol 12-myristate 13-
acetate (PMA) to induce T cell activation and immune responses. The PHA/PMA activated 
Jurkat T cells had a slow growth rate even when culturing under complete growth media 
which exhibited more than 50% reduction in proliferation upon activation. However, 
PHA/PMA activated Jurkat T cells still displayed a sensitivity to H-/G- CMSCs and AMSCs CM 
and similarly displayed a reduced proliferation rate following on from exposure. Likewise, 
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CM from both H-/G- CMSCs and AMSCs suppressed Jurkat T cells proliferation to a 
significantly greater extent with CM from H-/G- CMSCs. No differences in proliferative 
suppression by CMSCs/AMSCs CM were noted between healthy and GDM groups (Figure 3-
11B).  
Interleukin-2 (IL-2), produced upon PHA/PMA stimulation, regulates proliferation of 
activated T-cells and leads to immune response. As the significant inhibitory effect of H-/G- 
CMSCs/AMSCs CM on Jurkat T cells proliferation was observed from day 0-3 and cell growth 
resumed, the secretion of IL-2 was measured for a 3-day period. Jurkat T cells released 
sustainable levels of IL-2 and showed increased secretion over 3 days. In the first 24 hours 
after stimulating Jurkat T cells with PHA/PMA, IL-2 secretion did not show significant 
suppression by H-/G- CMSCs or AMSCs CM. However, the supernatant from activated Jurkat 
T cells cultured in H-/G- CMSCs CM contained significantly reduced levels of secreted IL-2 
on day 2 and 3. H-/G-AMSCs CM also suppressed IL-2 secretion but the suppressive effect 
was lower than that of H-/G-CMSCs CM (Figure 3-11C). 
The immunosuppressive capacity in H-CMSCs vs. G-CMSCs and H-AMSCs vs. G-AMSCs were 
rather comparable where no significant difference in inhibitory effect on Jurkat T cell 
proliferation and IL-2 secretion was observed. Healthy- and GDM- CMSCs showed a more 
pronounced effect on suppressing Jurkat T cell proliferation and diminishing the secretion 
of IL-2 than H-/G- AMSCs. 
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Figure 3-11. Suppression of T-cells proliferation and IL-2 secretion  
Jurkat T cells were cultured in the presence of Healthy- and GDM- CMSCs/AMSCs CM (A) 
without activating with PMA/PHA or (B) with 50 ng/ml PMA and 5 μg/ml PHA. Cell 
proliferative ability was measured by MTT assay in a 5-day period. #p < 0.001 H-/G-CMSCs 
vs. 10%FBS, ^p < 0.001 H-/G-AMSCs vs. 10%FBS (C) IL-2 secretion after PHA/PMA 
stimulation was measured by ELISA from day 0-3. Results were normalised to IL-2 secretion 
without PHA/PMA stimulation and presented as mean ± SEM of 5 independent experiments. 
Two-way ANOVA was conducted to determine the significant differences, continuous 
variable – days, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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3.4.6 Co-culture system of CMSCs/AMSCs and macrophage 
Distinct immunoregulatory properties of H-/G- CMSCs and AMSCs evaluated by 
macrophage modulation 
MSCs modulate immune cell function through a variety of mechanisms. In addition to T cell 
regulation, MSCs are also known to modulate macrophage-mediated inflammatory 
responses. Macrophages are key regulators of initiation and control of inflammation, and 
are typically divided into two types: classically activated type 1 macrophages (M1), 
characterised by the production of pro-inflammatory cytokines with an acute inflammatory 
phenotype, and alternatively activated type 2 macrophages (M2), secreting anti-
inflammatory cytokines and promoting wound healing256. THP-1 is a human immortalised 
monocyte-like cell line derived from an acute monocytic leukemia patient257.  
The secretome of MSCs has known to mediate immune responses and modulate 
macrophage population. Bone marrow MSC-derived soluble factors showed the ability to 
promote the conversion on monocytes or inflammatory M1 macrophage into anti-
inflammatory M2 macrophage258, 259. To investigate the immunomodulatory function of H-
/G- CMSCs’ and AMSCs’ secretome on macrophage polarisation, H-/G- CMSCs/AMSC were 
cultured in a co-culture Transwell with THP-1 monocytes without direct contact.  
Suspension-cultured THP-1 monocytes were differentiated into macrophages (M0) in the 
presence of PMA (PMA-THP1) where they adhere to the culture plate and can be further 
polarised into M1 or M2 macrophages. For M1 and M2 polarisation control260, PMA-THP1 
(M0) was activated by interferon-γ (IFN-γ) and lipopolysaccharide (LPS) in order to obtain 
inflammatory M1 macrophages while interleukin 4 (IL-4) was used to induce anti-
inflammatory M2 macrophages. To investigate H-/G- CMSCs/AMSCs paracrine effects on 
M0 macrophage polarisation, PMA-THP1 (M0) without any stimulation was seeded in the 
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lower chamber and co-cultured with H-/G- CMSCs or AMSCs in the upper Transwell inserted 
chamber (Figure 3-12). 
 
Figure 3-12. Schematic representation of macrophage polarisation 
A co-culture system of the macrophage polarisation procedure. THP-1 cells were pre-
treated with 50 ng/ml PMA for 24 hours to obtain M0 macrophage. For M1 and M2 
macrophage phenotype controls, M0 macrophages were stimulated with 20 ng/ml IFN-γ 
and 10 pg/ml LPS to obtain M1 polarisation while stimulated with 20 ng/ml IL-4 for M2 
polarisation. To examine the effect of H-/G- CMSCs’/AMSCs’ secretome on M0 polarisation, 
5 × 105 H-/G- CMSCs/AMSCs were seeded in an upper Transwell chamber and 5 × 105 M0 
macrophages were seeded in the lower chamber. After co-culture for 24 h, supernatant was 
collected from all samples for ELISA analysis, and RNA was extracted from H-/G- 
CMSCs/AMSCs-co-cultured M0 macrophages and M1/M2 controls for further 
characterisation of macrophage phenotypes.   
 
Following co-culture of H-/G- CMSCs or AMSCs with PMA-THP1, PMA-THP1 were collected 
to examine the macrophage polarisation through gene expressions. M1 macrophages are 
characterised by the expression of inflammation-related genes and the production of 
inflammatory cytokines. High level of inflammatory marker expression, including IL-1β, IL-
12, and CXCL8 were detected in IFN-γ/LPS-treated PMA-THP1, suggesting the induction of 
M1 polarisation (Figure 3-13A). When PMA-THP1 co-cultured with H-/G- CMSCs or AMSCs, 
 112 
 
there was no significant increase in inflammatory marker - IL-1β, IL-12, and CXCL8 
expression, compared to PMA-THP1 (M0) and M1 macrophages (Figure 3-13A). Notably, 
CXCL8 was significantly induced in PMA-treated THP1 (M0) while the expression was 
significantly suppressed after co-culturing with H-/G- CMSCs/AMSCs. Although the 
expression of CXCL8 was higher in H-/G- AMSCs-co-cultured than H-/G- CMSCs-co-cultured 
PMA-THP1, the expression levels were significantly lower than M1 macrophages controls. 
Thus, the data suggested that the secretome of H-/G- CMSCs and AMSCs did not promote 
M1 macrophage polarisation of THP1 cells.   
On the other hand, anti-inflammatory M2 macrophages are characterised by increased 
expression of IL-10, MRC1, and CCL-17 which were detected in IL-4 stimulated PMA-THP1, 
suggesting the induction of M2 polarisation (Figure 3-13B). High levels of M2 macrophage 
markers were also observed PMA-THP1 when co-cultured with H-/G- CMSCs or AMSCs, 
indicating that PMA-THP1 were polarising towards M2 phenotypes through the regulation 
of H-/G- CMSCs’/AMSCs’ secretome. PMA-THP1 co-cultured with H-/G- CMSCs expressed 
significantly higher levels of MRC1 and CCL-17 than co-cultured with H-/G- AMSCs, which 
suggested that H-/G- CMSCs had a more profound effect on promoting M2 marker 
expression in PMA-THP1 than H-/G- AMSCs. Moreover, no significant difference was 
detected in the ability to induce M2 macrophage polarisation in H-/G- AMSCs but in CMSCs 
higher MRC1 and CCL-17 expression could be observed when PMA-THP1 co-cultured with 
H-CMSCs than with G-CMSCs (Figure 3-13B). 
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Figure 3-13. Examination of M1/M2 marker expression in THP1 
THP1 monocytes polarisation was examined by M1/M2 marker gene expression. Apart of 
negative control (THP1), all groups were treated with PMA for 24 hours to induce M0 
macrophages. M1 phenotypes were further induced with IFN-γ and LPS while M2 
phenotypes were induced with IL-4. To examine the effect of H-/G- CMSCs/AMSCs on THP1 
polarisation, PMA-treated THP1 were co-cultured with H-/G- CMSCs/AMSCs for 24 hours 
and RNA from THP1 cell were extracted for gene expression analysis. All cells were cultured 
in the same basal media, 10% FBS DMEM. (A) M1 macrophage markers - IL-1β, IL-12, CXCL8 
and (B) M2 macrophage marker - IL-10, MRC1, CCL-17 expressions were examined by real-
time PCR. The values were normalised to GAPDH and fold changes were calculated by 
comparing to THP1 control. Each data shown represents mean ± SEM of 6 independent 
experiments. One-way ANOVA was conducted to determine the statistical significance, 
*p < 0.05, **p < 0.01, ***p < 0.001 relative to PMA-treated control.  
 
Macrophages exert their functions by releasing a series of cytokines to activate and recruit 
other immune cells during immune responses. Cytokines secretion bias the macrophage’s 
phenotypes towards M1 or M2 macrophage. M1 macrophages secrete pro-inflammatory 
cytokines TNF-α, IL-1β, IL-6, IL-12, IL-23 while M2 macrophages secrete high levels of 
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immunosuppressive cytokine IL-10 and also a little amount of pro-inflammatory cytokines. 
Supernatant from co-culture of PMA-THP1 and H-/G- CMSCs/AMSCs was collected to 
examine TNF-α and IL-10 release for identifying M1 or M2 phenotypes. No significant 
increase in TNF-α secretion (Figure 3-14A) was seen but an upregulation in IL-10 (Figure 3-
14B) was detected when co-culturing PMA-THP1 with H-/G- CMSCs or AMSCs. Comparing 
with M2 markers gene expression (Figure 3-13B), though H-/G- AMSCs co-cultured PMA-
THP1 expressed lower levels of M2 markers, the IL-10 secretion was comparable to H-/G- 
CMSCs co-cultured PMA-THP1. Overall, CMSCs and AMSCs derived from healthy or GDM 
placenta were equally capable of promoting PMA-THP1 towards M2 polarisation. The GDM 
environment did not significantly alter macrophage regulation ability in G-CMSCs and G-
AMSCs, compared to their healthy counterparts. 
 
Figure 3-14. Cytokines release by M1/M2 macrophages  
Cytokines secretion from PMA-THP1 in H-/G- CMSCs or AMSCs co-culture was examined by 
ELISA. Supernatant was collected after 24 h co-culture and measured the levels of TNF-α 
and IL-10 secretion. Each data shown represents mean ± SEM of 6 independent 
experiments. One-way ANOVA was conducted to determine the statistical significance, ***p < 
0.001. 
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3.5 Discussion 
The placenta, usually discarded after delivery, is a valuable source of plentiful perinatal 
MSCs for regenerative medicine without ethical concerns. Cell therapies using placental-
derived MSCs have already been applied to various disorders treatment in animal models261 
and some clinical trials, such as ischaemic stroke, Crohn’s disease, and idiopathic pulmonary 
fibrosis242, 262, 263. However, few studies have investigated differences in therapeutic 
potential of placenta-derived MSCs from women with pregnancy complications. In this 
study, we provided a thorough comparison of CMSCs vs. AMSCs and reported the effects of 
GDM environment on CMSCs and AMSCs biological properties.  
Biological characterisation of H-/G- CMSCs/AMSCs 
Derived from different layers of the same placental membrane, CMSCs and AMSCs show 
diverse cell biological characteristics. AMSCs have been widely studied as the clinical 
applications of amniotic membrane began several years ago. The isolation process of 
AMSCs has also been well-established; however, the role of CMSCs remained unclear until 
recent years. The observation of the reduced proliferation rate of AMSCs compared with 
CMSCs in our study is consistent with some recent reports. A study demonstrated the 
limited ex vivo expansion potential of AMSCs, where CMSCs were found to have higher 
proliferation ability than AMSCs and BM-MSCs264. Likewise, Araujo et al. compared the 
growth kinetics of amniotic (AMSCs), chorionic (CMSCs), placental decidua (DMSCs) and 
umbilical cord MSCs. They found the superior proliferation ability in CMSCs and DMSCs 
which were able to maintain a steady growth rate until passage 10 while AMSCs had a short 
lifespan, low doubling time, and were unable to expand after passage 5265. Indeed, we also 
noticed the difficulty in AMSCs expansion at late passages.  
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We further investigated differences in growth ability between GDM and healthy 
CMSCs/AMSCs via direct counting of viable cells and measurement of metabolic activity. It 
has been suggested previously that umbilical cord derived-MSCs from GDM women 
displayed decreased cell growth with early cellular senescence accompanied by the 
expression of p16 and p53266. Alternatively, Pierdomenico et al. described MSCs obtained 
from umbilical cord of both healthy and diabetic mothers where the later demonstrated 
an increased proliferative ability along with an upregulation of CD44, CD29, CD73, CD166, 
SSEA4 and TERT267. We found that GDM had distinct effect on CMSCs and AMSCs 
proliferation, where G-CMSCs displayed reduced rates when compared to H-CMSCs while 
G-AMSCs, by contrast, showed higher proliferation rates than H-AMSCs. As AMSCs are 
derived from the amniotic membrane adjacent to the fetus, the higher proliferation rate 
of diabetic AMSCs may reflect features of GDM including heavier fetal weights on resultant 
cell phenotype.  
Immunophenotypic analysis characterised H-/G- CMSCs/AMSCs surface marker expression 
(positive for CD90, CD73, CD105; negative for CD14, CD19, CD34, CD45 and HLA-DR). 
Overall, H-/G- CMSCs and AMSCs express similar levels of surface markers and all meet the 
minimal criteria for MSC definition. However, the surface protein expression proﬁle may 
vary depending on different MSC sources. The level of CD45 expression was higher in both 
G-CMSCs and G-AMSCs compared to healthy counterparts. CD45 is a transmembrane 
protein tyrosine phosphatase that regulates signal transduction in immune cells and mainly 
expressed on hematopoietic stem/progenitor cells (HSCs)268. CD45 also plays a role in 
regulating the motility of bone marrow progenitor cells and their retention. CD45 knockout 
bone marrow progenitors showed increased cell adhesion and defective motility, mediated 
by reduced matrix metalloproteinase 9 secretion and imbalanced Src kinase activity269. Our 
study showed that approximately 17% of G-CMSCs and 19% of G-AMSCs were positive for 
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CD45 expression. Although we were unclear whether higher CD45 expression in G-
CMSCs/AMSCs was associated with cell motility, the enhanced migration in ability in G-
CMSCs was demonstrated in chapter 5 via microarray analysis and in vitro migration assays. 
In fact, CD45 is a typical HSC marker but BM-MSCs can still express some degree of CD45 
under certain condition. The CD45 expression was found around 15% in BM-MSC derived 
from older donor at passage 1 while the expression decreased at later passage270. 
Approximately 15% of decidual MSCs271 and 17% of AMSCs272 shown positive for CD45 
expression were also reported in some studies. However, we performed 
immunophentyping at passage 3 and did not examine the possible expression change at 
later passage.  
GDM pregnancy and adipogenesis tendency in MSCs 
Emerging research has highlighted the importance of the intrauterine environment as a risk 
factor in the likelihood of offspring developing obesity and metabolic diseases273, 274. The 
underlying biological mechanism for the link between GDM and the increased risk of future 
diabetes is poorly understood, although the GDM environment has potential to modify the 
epigenetic state of fetal genes. Increased methylation of PYGO1 and CLN8 genes in offspring 
exposed to a GDM environment is proposed as being associated with long-term adverse 
effects on fetal health275, 276. GDM is associated with newborn hyperinsulinemia with effects 
on offspring fat mass seen until 6 weeks. Elevated preperitoneal adipose tissue in newborns 
is linked with increased risk of obesity in later life277. We found that the CMSCs and AMSCs 
differentiation potential are influenced by maternal environment during gestation. Under 
the same culture condition, elevated adipogenic differentiation was found in GDM-MSCs 
than with MSCs from healthy pregnancies. Moreover, higher basal expression levels of 
adipogenic transcription factors in G-CMSCs and subsequent lipid content associated with 
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increased transcription factor expression during differentiation indicated an enhanced 
adipogenic potential when compared to H-CMSCs and H-/G- AMSCs. This suggests that the 
GDM environment itself may have less of a role in affecting fetal cell properties than that 
of the membrane itself.  
In addition, although H-/G-CMSCs demonstrated adipogenic potential verified by 
substantial lipid droplet accumulation and increased adipogenesis-associated gene 
expression, the reduced expression in PPARγ and ADIPOQ was noticed on day 21. The 
adipogenic transcription factor, PPARγ plays a critical role in initiating adipogenesis and 
ADIPOQ is involved in adiponectin formation278. The reduced expression may reflect the 
loss of adipocyte phenotype. For instance, the deletion of PPARγ in adipose tissues 
contributed to impaired adipocyte function and maturation, adipocyte death, and reduced 
fat weights or lipodystrophy279, 280. On day 14 and 17, PPARγ and ADIPOQ showed high 
expression levels in differentiated H-/G- CMSCs, which may suggest the optimal induction 
period. Some studies demonstrated adipocyte maturation during 14-day adipogenesis 
protocols from bone marrow MSCs281, umbilical cord MSCs282, and placental MSCs283. As 
adipogenesis protocols for different cell types may vary from 14-21 days, our data might 
suggest that a 17-day culture period with adipogenesis media might be ideal for H-/G- 
CMSCs differentiation. However, it is still unclear whether H-/G- CMSCs differentiated into 
fully mature adipocytes or remained in immature state. To optimise the ideal differentiation 
protocol, it may benefit from the comparison between human adipocytes and MSC-
differentiated adipocytes at different time points during adipogenesis process. 
Immunosuppression of H-/G- CMSCs/AMSCs 
For successful clinical application of MSC therapy, the immunoregulatory potential of H-/G- 
CMSCs and AMSCs is an important area of consideration. The immune responses mediated 
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by T-cells may lead to cell transplant rejection or Graft-versus-Host disease284. MSCs have 
been reported to modulate the proliferation and function of immune cells by both cell-to-
cell contact and the secretion of growth factors, cytokines, and chemokines285. 
Immunosuppressive capacity of MSCs is a therapeutic option for the treatment of various 
immunological disorders. Given that the placenta plays a critical role in fetal-maternal 
tolerance and contains cells that display immunomodulatory properties, MSCs derived from 
placenta not only have superior immunomodulatory potential but also have therapeutic 
potential for the mothers and offspring286. In our study, H-/G- CMSCs and AMSCs displayed 
differential levels of immunosuppressive capacities in T-cell regulation. Both H-/G- CMSCs 
and AMSCs suppressed T cell proliferation while H-/G- CMSCs showed superior inhibitory 
effect than H-/G- ASMCs. The mechanism of MSCs suppressing T-cell proliferation has been 
widely investigated. BM-MSCs are able to inhibit T-cell proliferation through the induction 
of cell division arrest287, apoptosis via Fas ligand-dependent apoptotic pathway288, and 
blocking T cell effector function via contact-dependent interaction289. 
Moreover, T-cell mitogenic cytokine IL-2 is released upon T-cell activation. The suppressive 
effect of IL-2 production was more profound in H-/G- CMSCs CM than H-/G- ACMSC CM 
while GDM environment did not show significant alteration in CMSCs/AMSCs ability to 
supress T cell activation. IL-2 is associated with various immune responses, including T cell 
proliferation, survival, differentiation, supporting the activation of natural killer cells, and 
promoting activation-induced cell death290. The reduction of IL-2 secretion by MSCs 
suppresses immune reactions triggered by T cells and improves engraftment in cell 
transplant291. 
Apart from well-studied mechanisms of MSC-mediated T-cell activity, there is an increasing 
interest in MSCs immunomodulation on macrophages over the past few years. MSCs 
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involve in regulating innate immune response by modulating macrophage polarisation and 
inhibiting the secretion of inflammatory cytokines292, 293. M1 macrophage induced by 
intracellular pathogens, tissue damage and infection, is associated with inflammation, 
along with the secretion of inflammatory cytokines. M2 macrophages have high 
phagocytosis capacity, tissue remodelling ability, and involve in producing extracellular 
matrix (ECM) components and anti-inflammatory factor, IL-10. Transferring M2 
macrophages into autoimmune type 1 diabetes mouse models showed protection against 
inflammation and the transferred M2 macrophages homed to the inflamed pancreas, 
promoting β-cell survival294. The transplantation of MSCs into an in vivo model showed 
increased recruitments of M2 macrophages to the wound site and enhanced damaged 
tissue repair295. More and more evidences indicate the interaction between MSCs and 
macrophages recently, for instance, increased expression of M2 macrophage makers was 
observed following the injection of MSCs to rat infarct myocardium which was initially 
infiltrated with M1 macrophage296.  
In our finding, H-/G- CMSCs and AMSCs were evidenced to divert the differentiation of 
naïve macrophages (M0) into M2 phenotypes through a co-culture system, which also 
implied that CMSCs/AMSCs were able to regulate macrophage differentiation through their 
secretome functions without the need of direct cell-cell contact. Several soluble factors 
secreted by MSCs have been considered as mediators to regulate immune cells, such as IL-
6, prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and lactate297, 298. Moreover, 
some studies have demonstrated the possibility of MSCs-mediated macrophage activation 
shift from M1 to M2 phenotypes296. BM-MSCs attenuated M1 macrophage function with a 
concomitant shift towards M2 state through the alteration in AMPK and mTOR pathway 
activities299. These findings could be beneficial for the treatments of inflammatory diseases 
such as rheumatoid arthritis, asthma, or fibrosis where M1 macrophages play a vital role in 
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disease progression. 
Although H-/G- CMSCs and AMSCs were capable of promoting M2 polarisation, the higher 
expression of MRC1 and CCL17 were found in H-/G- CMSCs than H-/G- AMSCs co-cultured 
macrophages, particularly the highest expression in H-CMSCs. MRC1 (C-type mannose 
receptor 1), also known as CD206, is a typical M2 macrophage marker which binds to 
glycoproteins and collagen ligands. A recent study showed that CD206+ M2-like 
macrophages in adipose tissues created a microenvironment that inhibited growth and 
differentiation of adipocyte progenitors. In the in vivo mouse model, the reduction in the 
numbers of CD206+ M2-like macrophages resulted in a down-regulation of TGFβ signalling, 
together with upregulated adipocyte progenitors differentiation300. M0 macrophages under 
H-CMSCs co-culture displayed significantly upregulated levels of CD206 expression than G-
CMSCs co-cultured macrophages. The increased adiposity in GDM pregnancy may 
somehow reflect the significantly lower CD206 expression in G-CMSC-induced than H-
CMSC-induced M2 macrophages. However, immune functions of CD206 has not yet fully 
understood while CD206 is also involved in migration, pro-inflammatory cytokine secretion, 
and fetal-maternal immunological tolerance301. Besides, CCL-17 and IL-10 released by M2 
macrophage are known to have a critical role in inhibiting M1 macrophage polarisation302. 
Although CCL-17 was lower in M2 macrophage under H-/G- AMSCs than H-/G- CMSCs co-
culture, the secretion of IL-10 was comparable in all groups. 
Notably, the GDM environment had no significant effects on the immunosuppressive ability 
of MSCs in all aspects. Despite an increase in M2 marker expressions after co-culturing 
PMA-THP1 with H-CMSCs, which might suggest a better macrophage modulation potential 
in H-CMSCs than G-CMSCs, G-CMSCs showed a comparable ability in regulating Jurkat T 
cells activity and modulating cytokine secretion. Likewise, the responses from Jurkat cells 
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treated with G-AMSCs conditioned media or macrophages co-cultured with G-AMSCs were 
similar to the results from H-AMSCs. 
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3.6 Summary 
In summary, human placenta is comprised of several stem cells niches that mostly originate 
from extraembryonic tissue, and connect to maternal tissues, which may be a promising 
autologous source for cell therapy in both the mother and her offspring. Bone marrow 
MSCs isolated from elder donors have been reported to have reduced biological activity, 
thus leading to poor therapeutic potential303. Insufficient numbers of MSCs or impaired 
MSCs function from patients with rheumatoid arthritis and diabetes, respectively, have also 
been reported 304, 305. Therefore, an understanding of MSC behaviours under different 
growth environment is essential. In this study, we provide a comparison between CMSCs 
and AMSCs from healthy and GDM placenta, and evaluate the biological characteristics of 
both. CMSCs and AMSCs have distinct biological properties. The superior proliferation, 
differentiation and immunomodulatory properties in CMSCs than AMSCs make them a 
promising alternative source for autologous cell transplantation. In addition, we 
demonstrated the importance of the maternal GDM intrauterine environment and its 
differential effects on CMSCs and AMSCs 
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Generation of insulin producing cells 
from Healthy- and GDM- AMSCs/CMSCs 
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4.1 Introduction 
Women with a history of GDM have an increased risk of developing type 2 diabetes 
postnatally compared with women without previous GDM. Roughly 5-10 years following on 
from a GDM-affected pregnancy approximately half of these women are diagnosed with 
type 2 diabetes34, 37. GDM is associated with gestational programming in the fetus and may 
predispose offspring to an increased incidence of childhood obesity and impaired glucose 
tolerance, leading to type 2 diabetes later in life306, 307. Evidence has demonstrated a 
positive correlation between GDM and the risk of developing type 2 diabetes in women 
with a history of GDM, as well as children from GDM pregnancies308, 309. 
Patients with type 2 diabetes require lifelong anti-diabetic drug or insulin treatment. 
However, neither of these either reverse the disease or correct the beta cell dysfunction310, 
311. Transplantation of cadaveric islet cells has therefore become a promising therapeutic 
strategy for diabetes, and though first conducted in 1999312 a shortage of donors and 
immune rejection have limited its clinical usage. Nowadays, mesenchymal stem cells (MSCs) 
which possess a multi-lineage differentiation potential coupled to immunomodulatory 
properties offer an alternative to β-cell replacement therapy313.  
IPC generation protocols 
Several studies have reported the generation of insulin-producing cells (IPCs) from adult 
tissue-derived MSCs, such as bone marrow314, 315, adipose tissue210, and liver316. However, 
these existing approaches lack a consistent protocol applicable to all source of MSCs317. The 
IPC differentiation method was originally developed from mouse embryonic stem cells 
(mESCs)318 and then modified for generating IPC from human ESCs (hESCs)319. The 
successive exposure of hESCs to different growth factors and small molecules in order to 
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mimic the environment during pancreagenesis in vivo has successfully generated 
endocrine-like tissue from hESCs. Figure 4-1 lists a variety of multistep procedures to induce 
differentiation of hESCs into IPCs.  
Due to the limited availability and ethical concerns of using hESCs, some studies have 
modified and applied IPC generation method to bone-marrow MSCs (BM-MSCs). However, 
a major limitation of MSCs derived from adult tissues is that they are considered more likely 
to differentiate toward mesenchymal lineages due to their mesodermal origin, while β-cells 
are of endodermal origin320. Inducing definitive endoderm is an essential step for IPCs 
generation. To do this, activin A is commonly used for definitive endoderm formation321 
although administration concentrations may vary depending on different conditions. Other 
challenges include the low generation rate of IPCs from BM-MSCs or the immature state of 
the IPCs where they fail to release insulin322, 323. 
MSCs from fetal origins, such as placenta and amniotic fluid, on the other hand have been 
demonstrated to express endoderm lineage and embryonic markers324, 325. This is 
suggestive of a less restricted potency of fetal-related tissue derived MSCs and a potentially 
broader differentiation potential.  
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Figure 4-1. Time lines of multistep procedures for IPC differentiation. 
Various protocols to induce IPC differentiation from hESCs. ActA, Activin A; bFGF, basic fibroblast growth factor; BMP4, bone morphogenetic 
protein 4; CM, conditioned media; DAPT, γ-secretase inhibitor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IGF1/2, insulin-
like growth factor 1/2; KGF, keratinocyte growth factor; MEFs, mouse embryonic fibroblast feeders; Nic, nicotinamide; RA, retinoic acid. 
Reprinted from Van Hoof et al., 2009319
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A common feature of the various strategies described for the differentiation of MSCs into 
IPCs is a high glucose culture environment326, 327. During pancreatic islet development 
multiple stimuli are required including hormones, growth factors, and nutrients328. Within 
all these stimulators, glucose is suggested to play an important regulatory role in β-cell 
growth, survival, and proliferation329. In the human body, elevated blood glucose level is a 
primary activator of β-cell expansion in situations where β-cell compensation is required 
due to increased metabolic demand330. A glucose concentration of 20-30-mM was sufficient 
to significantly enhanced β-cell replication in both in vitro and in vivo models331. With 
human bone marrow MSCs a culture environment containing 23.3 mM glucose for 15 days 
was shown to stimulate expression of pancreatic-related genes; PDX1, PAX4, GLUT2, and 
INS and induce the formation of β-cell precursors332. Collectively, glucose seems to be an 
essential factor for IPC generation. GDM-CMSCs/AMSCs are under prolonged exposure due 
to hyperglycaemia during pregnancy, the suitability of the high glucose concentration, 
applied in many IPC differentiation protocols, used to mimic the β-cell development 
environment, for GDM-CMSCs/AMSCS remains to be determined. 
Makers for beta-cell maturity 
A human islet cluster contains not only insulin-secreting β-cells but also several endocrine 
cell types which secrete different hormones, including α-cells, δ-cells, PP-cells, and ε-cells 
that express glucagon, somatostatin, pancreatic polypeptide, and ghrelin, respectively333. 
Given the common origin and the similar environment for these pancreatic cells 
development, the examination of marker expressions is hence useful for identifying 
different pancreatic cell types and staging the differentiation of MSCs to β-cells whether in 
vivo or in vitro. The expression of pancreas-associated transcription factors at intermediate 
developmental stages are shown in Figure 4-2. Some of the markers used in this chapter 
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are described in detail below. 
The expression of transcription factor neurogenin 3 (NGN3 or NEUROG3) induces endocrine 
lineage development and functions as an activator of several endocrine gene transcriptions 
in progenitor cells334. The NGN3 expression peaks at endocrine stage and reduces in mature 
β-cells335. Insulin gene enhancer binding protein-1 (ISL1) is one of the endocrine lineage 
markers that controls the proliferation and survival of endocrine cells during islet 
developmental stage336. ISL1 also involves in cell fate specification regulating the endocrine 
cells lineage commitment into different pancreatic cell subtypes337.  
With regard to pancreatic development, insulin promoter factor 1 (PDX1) is the most 
studied marker, expressed during early development of endocrine cells and sustained 
presence in mature islets319. PDX1 is involved in several regulations of β-cell function and 
survival. The deficiency of PDX1 is associated with pancreatic agenesis, β-cell dysfunction, 
and increases cell death and diabetes both in rodent and human338. The transcription factor 
paired box protein PAX6 is generally expressed in terminally differentiated endocrine cells 
in the process of developing into pancreatic hormone-producing cells339. Both PAX6 and 
PDX1 are crucial for insulin synthesis in β-cells through the transcriptional regulation of 
insulin gene340, 341.  
The insulin (INS) and major glucose transporter GLUT2 are expressed in mature β-cells and 
essential for glucose stimulated insulin secretion (GSIS). The genetic inactivation of GLUT2 
significantly suppressed glucose uptake and GSIS pathways342, suggesting an important role 
of GLUT2 in glucose sensing and homeostasis343. 
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Figure 4-2. Defined transcription factors for pancreatic development  
Different cell types in pancreatic islets are derived from a common precursor. The 
developmental stages are marked by expression of a number of pancreas-associated 
transcription factors. Reproduced from Van Hoof et al., 2009319 
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4.2 Aim 
Given that both the woman and child from a pregnancy affected by GDM have an increased 
risk of developing diabetes, autologous AMSCs and CMSCs provide a potentially valuable 
source as a cell therapy. In an attempt to establish a therapeutic use potential of autologous 
placental membrane-derived MSCs for diabetes treatment, we aimed to establish a feasible 
approach for the generation of IPCs from CMSCs/AMSCs and determine the role, if any, of 
GDM in this capacity. 
The main objectives of the chapter: 
 Investigate high glucose culture effect on H-/G- CMSCs and AMSCs 
 Establish a step-wise approach for IPC generation from H-/G- CMSCs/AMSCs 
 Characterise H-/G- CMSC/AMSC derived IPCs via morphological changes, marker 
expression, and insulin release. 
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4.3 Methods  
All maternal and fetal details of placentas used in this chapter were described in chapter 2 
section 2.2. Pluripotent marker expression of CMSCs and AMSCs were analysed by real-time 
PCR for pluripotent gene expressions (section 2.8) and performed with all placenta samples. 
For high glucose effect investigation, healthy samples used for analysis were from 
Healthy03, 06, 07, 08 and GDM samples were from GDM05, 06, 07, 08 (Table 2-1). Prior to 
high glucose exposure, Healthy- and GDM- CMSCs/AMSCs were cultured in 5.5 mM glucose 
DMEM supplemented with 10% FBS, 1% L-glutamine, 1% NEAA and 1% Penicillin-
Streptomycin from passage 0-3. At passage 3, media were switched to 25 mM glucose 
DMEM. Cells were cultured for indicated periods (10, 20, 30 days) and then examined for 
cell death/survival by cell viability assay (section 2.11) and cellular senescence by β-
galactosidase activity assay (section 2.12). 
For three-stage IPC differentiation protocol development, 6 healthy samples (Healthy03, 06, 
07, 08, 10, 11) and 7 GDM samples (GDM03, 04, 05, 06, 07, 08, 10) were used. Molecules 
and growth factors used in differentiation protocols are described in detail in section 4.4.4. 
Briefly, cells at passage 3 were pre-cultured in 25 mM glucose DMEM for 10 days and then 
trypsinised, re-suspended in stage 1 differentiation media, and seeded at a density of 1 x 
106 cells/well in a six-well plate. For stage 1, cells were cultured in serum-free 17.5 mM 
glucose DMEM/F12 that contained 1% BSA, 50 μM 2-mercaptoethanol, 1mM sodium 
butyrate, and 50 ng/ ml activin A for 3 days before adding 2 μM retinoic acid to the media 
and culturing for an additional 3 days. At stage 2, cell media was switched to DMEM/F12 
containing 1% BSA, 20 ng/ml EGF and 0.3mM taurine for 3 days. At stage 3, 10 mM 
nicotinamide and 50 nM glucagon-like peptide (GLP)-1 were added to stage 2 media to 
induce IPC maturation and insulin formation, and 1% NEAA were added to support cell 
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growth. Cell were cultured in stage 3 media for another 7 days. To further induce AMSC-
IPCs maturation, exendin-4 and betacellulin known to induce insulin secretion were used at 
stage 3 to replace GLP-1. The purpose of exendin-4 or betacellulin supplementation is 
described in result section 4.4.5.  
IPC characteristics were assessed by cell morphological observation (section 2.4.2), 
pancreatic marker examination through real-time PCR (section 2.8), immunofluorescence 
staining (section 2.13), and ELISA (section 2.10.2). The experimental flow and methodology 
adopted in this chapter are summarised in Figure 4-3. 
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Figure 4-3. Summary of the methodology in chapter 4 
Statistical analysis 
The percentage of SA-β-gal-positive cells, cell viability, real-time PCR results of IPCs marker 
expression, and ELISA for protein secretion were compared using one-way ANOVA and 
Tukey post-hoc tests. 30-day high glucose treatment on pancreatic gene expression changes 
were analysed by two-way ANOVA to determine the statistical significance among different 
groups, p-value below 0.05 was considered significant. Analysis was performed using 
GraphPad Prism (GraphPad Software). The data was presented as mean ± SEM. 
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4.4 Results  
4.4.1 Pluripotent markers expression 
Transcription factors which help to maintain the pluripotent state in stem cells include 
NANOG, SOX2, and OCT4. These are highly expressed in undifferentiated embryonic stem 
cells (ESCs) and provide an indication of the capacity of self-renewal, proliferation, survival, 
and multi-lineage differentiation potential. The expression of pluripotent markers is usually 
low in adult tissue-derived MSCs and gradually decreases further as the passage number 
increases344. The gene expressions of NANOG, SOX2, and OCT4 in H-/G- CMSCs/AMSCs were 
examined and compared to ESCs and BM-MSCs.  
ESCs expressed significantly higher levels of NANOG and OCT4 than BM-MSCs. Similarly, 
placental MSCs (H-/G- CMSCs/AMSCs), NANOG and OCT4 expression were also significantly 
lower than ESCs. The NANOG expression in H-/G- CMSCs and AMSCs was comparable and 
significantly higher compared to BM-MSCs (Figure 4-4A). Likewise, the placental MSCs 
expressed significantly higher levels of OCT4 than BM-MSCs; in addition, G-AMSCs showed 
an increased OCT4 expression than H-AMSCs (Figure 4-4B). 
Placental MSCs expressed high levels of SOX2, particularly in H-/G- CMSCs which showed 
significantly increased SOX2 expression than in H-/G- AMSCs, ESCs, and BM-MSCs (Figure 
4-4C). Overall, H-/G- CMSCs and AMSCs showed higher level of NANOG, SOX2, and OCT4 
than BM-MSCs which may indicate a broader differentiation capacity. 
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Figure 4-4. Pluripotent marker expression 
Gene expression levels of pluripotent markers – NANOG, OCT4, and SOX2 in H-/G- CMSCs 
and AMSCs compared with embryonic stem cell line (SHEF2) and BM-MSCs. Results 
represent mean ± SEM. One-way ANOVA was conducted to determine the significant 
differences, *p< 0.05, **p < 0.01, ***p < 0.001. ESCs, embryonic stem cells; BM-MSCs, bone 
marrow MSCs, NANOG, nanog Homeobox; OCT4, octamer-binding transcription factor 4; 
SOX2, SRY (sex determining region Y)-box 2.  
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4.4.2 High glucose effect on H-/G- AMSCs/CMSCs 
Prolonged exposure of CMSCs/AMSCs to high glucose culture induces morphological 
changes, premature senescence , and decreased cell viability 
As glucose concentration is crucial for β-cell growth, replication, and widely used in the IPC 
generation process, we investigated the effect of high glucose on H-/G- CMSCs/AMSCs as a 
first step in determining a suitable environment for IPC differentiation from placental MSCs. 
CMSCs and AMSCs were cultured in high glucose (HG) DMEM (25 mM) and low glucose (LG) 
DMEM (5.5 mM) media containing 10% FBS for a 30-day period. H-CMSCs cultured under 
HG conditions began to form condensations after day 20 where the number and dimension 
of cell condensations continued to increase until day 30. Similar, though less pronounced, 
changes were also observed in G-CMSCs under the same conditions whereas no apparently 
morphological change was observed after 10-day HG culture in either H-CMSCs or G-CMSCs 
(Figure 4-5). 
H-/G- AMSCs demonstrated less obvious morphological changes in HG culture. Some small 
cell condensations were detected in H-AMSCs whereas no distinguishable difference in 
morphology of G-AMSCs was observed during the 30-day culture period in either HG or LG 
conditions (Figure 4-5). 
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Figure 4-5. Morphological changes in HG culture 
H-/G- CMSCs/AMSCs were cultured in 5.5 mM glucose DMEM until passage 2 and then 
exposed to 25 mM glucose (HG) DMEM to investigate the effect of glucose on 
morphological changes. Controls were maintained in 5.5 mM glucose (LG) DMEM. Phase 
contrast images of H-/G- CMSCs/ASMCs in HG culture over 10, 20, 30 days. H-/G- 
CMSCs/AMSCs in LG condition showed steady growth in the same time period and 
remained adherent fibroblast-like morphology. Representative image was from one of four 
independent experiments. Scale bar, 200 μm; HG, high glucose; LG, low glucose. 
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In addition, live/dead fluorescence staining indicated that long-term HG exposure 
contributed to significantly reduced cell viability. Intracellular esterase activity discriminates 
live from dead cells by staining with calcein-AM (green) while ethidium homodimer-1 (red) 
indicates dead cells with loss of plasma membrane integrity. The reduced cell viability was 
observed in H-CMSCs and G-CMSCs under HG culture for 20 and 30 days. (Figure 4-6A). 
Viable H-CMSCs percentage declined from 97.7 ± 2.1% on day 20 to 90.6 ± 3% on 30 while 
viable G-CMSCs were also reduced with the percentage of 93.5 ± 3.6% and 87.8 ± 2.5% on 
day 20 and 30, respectively. There was no significant difference in decreasing rate of cell 
viability between H-CMSCs and G-CMSCs.  
Likewise, H-AMSCs and G-AMSCs exposed to HG concentration resulted in lower viable cell 
numbers when compared with LG control (Figure 4-6B). Significant reductions in H-/G- 
AMSC viability was observed from day 20-30 with the percentage decreasing from 93.2-
80.6% in H-AMSCs and 92.5-77.8% in G-AMSCs. The reduction was more marked in H-/G- 
AMSCs than CMSCs. Although HG culture contributed to significantly reduced cell viability, 
H-/G- CMSC and AMSC viability was maintained around 99-100% in 10-day HG culture. 
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Figure 4-6. Decreased cell viability in HG culture  
Left panel: Fluorescent images of the viable or dead H-/G- CMSCs/AMSCs using calcein-AM (green, alive cells) and ethidium homodimer-1 (red, 
dead cells) Scale bar, 400 μm. Right panel: the mean percentage of live and dead cells calculated from 3 independent experiments.  
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Cellular senescence is considered as an irreversible cellular state of growth arrest. HG was 
noted to induce senescence in H-/G- CMSCs and AMSCs with increased incubation time. 
The staining of senescence-associated-beta-galactosidase (SA-β-Gal) activity is used to 
identify the occurrence of senescence345. Significantly elevated SA-β-Gal was first detected 
after 20 days of HG culture in G-CMSCs rising to approximately 30% of cells by day 30. On 
the other hand, significant elevation of SA-β-Gal was only seen at day 30 in H-CMSCs with 
around 15% of the population staining positively (Figure 4-7A and C). G-CMSCs showed an 
earlier and more profound HG-induced senescence response than H-CMSCs on both day-
20 and day-30 HG culture.  
H-AMSCs and G-AMSCs both displayed elevated SA-β-Gal from day 10 onwards with 
markedly elevated and significant increases seen thereafter (Figure 4-7B). A greater number 
of senescent cells were detected in G-AMSCs than in H-AMSCs from day 20 onwards 
reaching 75% by day 30 vs. 55% with H-AMSCs (Figure 4-7C).  
Prolonged HG culture contributed to higher levels of SA-β-Gal staining in GDM- than 
Healthy- CMSCs/AMSCs. However, this did not occur in LG culture with SA-β-Gal activity in 
H-/G- CMSCs remaining unchanged during the culture period while an increase in SA-β-Gal 
activity was observed in H-/G- AMSCs on day 30 (Figure 4-7C). 
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Figure 4-7. Cellular senescence in HG culture  
(A and B) Representative images of cellular senescence was examined on day 10, 20, 30 in 
both HG and LG culture. Senescent cells showed positive staining of SA-β-Gal. Scale bar, 
200μm. (C) Quantification of SA-β-Gal-positive cells. The SA-β-Gal-positive cells of 100 
random cells was counted from at least three images of each sample (n=3) using phase-
contrast microscopy. Data are expressed as mean ± SEM. Statistical significance were 
calculated by one-way ANOVA, ***p<0.001  
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4.4.3 High glucose induces pancreatic lineage markers  
MSCs exposed to HG condition has been suggested to induce endocrine lineage markers 
expression and promote β-cell differentiation346. Thus, the expression of pancreatic lineage 
genes (NEUROG3, PDX1, INS) under HG culture were examined by real-time PCR. The fold 
changes of genes were calculated by comparing with the expression level on day 0 and the 
significant upregulation was compared to LG-Day30.  
When exposing H-/G- CMSC to HG condition for 10 days, there was an induction in PDX1 
(Figure 4-8A) and NEUROG3 (Figure 4-8B) expression. PDX1 expression in H-CMSCs was 
significantly elevated at day 10 and gradually increased until day 30. NEUROG3 expression 
in H-CMSCs was also significantly elevated at day 10 and thereafter. G-CMSCs similarly 
displayed upregulated PDX1 and NEUROG3 expression at day 10 but which both then 
declined with continued culture. HG-cultured H-AMSCs and G-AMSCs had similar 
expression patterns of NEUROG3 and PDX1. PDX1 and NEUROG3 in H-/G- AMSCs were both 
significantly increased after initial HG culture with both undergoing reductions across the 
remaining time course (Figure 4-8A and B). Moreover, mature β-cell marker, insulin (INS) 
expression was examined (Figure 4-8C). The expression of INS showed no increase in G-
CMSCs and H-/G-AMSCs over the 30-day HG culture period; however, H-CMSCs had an 
approximately 5-fold increase in INS expression. Taken together this is suggestive that while 
HG culture was inductive for pancreatic lineage differentiation conversion of H-/G- CMSC 
and AMSCs into mature insulin producing cells (IPCs) required additional factors. 
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Figure 4-8. Pancreatic markers expression in HG culture 
Gene expression (NEUROG3, PDX1, INS) was analysed by real-time PCR at day 10, 20, and 
30 of HG culture. The expression was normalised to GAPDH and the fold change was 
calculated by comparing to the expression level on day 0. There was no change in PDX1, 
NEUROG3, and INS expression under LG culture in each group. Data are expressed as mean 
± SEM of 4 independent experiments. One-way ANOVA was used to determine statistical 
significance, *p< 0.05, **p< 0.01, ***p< 0.001 
 145 
 
4.4.4 Stepwise differentiation and IPC morphology 
A three-stage differentiation protocol for reprogramming H-/G- CMSCs and AMSCs into 
IPCs after high glucose pre-culture  
HG culture promoted formation of H-/G- CMSC condensations and while H-CMSCs 
displayed elevated pancreatic β-cell marker, G-CMSCs did not. Further, neither H-AMSCs 
nor G-AMSCs formed condensations or displayed upregulated β-cell markers. Long-term 
HG culture resulted in cell death and accelerated cellular senescence; however, the critical 
transcription factors for β-cell development were induced after 10-day HG culture. 
Therefore, we primed H-/G- CMSCs and AMSCs in 25mM glucose media for 10 days and 
sequentially stimulated cells with small molecules and growth factors to induce IPC 
maturation.  
To induce definitive endoderm cell populations were then switched into a 17mM glucose 
DMEM/F12 containing bovine serum albumin (BSA), sodium butyrate, 2-mercaptoethanol 
base media for 3 days with Activin A347 followed by 3 days with Retinoic Acid348. The base 
media was used to protect against cellular stress induced by serum free media and promote 
chromatin rearrangements349, 350. Next, cells were cultured for a further three days in 
DMEM/F12 supplemented with BSA, EGF and Taurine. EGF was used to enhance the growth 
of endocrine progenitor cells and Taurine, a beta-sulfonic acid, was known to induce insulin 
production and release at different concentrations in pancreatic beta cells in vitro culture351 
as well as type 1 diabetic and obese-induced diabetic mouse models352. It has been 
suggested that using Taurine at low concentration promoted pancreatic specialisation in 
endocrine lineage cells317, 353, 354. Thus, Taurine was used at 0.3 Mm at stage II media and 
increased to 3 mM at stage III with the additional supplementation of GLP-1, nicotinamide, 
and NEAA to induce the maturation and proliferation of IPCs355, 356 (Figure 4-9A). GLP-1, 
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with many important physiological functions in fetal beta-cell development, insulin 
synthesis, and secretion357 has been widely used in IPC differentiation protocols, including 
embryonic stem cells358 and bone-marrow MSCs359 while the supplement of 10 mM 
nicotinamide was showed to increase the function of GLP1 in insulin production355.   
H-CMSCs and G-CMSCs were seeded and grown in adherent monolayers for HG pre-
treatment before stimulating with IPC differentiation media. After the exposure to stage 1 
differentiation media, H-/G- CMSCs formed small condensations which seemed to loosen 
but yet to detach from the substrate. The subsequent incubation with stage 2 
differentiation media promoted suspension cell clusters formation in both H-CMSCs and G-
CMSCs. In stage 3 increased dimension and mass of spheroid clusters was accompanied by 
detachment from the substrate and continued culture as organoids. H-CMSCs and G-CMSCs 
had similar morphological changes at each stage of the differentiation process (Figure 4-
9B).  
In contrast, H-/G- AMSCs cultured under the same differentiation condition displayed 
evidence of condensation formation during stage 1 and 2 whereas the adherent 
condensations showed no sign of detaching. The increasing size of condensations was 
observed at subsequent differentiation stages, along with some single cells suspending in 
the media. Suspension cells were collected during media change and transferred to a new 
culture plate; however, these cells did not grow, form clusters, or re-attach to culture plate. 
The suspension H-/G- AMSCs observed during IPC differentiation from were removed with 
differentiation media change. At the end of 3-stage differentiation process, H-/G- AMSCs 
still remained adherent without any detached spheroid formation (Figure 4-9B).  
 147 
 
 
Figure 4-9. Optimised IPC differentiation approach and IPC morphology 
(A) Differentiation scheme for IPC generation illustrates the growth factors, small molecules, 
and incubation time at each stage. BSA, bovine serum albumin; 2-ME, 2-mercaptoethanol; 
EGF, epidermal growth factor; GLP-1, glucagonlike peptide-1; NEAA, non-essential amino 
acids; IPC, insulin-producing cell. (B) Morphological changes during IPC differentiation. 
Control images were undifferentiated H-/G- CMSCs/AMSCs cultured in complete growth 
media (5.5 mM glucose DMEM containing 10% FBS) which remained fibroblast-like 
morphology. The image was a representative image of six independent experiments (scale 
bar, 200 μm). 
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4.4.5 Expression of pancreatic markers expression 
H-/G- CMSC-IPCs exhibited high level of pancreatic lineage markers whilst the lack of 
mature beta-cell markers in H-/G-AMSC-IPCs was improved by betacellulin  
To determine whether H-/G- CMSCs/AMSCs were programmed into endocrine hormone-
producing cells, pancreatic lineage marker expression was examined by real-time PCR. The 
differentiated H-/G- CMSCs and AMSCs showed evidence of IPC differentiation by the 
expression of endocrine progenitor markers (NEUROG3, ILS1) and pancreatic lineage 
transcription factors (PDX1, PAX6). Gene expression was examined at the end of 3-stage 
differentiation process and the increased fold changes of each gene were calculated by 
comparing to undifferentiated H-/G- CMSCs/AMSCs.  
NEUROG3 and ILS1, promoting endocrine lineage differentiation, expression was noted in 
H-/G-CMSC-IPCs and showed comparably upregulated levels in both healthy and GDM 
group with approximately 13-fold increase in NEUROG3 and 10-fold in ILS1. The 
upregulation of NEUROG3 and ILS1 displayed significantly enhanced levels in H-/G-AMSC-
IPCs vs. H-/G-CMSC-IPCs. H-AMSC-IPCs and G-AMSC-IPCs both showed an 18-20-fold 
increase in NEUROG3 and ILS1 expression (Figure 4-10A).  
Pancreatic lineage differentiation and β-cell development transcriptional markers, PAX6 
and PDX1, were also significantly induced in differentiated groups. H-CMSC-IPCs expressed 
higher level of PAX6 induction than G-CMSC-IPCs while the expression of PAX6 in H-AMSC-
IPCs and G-AMSC-IPCs were comparable. Notably, there was a significantly increased 
expression of PDX1 in H-/G-AMSC-IPCs compared with H-/G-CMSC-IPCs (Figure 4-10B).  
The induction of endocrine progenitor and pancreatic lineage markers was previously 
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shown to be enhanced in 10-day HG culture without further stimulation by any compounds. 
The 3-stage differentiation protocol did not enhance the induction of these markers in H-
/G- CMSCs but had a significant effect on promoting H-/G- AMSCs pancreatic markers 
expression. However, the 3-stage differentiation protocol was intended to promote the 
maturation of IPCs that failed to achieve in HG culture. 
Mature β-cell markers, INS and GLUT2 were examined by real-time PCR. Significantly 
elevated expression of INS and GLUT2 were observed in H-/G- CMSC-IPCs (vs. H-/G- AMSC-
IPCs) with approximately 30-fold and 10-15-fold induction, respectively. On the other hand, 
H-/G-AMSC-IPCs expressed significantly lower levels of mature β-cell marker expression. 
The expression of both INS and GLUT2 displayed no significant changes vs. undifferentiated 
H-/G- AMSCs (Figure 4-10C).  
Direct comparison of IPCs generated from GDM- and Healthy- CMSCs established that, with 
the exception of PAX6 which was lower in G-CMSC-IPCs, both expressed comparable level 
of progenitor and, pancreatic transcription factors, and mature β-cell genes. Given the level 
of endocrine progenitor markers expression (NEUROG3, ISL1, and PDX1) and β-cell markers 
(INS and GLUT2) in H-/G- AMSC-IPCs vs. CMSC-IPCs it remains possible that the IPCs derived 
from H-/G- AMSCs may reflect an immature β-cell state.  
 150 
 
 
Figure 4-10. Induction of pancreatic markers by IPC differentiation protocol 
Gene expression was analysed by real-time PCR. The relative expression level of (A) 
endocrine progenitor markers, NEUROG3 and ILS1 (B) pancreatic lineage transcription 
factors, PDX1 and PAX6 (E) mature β-cell makers – INS and GLUT2, were normalised to 
GAPDH and compared with undifferentiated CMSCs/AMSCs. Data are expressed as mean ± 
SEM of 6 independent experiments. One-way ANOVA was used to determine statistical 
significance, *p< 0.05, **p< 0.01, ***p< 0.001. 
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The basal induction of mature β-cell marker expression in H-/G- AMSC-IPCs was 
inconsistent with endocrine and pancreatic lineage gene expression. To explore induction 
further we explored additional supplementation with three molecules to improve their 
maturation; GLP-1, Exendin-4, and Betacellulin. GLP-1 was incorporated at Stage III of our 
original protocol (at the concentration of 50 nM) to promote IPC maturation Both exendin-
4, a synthetic stable GLP-1 analogue, and betacellulin, a member of the epidermal growth 
factor family, have been demonstrated to improve β-cell maturation, proliferation and 
increase insulin content360, 361. Dosage used in the screening was based on literature finding.  
Figure 4-11 showed the result of INS and GLUT2 expression in H-/G- AMSC-IPCs when 
replacing GLP-1 with exendin-4 or betacellulin at stage 3. GLP-1 induced INS expression with 
an approximately 5-fold increase in H-/G- AMSC-IPCs compared to undifferentiated AMSCs 
while the induction showed no dose-dependent effect on INS expression levels. There was 
no significant induction of GLUT2 expression under either 50 nM or 100 nM GLP-1 
supplementation.  
Exendin-4 at the concentration of 10 nM was reported to induce insulin expression in 
umbilical cold MSCs362. We showed that the induction of INS expression showed a 5-fold 
increase in H-/G- AMSC-IPCs vs. undifferentiated AMSCs at 10 nM exendin-4 
supplementation while there was no dose-dependent effect with higher exendin-4 
concentration. Exendin-4 at 10 nM induced GLUT2 expression in H-AMSC-IPCs but no effect 
on GLUT2 expression in G-AMSC-IPCs.  
Betacellulin was used in many IPCs differentiation protocols, including bone-marrow MSCs, 
embryonic stem cells, and umbilical cord MSCs at various concentrations363-367. Whilst 1 nM 
betacellulin was the most common concentration used in literature, we investigated the 
effect of betacellulin at the concentration of 1 and 2 nM on H-/G-AMSC-IPCs maturation. 
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The expression of INS and GLUT2 was significantly improved by 1 nM betacellulin and with 
higher concentration of betacellulin (2 nM), further enhanced expression of INS was 
observed in H-/G-AMSC-IPCs. H-/G-AMSCs were found to be more responsive to 
betacellulin stimulation for β-cell maturation than GLP-1 or exendine-4. 
 
 
Figure 4-11. Improving AMSC-IPC maturation by betacellulin 
The improvement of INS and GLUT2 expression in H-/G-AMSC-IPCs by GLP1, exendin-4, or 
betacellulin supplementation. The gene expression was normalised to GAPDH and y-axis 
shows the fold increase by comparing with undifferentiated H-/G-CMSCs/AMSCs. Data 
represent mean ± SEM. One-way ANOVA was used for statistical significance, #p<0.001 
indicates significantly increased gene expression under betacellulin compared with GLP-1 
or Exendin-4 supplementation. 
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4.4.6 Immunofluorescence staining and ELISA 
Comparable insulin protein expression in H-/G- CMSC-IPCs and AMSC-IPCs but insufficient 
insulin secretion function in AMSC-IPCs 
Immunofluorescence staining was used to verify protein expression of β-cell markers but is 
not a precise measurement of protein expression levels due to variations from staining and 
imaging procedures depending on morphological differences. H-/G- CMSCs were 
differentiated to IPCs using original protocols with the stimulation of GLP-1 at stage 3 while 
H-/G- AMSCs was induced to IPCs via optimised protocol where GLP-1 was replaced with 
betacellulin at the last differentiation stage. Cells were fixed on the last day of 
differentiation and stained for insulin (red) and transcription factor PDX1 (green) expression 
(Figure 4-12). 
Immunofluorescence labelling indicated that Insulin was co-expressed with transcription 
factor PDX1 in both Healthy- and GDM- CMSC-IPC spheroids. On the other hand, suspension 
spheroid cultures were not observed with H-/G- AMSC-IPCs with little progression beyond 
cell condensations at the end of differentiation process. However, irrespective of above co-
expression of insulin and PDX1 was noted in H-/G- AMSC-IPCs (Figure 4-12). 
The result confirmed the mature IPC differentiation and suggested that the upregulated 
pancreatic lineage genes were also expressed on protein levels in differentiated groups (H-
/G- CMSC-/AMSC- IPCs) compared to undifferentiated H-/G- CMSCs/AMSCs. 
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Figure 4-12. Confocal images of insulin and PDX1 expression 
(A) Fluorescence microscopic imaging of immunostaining for insulin and PDX1. After 3-stage 
IPC differentiation, cells were stained with antibodies against insulin (red) and PDX1 (green), 
followed by appropriate secondary antibodies conjugated. Merged images show 
localisation of insulin and PDX1 co-expression in H-/G- CMSC/AMSC IPCs. DAPI was used as 
nuclear counterstain in blue. (scale bar, 100 μm) (B) 20x magnification images and 
undifferentiated H-/G- CMSCs and ASMCs staining image of insulin and PDX-1 expression 
showed at the bottom left corner. (scale bar, 50 μm) (C) secondary antibody IgG control (D) 
40x magnification images of inulin and PDX1 localisation  
 
 
 
Functional β-cells are characterised by the ability to secrete adequate amounts of insulin in 
response to a glucose challenge. To establish functionality of IPC, we performed ELISA 
assays to investigate the secretion of insulin and C-peptide following glucose challenge 
(Figure 4-13). C-peptide is a by-product from the maturation process of insulin which is 
stored and released in equimolar quantities with insulin granules. H-/G- CMSC-IPCs and 
AMSC-IPCs were incubated in glucose free media for 2 hours prior to sequentially 
challenging with low glucose (5.5mM) for 1 hour and high glucose (25mM) for 2 hours, 
followed by measurement of insulin release into supernatants. The phosphodiesterase 
inhibitor, 3-isobutyl-1-methylxanthine (IBMX) known to induce insulin secretion368 was 
supplemented at the concentration of 0.5 mM to 5.5 mM and 25 mM glucose media. 
Undifferentiated H-/G- CMSCs and AMSCs released low or undetectable basal level of 
insulin and C-peptide into the media. H-CMSC-IPCs and G-CMSC-IPCs secreted insulin to 
low glucose challenge and released an increased amount of insulin in response to glucose 
content changes (Figure 4-13A). Likewise, a similar result was demonstrated in C-peptide 
release, where the increased C-peptide production was observed from low to high glucose 
challenge (Figure 4-13B). The insulin and C-peptide release levels showed no statistical 
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differences between H-CMSC-IPCs and G-CMSC-IPCs. 
In contrast, IPCs derived from H-/G- AMSCs released insulin and C-peptide in response to 
low glucose challenge but failed to produce increased amount of insulin at high glucose 
stimulation. Similar levels of insulin release in H-/G- CMSC-IPCs and AMSC-IPCs were noted 
when challenging with 5.5 mM glucose concentration. However, when increasing the 
glucose to 25 mM, around 50% of H-AMSC donor samples displayed evidence of glucose 
sensitivity while G-AMSC-IPCs failed to consistently produce insulin responsive to glucose 
concentration changes (Figure 4-13A). The C-peptide expression was consistent with insulin 
release in H-/G-AMSC-IPCs (Figure 4-13B). 
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Figure 4-13. Insulin and C-peptide ELISA 
Functional IPCs were accessed by insulin releasing capacity upon glucose challenge. IPCs 
were subsequently incubated with 5.5 mM glucose DMEM containing 0.5 mM IBMX for 1 
hour and switched to 25 mM glucose DMEM containing 0.5 mM IBMX for 2 hours. The 
supernatant was collected and measured for (A) insulin and (B) C-peptide release by ELISA. 
Left panels show the secretion level measured by ELISA and right panels show the 
percentage of increased insulin/C-peptide secretion in 25 mM glucose vs. 5.5 mM glucose. 
Data were normalised to undifferentiated H-/G- CMSCs/AMSCs and expressed as mean ± 
SEM. Each data point was conducted in duplicates. One-way ANOVA was used for statistical 
significance, ***p < 0.001.  
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Finally, we examined the intracellular insulin protein content to further understand 
whether the poor response to glucose stimulation in H-/G- AMSC-IPCs was caused by low 
insulin synthesis during differentiation. H-/G- CMSC-IPCs and AMSC-IPCs were lysed and 
insulin content was measure by ELISA normalising to total protein content within the cells. 
Significantly increased insulin content was observed in IPC groups compared to 
undifferentiated H-/G- CMSCs/MASCs. Surprisingly, no significant difference in intracellular 
insulin level was observed across all IPCs suggesting a broad comparability in insulin 
synthesis ability (Figure 4-14). The insufficient insulin secretion from H-/G- AMSC-IPCs 
might due to impaired glucose uptake or inadequate insulin exocytosis rather than insulin 
synthesis. 
 
Figure 4-14. ELISA of intracellular insulin  
Insulin content in H-/G- CMSC-/AMSCs- IPCs were measured by ELISA after incubating with 
25 mM glucose challenge. The expression levels were normalised to total protein content. 
Each data point was conducted in duplicates. One-way ANOVA was used for statistical 
significance, ***p< 0.001 indicates significant difference compared to undifferentiated 
MSCs; ns, no significant difference between each group. 
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4.5 Discussion  
Embryonic stem cells normally express high levels of NANOG, SOX2, and OCT4. We 
demonstrated that H-/G- CMSCs and AMSCs showed either higher or comparable levels of 
SOX2 expression than embryonic stem cells although the high expression levels were not 
found in NANOG and OCT4. Notably, H-/G- CMSCs/AMSCs showed significantly increased 
expression of NANOG, SOX2, and OCT4 than bone morrow MSCs. Neonatal tissue-derived 
MSCs have been reported to express higher levels of stemness markers than bone marrow 
MSCs in some studies. For instance, amniotic epithelial cells and mesenchymal cells showed 
more OCT3/4, NANOG, and KLF4 expression than bone marrow MSCs272. Chorion stem cells 
were highly positive for OCT-4, NANOG, SSEA-3, and TRA-1–60 expression369. Our results 
show that AMSCs and CMSCs from both healthy and GDM women have higher levels of 
stemness markers than bone-marrow MSCs. 
Glucose effect on pancreatic development 
Adult β-cells are mostly quiescent with only a small proportion having the ability to 
proliferate in respond to hyperglycaemia370. Owing to the limited regenerative capacity of 
endogenous β-cells, researchers have been looking for alternative approaches to restore or 
promote β-cell function for diabetes patients. Generation of functionally mature β-cell from 
MSCs is one of the attractive alternative for β-cell replacement therapies. Various extrinsic 
factors have been used to mimic the environment in order to facilitate β-cell differentiation. 
Glucose is a critical factor for pancreatic islet development in vitro and in vivo371. During 
pregnancy, maternal glucose levels raise to allow fetus to have sufficient nutrients for 
development in the late second to third trimester, which is also the crucial period for 
pancreatic islet development while the remodelling and maturation of fetal pancreas 
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continues until early childhood372. In in vivo animal studies, elevated maternal glucose 
levels contributed to increased fetal pancreatic insulin content, promoted β-cell 
proliferation, and enhanced insulin secretion in response to glucose373, 374. The influential 
role of glucose in β-cell development, survival and insulin biosynthesis and secretion has 
also been evidenced in many studies375, 376. Therefore, glucose is considered as an inducer 
for β-cell differentiation and commonly used in IPC generation protocols377. 
Although glucose availability regulates fetal islet development, it is known that abnormal 
maternal hyperglycaemia may lead to adverse effects and cause β-cell exhaustion378. Given 
that GDM-MSCs were under prolonged exposure to hyperglycaemia during pregnancy, to 
know whether glucose is a suitable factor for IPC generation from GDM-MSCs, we exposed 
H-/G- CMSC/AMSCs to HG culture for a 30-day period. Reports have indicated that with a 
glucose concentration at 20-30, β-cell replication was significant enhanced379. The 
starvation of bone-marrow MCSs in serum-free LG media prior to 7 days 25 mM glucose 
(high glucose) culture resulted in the formation of small spheroid clusters and upregulated 
expression of GLUT2, glucagon, and insulin380. We did not observe 7-day HG culture-
induced spheroid cluster formation with either H-/G- CMSCs or AMSCs. The obvious cell 
condensations formed around 20-day of HG culture in H-/G- CMSCs while the 
morphological changes were not profound in H-/G- AMSCs. However, we did note 
upregulated pancreatic transcription factor expression following on from short-term HG 
exposure. The increased expression of PDX1 and NEUROG3 in HG-cultured H-/G- 
CMSCs/AMSCs indicated the formation of endocrine progenitor cells while the lack of INS 
expression suggested that those progenitor cells failed to differentiate into mature 
endocrine cells. PDX1 and NEUROG3 were reported to be essential factors for beta-cell 
development, where the expression of PDX1 remained high over the entire pancreatic islets 
development period and also in mature beta-cells381 whereas NEUROG3 was induced 
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during endocrine progenitor cells formation and the expression slightly reduced in mature 
beta-cells382. Although we detected the increase in PDX1 and NEUROG3, little or no 
increase in INS expression was observed across all populations under HG culture indicating 
failure to mature under HG culture alone even though HG concentration induced INS 
expression was shown in some studies380, 383, 384.  
In addition, long-term HG culture led to cell death in both Healthy- and GDM- 
CMSCs/AMSCs. HG is associated with reactive oxygen species production and induced cell 
apoptosis385. In BM-MSCs, HG was found to affect cell proliferation, mitochondrial function, 
and result in apoptosis386. Direct comparison of our findings to other studies is not possible 
though noteworthy comparisons are provided via elevated caspase-3 and caspase-8 pro-
apoptotic activity in adipose-derived MSCs from type 2 diabetes patients387.  
Cellular senescence is a state of growth arrest and an inability to proliferate which is 
generally present in primary MSCs culture, especially at late passage388. We found that 
prolonged HG exposure accelerated cellular senescence in both H-/G- CMSCs and AMSCs, 
but showed its greater effect on GDM samples than Healthy counterparts. Glucose at the 
concentration of 25 mM promoted BM-MSCs premature senescence through the 
expression of p16 and p21 over 28 days culture389. In many IPC differentiation studies, MSCs 
were under a long period of HG culture from a couple of weeks to four months346, 390, 391. 
Although some research showed positive results of IPC generation through HG culture, we 
pointed out the adverse effect of long-term HG culture, including increased cell death and 
cellular senescence which might affect the differentiation capacity for IPC generation. High 
glucose environment leading to cell senescence and impaired beta-cell survival was 
reported in many in vivo studies. In high-fat diet-induced diabetic mice, hyperglycaemia 
resulted in beta-cell senescence with recued beta-cell mass and insufficient insulin 
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release392. The glycaemic level changes in obesity mice were associated with beta-cell death 
and dedifferentiation, leading to loss of functional beta-cell population393. Glucose is an 
important factor for pancreatic beta-cell development but long-term exposure may cause 
adverse effects.    
Optimised IPC generation approach 
Short-term HG culture provided a balance point with low levels of cell death, senescence, 
and elevated β cell-linked transcripts for priming of placental membrane MSCs followed by 
incubation and induction of mature IPC differentiation following our three-stage 
differentiation process. 
Our three-stage protocol was modified from previously published protocol by Chandra et 
al.353 who generated IPCs from adipose derived-MSCs. The protocol has also been applied 
to umbilical cord-derived MSCs by Wang et al394. However, several steps were modified in 
our study. Firstly, the ITS (insulin-transferrin-selenium) used in Chandra’s differentiation 
media was withdrawn in our protocol. ITS is commonly used in serum free media to 
maintain cell growth whereas BSA and 2-mercaptoethanol were sufficient to support most 
of CMSC/AMSCs survival in serum free media. The insulin contained in ITS may enhance the 
chance of taking up insulin from differentiation media instead of insulin synthesis in IPCs. 
Secondly, after stimulating with activin A, an inducer for definitive endoderm formation321 
at the stage 1, the additional 2-day retinoic acid (RA) stimulation combined with activin A 
improved morphological changes towards condensations and spheroid cluster formation at 
later stages (Figure 4-9B). RA signalling is essential for pancreatic development that induces 
the generation of endocrine progenitors and functions as an effective inducer for pancreatic 
transcription factor PDX1 expression while the disruption of RA signalling leads to 
pancreatic agenesis361, 395, 396. Thirdly, Chandra’s protocol established a 10-day maturation 
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protocol for IPC generation; however, it was not reproducible with H-/G- CMSCs or AMSCs. 
A longer incubation time was required especially for the last maturation stage, as well as 
the additional supplementation with EGF and nicotinamide to enhance the growth and 
maturation of IPCs397, 398. 
In the present three-stage IPC differentiation approach, among all various factors GLP-1 
plays a crucial role in promoting the maturation of IPC. GLP-1 has important physiological 
functions in fetal β-cell development, insulin synthesis, and secretion399, 400; therefore GLP-
1 has been widely used at the last differentiation stage in many IPC differentiation 
protocols. H-/G-CMSCs displayed good responsiveness to our IPC induction protocol with 
enhanced mature beta-cell marker expression and the ability to secrete insulin. However, 
in immunostaining, we found that some cell populations showed PDX-1 positive but not 
insulin. These cell populations may be at immature differentiation stage or other endocrine 
cell types. PDX1-expressing progenitor cells give rise to β-cell and also α-cells and δ-cells 
that secrete glucagon and somatostatin, respectively401. It is likely that the cell clusters 
formed in H-/G-CMSC-IPCs may contained different endocrine cell types.   
Given the low expression of mature beta-cell markers in H-/G-AMSCs, we further optimised 
our protocol for promoting AMSC-IPCs maturation. We explored the supplementation with 
either exendin-4 or betacellulin as a substitute for GLP-1 in the last IPC maturation stage. 
Exendin-4 is a GLP-1 agonist which improves glucose tolerance in diabetes patients via 
enhanced insulin secretion402, 403. A previous report has indicated that exendin-4 
supplementation promoted β-cell gene transcription in mouse embryonic stem cell-derived 
IPCs404. In this instance we saw no significant, or dose-dependent, induction of either INS 
or GLUT2 transcription in H/G-AMSC-IPCs following exendin-4 supplementation.  
In contrast, we noted significant increases in both INS and GLUT2 in H-/G- AMSCs following 
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betacellulin supplementation. Betacellulin is an epidermal growth factor (EGF) family 
member with demonstrable regulation of pancreatic regeneration through activation of 
EGF receptors (EGFR), ErbB1 and ErbB2405. Further, in β-cell development from human 
embryonic stem cells the addition of betacellulin sustained PDX1 expression and improved 
the differentiation process406. In present study, H-/G-AMSCs were more responsive to 
betacellulin than GLP-1 or exendin-4. GLP-1 and exendin-4 interact with the high affinity 
receptor, GLP-1R, while GLP-1R lacks kinase activity and depends on EGFR to activate its 
downstream pathways407. In turn, signal transduction of GLP-1R via EGFR require the 
proteolytic processing of membrane-anchored betacellulin or other EGF-like ligands408. 
Therefore, the direct treatment of betacellulin likely had a more direct effect on EGFR 
regulation of insulin expression.  
Irrespective of above, successful induction of insulin gene and protein expression was not 
reflected in significant increases in insulin secretion from H-/G-AMSC-IPCs upon glucose 
challenge, regardless of their comparable pancreatic gene and intracellular insulin 
expression levels with H-/G-CMSC-IPCs. Notably, three H-AMSC-IPCs samples (Healthy 03, 
06, 10) were able to release insulin in response to high glucose environment but AMSC-
IPCs derived from Healthy 07, 08, and 11 failed to secrete increased insulin. Although 
Heathy 07 and 08 had a history of smoking which might affect cell biological properties, 
such as DNA methylation409, we were unable to identify whether smoking has a direct effect 
on poor insulin secretion. However, cigarette and nicotine were found to have impacts on 
impaired insulin secretion and insulin resistance410, 411. Moreover, we noticed that AMSC-
IPCs derived from Heathy 08 and 11 had lower expression of GLUT2 gene. The glucose 
transporter, GLUT2 plays an important role in glucose sensing and homeostasis412. The low 
expression of GLUT2 may reflect the less responsiveness to high glucose environment in H-
AMSC-IPCs.    
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A notable difference between H-/G-AMSC-IPCs and H-/G-CMSC-IPCs during differentiation 
was that the former displayed a morphology of attached cell condensations which did not 
progress into suspension spheroids. Current perspectives have suggested β-cell glucose 
stimulation requires the formation of small spheroid clusters either in suspension or loosely 
adhered to extracellular matrix and that single cells are not responsive413, 414. This reflects 
our observations where spontaneously detached, spheroid cultures, supported IPC 
differentiation and maturation in H-/G-CMSCs 
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4.6 Summary  
Coupled to the growing interest in autologous, and allogeneic, cell therapy, an 
understanding of how disease state impairs the regenerative capacity of endogenous MSCs 
is crucial. In this study we have provided three key observations; the first being the 
description of a comprehensive protocol for the generation of IPCs from placental chorionic 
membrane-derived MSCs, the second being that amniotic membrane-derived MSC are 
refractory to IPC differentiation, and the third being that the above primary characteristics 
are GDM-independent. GDM-derived CMSCs were capable of transdifferentiation into IPCs, 
expressing β-cell markers and functionally indistinguishable from healthy CMSC-IPCs but G-
AMSCs failed to differentiate into mature IPCs. This suggests that the pathophysiological 
state of GDM may cause irreversible impairment in the differentiation capacity of AMSCs. 
Notably, G-CMSCs possessed comparable IPC differentiation potential to H-CMSCs. 
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Microarray study of Healthy- and 
GDM- CMSCs transcriptional profile 
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5.1 Introduction 
Mesenchymal stem cells (MSCs) are present in many adult tissues and responsible for tissue 
regeneration and maintenance. Their regenerative potential provides numerous benefits 
for disease treatment. In terms of differentiation potential toward multiple lineages and 
immunomodulatory capacity MSC may share certain levels of common transcriptional 
signature415. However, transcriptional profile can also be unique to MSCs derived from 
different tissues. Stem cell therapies are somehow hampered by our incomplete knowledge 
of their fundamental differences416. Unlike embryonic stem cells, MSCs niche in adult 
tissues may affect and determine the gene expression in specific tissue-derived MSCs. It is 
likely that many genes critical to regenerative functions of MSCs or altered gene signature 
in different MSC sources are not yet fully understood. A better knowledge of MSCs gene 
profile provides more effective strategies for using MSCs in regeneration medicine. 
DNA microarray is a powerful tool to study genomic-scale transcriptome profiling and 
through various bioinformatic methods, image data can be processed and converted to 
gene expression values. Even when the microarray data is processed to gene expression 
value, thousands of genes expressed within the cells make the analysis of these complex 
datasets challenging. There are a number of commercially or open source bioinformatic 
software available to assist microarray studies and analyse biological significance417. In this 
chapter, analysis methods, including identification of differentially expressed genes, 
clustering of data, relevant biological function analysis, and interaction networks were used 
via different bioinformatics tools. Other bioinformatics analysis techniques such as 
biomarker identification has been widely used in cancer research and toxicogenomics is 
commonly used in drug screening.   
However, when microarray data is obtained from different platforms, the procedures can 
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vary greatly with gene expression. Reliability and reproducibility of microarray data has 
raised concerns. For example, two studies attempted to investigate survival after 
chemotherapy for diffuse large B-cell lymphoma by gene expression profiling using different 
microarray platforms. The results showed different gene classifiers with a low number of 
overlapping genes418-420. Likewise, inconsistent results were found in some stem cell studies 
on exploring gene signature of embryonic and adult stem cells421-423. Since the inconsistency 
issue has been addressed, the MicroArray Quality Control project initiated by the US Food 
and Drug Administration attempted to enhanced intra-platform and cross-platform 
consistency424 which has improved nowadays microarray technology. 
In addition, verification of microarray results through laboratory experiments is considered 
as a reliable method to validate the accuracy of microarray data. As DNA microarray 
analyses transcriptome activity, using semi-quantitative reverse transcription PCR or real-
time PCR to examine gene expression is a common first step to verify microarray data425. 
However, with the increasing availability of microarray chips and affordable prices, some 
studies are able to enhance the accuracy of microarray data and reduce sample-to-sample 
variance by improving sample size. These studies can thereby provide more powerful 
evidence and forgo performing validations through laboratory gene analysis assay426. Given 
that biological functions mainly depend on protein activities, validating array results at the 
protein level corresponding to gene expression is equally important425, 427. Validation of 
protein expression and its relevant biological functions revealed by microarray analysis can 
be carried out through immunoblotting, immunostaining, function assays, or in vivo 
experiments.  
Owing to the fact that umbilical cord blood-derived MSCs/HSCs (U-SCs) have been studied 
and applied in clinical therapies for many years, there are many U-SCs microarrays or gene 
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sequencing data available on GEO database (GEO, gene expression omnibus, 
https://www.ncbi.nlm.nih.gov/geo/). However, very few studies have investigated whether 
the genomic profile of these perinatal tissue-derived stem cells are altered by pregnancy 
complications. A microarray study on umbilical vein endothelial cells (HUVEC) derived from 
GDM pregnancies indicated altered gene expression in insulin sensing and extracellular 
matrix reorganisation428. Another study performed microarrays on umbilical cord tissue 
from diabetic pregnancies and found alterations in genes associated with vascular 
development and function429. However, the gene profiling research on regenerative ability 
of MSCs from GDM women is limited. Moreover, microarray data of CMSCs is yet to be 
found on GEO database.  
In chapter 3, we showed that CMSCs can be isolated in high numbers, with steady growth 
and proliferation rate under a standard culture environment. In addition, CMSCs derived 
from GDM and healthy women demonstrated comparable regenerative potential towards 
tri-lineage differentiation. These findings leading to conclude that the GDM environment 
did not significantly hamper the differentiation ability of CMSCs. GDM-CMSCs were able to 
behave similarly to healthy CMSCs and successfully reprogrammed into insulin producing 
cells as demonstrated in chapter 4. GDM-CMSCs seem to have promising potential to be 
used in regenerative medicine. Therefore, to further evaluate the therapeutic potential of 
CMSCs, we performed DNA microarray to comprehensively understand their gene profiles 
and investigate the potential clinical application based on their transcriptional signature. 
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5.2 Aim  
With increasing interest in the utilisation of placental MSCs and their banking for clinical 
purposes, understanding the characteristics and regenerative potential of placental MSCs 
has become an important subject. Thus, we sought to explore gene expression profiles 
between CMSCs from healthy and GDM placenta by DNA microarray analysis. Moreover, 
we aimed to investigate the biological differences or similarities based on gene expression 
and validate these changes in functionality through experimental assays to provide a 
comprehensive understanding of healthy and GDM CMSCs.  
 
The main objectives of the chapter: 
 Perform DNA microarray with 3 heathy and 3 GDM CMSC samples 
 Analyse microarray data using bioinformatic software 
 Validate gene expressions with 10 healthy and 11 GDM samples 
 Investigate biological differences through in vitro functional assays 
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5.3 Methods 
DNA microarray 
Samples used for microarray analysis were 3 H-CMSCs (Healthy03, 07, 08) of similar ages 
and BMI, and 3 GDM-CMSCs (GDM06, 07, 08) treated with either metformin (06), insulin 
(07), or both (08), representing the different severity of GDM. Cells were collected at 
passage 2 for microarray analysis. Apart from RNA extraction and microarray raw data 
collection conducted by Welgene Biotech Company, all analysis and validation experiments 
in this chapter were carried out by the author for this thesis.   
Microarray experimental flow is showed in Figure 5-1 conducted by Welgene Biotech 
Company. The 0.2 μg of total RNA was amplified and labelled with Cy3 (CyDye, Agilent 
Technologies) for in vitro transcription process. 0.6 μg of Cy3-labled cRNA was fragmented 
to an average size of about 50-100 nucleotides and then pooled and hybridized to Agilent 
SurePrint Microarray (Agilent Technologies) at 65 °C for 17 hours. After washing process by 
nitrogen gun blowing, microarrays were scanned with an Agilent microarray scanner and 
images were analysed by Feature extraction10.7.3.1 software (Agilent Technologies). 
 
Figure 5-1. Microarray experimental flow 
A common external RNA control, poly A+ RNA with Spike-IN, is a set of unlabelled, poly-
adenylated transcripts of known sequence and quantity used to calibrate measurements in 
RNA hybridization assays430. Microarray experiments were performed using Agilent 
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SurePrint technology by Welgene Biotech Company. 
Microarray analysis using bioinformatics software 
Venn diagram and hierarchical clustering heat maps were created by AltAnalyze software 
(Gladstone Institution, UCSF) used to identify commonly up-regulated or down-regulated 
genes and illustrate the differentially expressed gene lists of interest.   
Ingenuity Pathway Analysis (IPA, Qiagen; www.qiagen.com/ingenuity) was used to analyse 
the genes with fold changes greater than 1.5 in GDM samples vs. healthy samples 
(differentially expressed genes, DEGs). Overrepresented and underrepresented biological 
functions and canonical pathways were identified based on the DEGs involved in Ingenuity 
Knowledge Database (Qiagen). The chi-squared test and Fisher's exact test are used to 
compare statistical significance between two variables when the comparing groups are 
independent and not correlated. The chi-squared test applies when the sample size is large, 
while the Fisher's exact test runs an exact procedure as the chi-squared test but for a small 
sample size431. In this study, the two variables in the microarray analysis are the total DEGs 
(up-/down- regulated genes) and associated biological functions/pathways, when the 
independent comparing groups are Healthy and GDM. Due to the small-sized samples in 
our study, the Fisher's exact test was used for analysing significance via IPA software. The 
p-value is calculated by considering the number of DEGs that participate in a specific 
biological function vs. the total number of genes that are known to be associated with that 
biological function in the IPA database (Ingenuity Knowledge Base, Qiagen). The p value < 
0.05 indicates statistical significance. 
The downstream function analysis was used to identify biological functions that are 
expected to be increased or decreased based on the activation Z-score. The activation Z-
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scores were calculated by IPA, which assess the potential activation state of a biological 
function by using information about (1) the up- or down- regulatory state of each gene 
involved (2) the statistical significance of these genes in the biological function. The positive 
activation Z-score indicates increased activation and the negative activation Z-score 
indicates decreased activation. 
Pathway network visualisation was created by Cytoscape v.3.6.1. Enriched gene sets 
identified by IPA pathway analysis were selected and used as input nodes. The interaction 
network was generated according to literature findings and public database. The network 
was manually curated and distributed with circles for easier visualisation. 
The experimental workflow of microarray analysis and validation was demonstrated in 
Figure 5-2. 
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Figure 5-2. Summary of the methodology in chapter 5 
Validation and statistical analysis 
10 Heathy and 11 GDM CMSC samples were used for validating microarray data through 
gene expression and functional assays. The selected upregulated/downregulated genes in 
microarray data were validated by real-time PCR (Section 2.8). Functional assays were used 
use to validate enriched biological function in GDM-CMSCs, including Transwell migration 
assay (Section 2.14.1), wound healing assay (Section 2.14.2), ALDH activity analysis (section 
2.15) and ROS detection (Section 2.16). Real-time PCR and migration results were compared 
using Student’s t-test to determine the statistically significance between two groups. ALDH 
activity and ROS detection was analysed using one-way ANOVA to compare the significance 
between two groups at different time points. Analysis was performed using GraphPad Prism 
(GraphPad Software). 
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5.4 Results 
5.4.1 Identification of differentially expressed genes 
Gene expression profiling of CMSCs derived from 3 healthy (H-CMSCs) and 3 GDM women 
(GDM-CMSCs) were assessed by DNA microarray analysis at passage 2. The details of 
samples used for microarray analysis (Healthy03, 07, 08 and GDM06, 07, 08) are listed in 
Table 2-2. The 3 H-CMSCs (Healthy03, 07, 08) were chosen based on similar ages and BMI. 
GDM samples were selected from GDM patients that had received glycaemic control 
treatments during pregnancy, as this cohort showed excessive physiological glucose levels 
vs. healthy women or untreated GDM patients, and could be more representative cohort 
to explore hyperglycaemic effects on GDM-CMSCs. Two GDM samples (GDM 06 and 07) 
were treated with metformin and insulin, respectively while a sever GDM sample (GDM08) 
received a combined treatment with both metformin and insulin.  
Within the thousands of genes analysed in microarray, a small number of informative genes 
which display altered expression patterns and are mostly responsible for the differences 
between two biological conditions under investigation, are defined as differentially 
expressed genes (DEGs)432. DEGs can be identify by specific selection criteria. In this study, 
a cut-off of P < 0.05 and 1.5-fold change in gene expression were used to identify the DEGs 
between H-CMSCs and GDM-CMSCs. Compared to H-CMSCs, there is a total of 431 DEGs, 
including 162 up-regulated and 269 downregulated genes in all 3 GDM samples (Figure 5-
3). The sample from the women received both metformin and insulin treatment (GDM08) 
exhibited the highest number of total DEGs.  
The top 10 differentially upregulated or downregulated genes are listed in Table 5-1 with 
the expression log2 fold change. Functional interpretation of top ranked genes was defined 
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by Gene Ontology Consortium (http://www.geneontology.org/). In the down-regulated 
genes, PRKCB, FAM20A, ALDH1A1, and ATP8B4 were associated with catalytic activity; GJA8 
and ATP8B4 were involved in transport activity; and CXCL12, CXCL3, CXCL, and RSPO3 in 
chemokine activity. The majority of the top 10 up-regulated genes were related to protein 
or ion binding and RPS4Y1, COL17A1, SPRR3, KRT5, HAPLN1 were also involved in structural 
molecule activity.  
 
 
Figure 5-3. Venn diagrams of DEGs 
Venn diagrams show the numbers of genes that are up- or down- regulated 1.5-fold more 
in GDM-CMSCs vs. H-CMSCs. The overlapping areas of 3 circles were co-regulated genes in 
GDM-CMSCs, defined as differentially expressed genes (DEGs). 
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Table 5-1.Top ranked up- and down- regulated genes in GDM-CMSCs vs. Healthy-CMSCs 
 
5.4.2 Biological function analysis 
Wound repair and altered cardiovascular function in GDM-CMSCs 
Biological function analysis using DEGs that were identified in all 3 GDM-CMSCs samples 
was performed with Ingenuity Pathway Analysis (IPA) through two categories: “molecular 
and cellular functions” and “physiological system development and functions”. The 
“molecular and cellular functions” most represented in GDM-CMSCs were related to cell 
death and survival, cellular growth and proliferation, and cellular movement (Figure 5-4). 
  
Top 10 
Down-regulated 
genes 
Average log2 ratio 
 
Top 10 
Up-regulated genes 
Average log2 ratio 
PRKCB -5.566 RPS4Y1 9.873 
GJA8 -4.166 COL17A1 9.344 
CXCL12 -3.436 DDX3Y 8.528 
FAM20A -3.379 CDH1 8.376 
ALDH1A1 -3.315 KRT5 8.308 
PRRX2 -3.227 SCEL 8.207 
ATP8B4 -3.040 SPRR3 7.823 
RSPO3 -2.927 PLD5 7.293 
CXCL3 -2.925 HAPLN1 7.102 
CXCL1 -2.914 L1TD1 6.996 
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Figure 5-4. Enriched molecular and cellular function in GDM-CMSCs  
Each pair of bars displays the significant state of over-represented functions in GDM-CMSCs 
compared to H-CMSCs and each colour represents each GDM sample. The p-value, 
calculated with the Fisher's exact test. 
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To further identify the altered cellular process of the most represented biological functions, 
downstream effects analysis was used to understand key biological processed influenced 
by DEGs. The activation z-score computed by IPA indicated the activation or inhibition state 
and gene enrichment of each downstream cellular process. A positive z-score indicates 
increased functional activity in GDM-CMSCs relative to H-CMSCs while a negative z-score 
indicates a reduction in activity.  
As indicated by IPA, genes enriched in GDM-CMSCs were related to enhanced abilities in 
cell survival, cellular motility, assembly and organization of cytoskeleton, and skin formation, 
which are critical functions in wound repair and tissue remodelling (Figure 5-5A). The 
positive associated downstream cellular processes in “molecular and cellular functions” 
revealed the potential of GDM-CMSCs in wound healing process. Although some negative 
activation was found in colony formation, proliferation, cellular infiltration, and homing, 
due to the smaller z-core value it would suggest less significance of gene enrichment and 
effect.  
To gain insight into the gene expression level of GDM and healthy samples, multiple 
functional gene clusters involved in cell movement and survival (Figure 5-5B), cellular 
assembly (Figure 5-5C), and development of epithelium (Figure 5-5D) were displayed on 
the clustering heat maps. The upregulated expressions of these gene sets were 
demonstrated in GDM-CMSCs associating with an increased function in healing process.  
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Figure 5-5. Downstream effects in molecular and cellular function 
(A) Activation state of top enriched downstream cellular processes in “molecular and 
cellular functions” using IPA activation z-score to identify the increased (positive z-score) or 
decreased activity (negative z-score) in GDM-CMSCs compared to H-CMSCs. (B-D) 
Hierarchical clustering heat maps of DEGs involved in cellular functions related to healing 
process. Expression levels are represented by log2 fold change (expression value in each 
sample vs. mean expression value in H-CMSCs). Colours are according to the scale 
representing high expression (red) and low expression (green) genes. 
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In order to explore the development/differentiation potential of GDM-CMSCs, DEGs were 
used to performed “physiological system development and function” analysis by IPA. The 
most represented biological function included cardiovascular system development and 
function, connective tissue development and function, and organ morphology. (Figure 5-6). 
 
Figure 5-6. Enriched physiological system development and function in GDM-CMSCs 
The most relevant biological functions in “physiological system development and function” 
category in GDM-CMSCs were identified by IPA. The p-value, calculated with the Fisher's 
exact test. 
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Further in-depth analysis of the downstream functional activation performed in relation to 
cardiovascular system development showed that cardiogenesis was the most significantly 
over-represented downstream cellular process with the highest positive z-score. Along with 
the positive association with development of cardiovascular tissue, it could imply the 
possibility of GDM-CMSCs giving rise to cardiogenic progenitors and their development into 
cardiomyocytes (Figure 5-7A). The heat map illustrated a set of genes involved in 
cardiogenesis that were highly expressed in GDM-CMSCs compared to H-CMSCs, 
contributing to greater potential in cardiac regeneration (Figure 5-7B). 
Cardiogenesis potential is what generates cardiac cells which can replace the loss of 
cardiomyocytes or insufficient endogenous regeneration of cardiomyocytes in some heart 
diseases. On the other hand, the ability of stem cells to promote angiogenesis is a reason 
for successful cell therapies in cardiac regeneration433, 434. However, in GDM-CMSCs the 
cellular processes of vasculogenesis and angiogenesis in cardiovascular development were 
identified to have decreased activation with negative z-score (Figure 5-7A). The heat map 
showed that the regulators in vasculogenesis and vasculature development, such as PRRX2, 
RSPO3, KITLG, and CXCL1, had lower expression in GDM-CMSCs compared with H-CMSCs 
(Figure 5-7C).  
Moreover, other enriched downstream cellular processes in the “physiological system 
development and function” category included respiratory system development, formation 
of lung and kidney with positive z-score while development of exocrine gland and 
connective tissue with negative z-score in GDM-CMSCs (Figure 5-8).  
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Figure 5-7 Downstream effects in cardiovascular system development  
(A) Enriched downstream cellular processes associated with “cardiovascular system 
development and function” in GDM-CMSCs. Activation state was calculated by IPA 
activation z-score. (B-C) Heat maps summarized DEGs involved in cardiogenesis and 
vasculogenesis. Colours indicates high expression (red) and low expression (green) 
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Figure 5-8. Downstream effects in physiological system development and function 
The relevant cellular processes related to development were identified and ranked by the 
IPA analysis based on DEGs. Activation state was calculated by IPA activation z-score. 
 
5.4.3 Validation of enriched biological functions 
Increased migration ability, wound healing potential, and cardiac development in GDM-
CMSCs 
To evaluate microarray data and functional differences between H-CMSCs and GDM-CMSCs, 
enhanced expression in genes involved in migration, survival, and cellular assembly ability 
in GDM-CMSCs were validated though real-time PCR analysis. Validated genes were 
selected mainly based on the significance of increased levels in microarray data and also 
the importance of the gene in the biological function.  
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In all 3 GDM-CMSCs microarray data, the highly glycosylated protein CD24 showed more 
then 10-fold increase. The expression of CD24 has been suggested to regulate cell migration 
in various cell types435, 436. A microarray study of overexpression and suppression of CD24 
in BM-MSCs indicated the regulatory role of CD24 in transforming growth factor (TGF)-β 
signal437 which is known to involve in many cellular functions, including cell growth, survival, 
and wound healing. Real-time PCR confirmed the significantly upregulated CD24 expression 
in GDM-CMSCs while the increased level varied from 5 to 15 folds (Figure 5-9A). 
Approximately 2 times higher expression of CELSR1, a membrane of cadherin superfamily 
involving in regulating adhesion and wound repair signalling, was found in GDM-CMSCs vs 
H-CMSCs. Filamin B (FLNB) and aquaporin 1 (AQP1) are involved in cytoskeleton 
arrangement and cellular assembly which showed a 2-3-fold increase in GDM06 and 
GDM07 microarray data while GDM08 had 3.7-fold upregulation in FLNB and 40-fold 
increase in AQP1. Real-time PCR verified the increased expression of FLNB, AQP1, CELSR1 
in GDM-CMSCs but the relatively high increase in AQP1 expression in GDM08 was not 
detected by real-time PCR analysis (Figure 5-9A).  
The selected genes related to skin formation, epithelial development, and healing process 
included endothelin 1 (EDN1) which was evidenced to accelerate wound healing 
processes438, and several growth factors; transforming growth factor (TGF), heparin-binding 
EGF-like (HBE)-GF, and connective tissue (CT)-GF which are known to promote wound repair 
and epithelium growth. The validation of EDN1, HBEGF, TGFB2, CTGF expression was 
consistent with microarray result, showing significantly upregulated in GDM-CMSCs 
compared to H-CMSCs (Figure 5-9B).  
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Figure 5-9. Real-time PCR validated the genes involved in wound healing 
Expression level of each gene was normalised to GAPDH expression. Results represent 
mean ± SEM. Statistical significance was determined by Student’s t-test, *p < 0.05, **p < 
0.01, ***p < 0.001. 
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To examine biological differences on a functional level in vitro assays were performed to 
evaluate the migration ability. The Transwell migration assay was used to analyse the 
motility of single cell to respond toward attractants. H-CMSCs or GDM-CMSCs were placed 
into the upper compartment of a Transwell in serum free media and the lower 
compartment was filled with complete growth media containing FBS as an attractant. After 
allowing migration for 8 hours, enhanced migration ability was observed in GDM-CMSCs 
with a greater numbers of cells having migrated across the membrane. Cells were 
continually incubated for 24 hours and both H-CMSCs and GDM-CMSCs were observed to 
pass through the Transwell filter, where more migrated GDM-CMSCs were observed than 
H-CMSCs. After either 8 or 24 hours of incubation, GDM-CMSCs had a significant increase 
in the number of migrated cells vs. H-CMSCs which verified the more mobile state of GDM-
CMSCs (Figure 5-10).  
Wound healing assay was used to determine the migration ability of cell populations. A 
wound was created by scratching with a pipette tip through a confluent monolayer of cells 
and the migration ability determined by wound closure percentage. The result showed that 
higher numbers of GDM-CMSCs migrated into the wound field at every observed time point 
(6, 12, 24 hours) than H-CMSCs. The closure percentages were significantly increased, with 
approximately 30% in GDM-CMSCs and 20% in H-CMSCs after 12 hours and increasing up 
to 60% in GDM-CMSCs and 40% in H-CMSCs after 24 hours (Figure 5-11). Collectively, both 
the Transwell migration and wound healing assay validated the enhanced migration ability 
in GDM-CMSCs. 
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Figure 5-10. Transwell migration assay 
Cell motility was evaluated by Transwell migration assay. Representative images are 
migrated H-CMSCs and GDM-CMSCs stained with crystal violet after 8 and 24 hours of 
migration period from 6 H-CMSCs (Healthy03-08) and 6 G-CMSCs (GDM04-09) samples in 
duplicate. Cell migration ability was calculated by counting migrated cells per field by image 
J. Results represent mean ± SEM. Statistical significance was determined by Student’s t-test, 
*p < 0.05, ***p < 0.001. 
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Figure 5-11. Wound healing assay 
Representative images of wound healing assay from 6 H-CMSCs (Healthy03-08) and 6 G-
CMSCs (GDM04-09) samples. Images were captured by light microarray after allowing H-
CMSCs and GDM-CMSCs to migrate into the middle wound field after 0, 6, 12, 24 hours. 
Scale bar, 150 μm. Percentage of wound closure was calculated by measuring the reduction 
in wound area after incubated for indicated time period. Images were modified (the yellow 
lines for edges of the wounds) and measured by image J. Numbers shown on the left corner 
represent the wound area. Statistical significance was determined by Student’s t-test, *p < 
0.05, **p < 0.01, ***p < 0.001. 
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Cardiovascular development was identified as the most enriched biological function in 
GDM-CMSCs. The related DEGs showed altered expression, especially in cardiogenesis and 
vasculogenesis. Transcription factor NK2 homeobox 5 (NKX2.5) which has an important role 
in functioning heart development and formation showed increased in GDM06 and GDM08 
microarrays, but a 1.6-fold decrease in GDM07. Validating NKX2.5 expression by real-time 
PCR, most GDM-CMSCs had a 2-fold upregulation while a more significant increase in 
NKX2.5 expression could be found in GDM03, GDM08 and GDM10 which showed more 
than 5-fold upregulated expression. Signalling transduction through platelet-derived 
growth factor (PDGF)-A and tyrosine kinase receptor mesenchymal epithelial transition 
factor (MET) is involved in early heart development439, 440. PDGFA and MET expression was 
consistent with microarray data, showing an average of 2-fold upregulation in GDM-CMSCs 
vs H-CMSCs. The increased expression of noggin (NOG) was also confirmed by real-time 
PCR with significant increases from 3-12 fold in GDM-CMSCs compared to H-CMSCs (Figure 
5-12A). 
The opposite trend was found in vasculogenesis-associated genes, which showed a 
significantly reduced expression in GDM-CMSCs. R-spondin 3 (RSPO3) and chemokine 
CXCL12 were two of the top 10 downregulated genes in GDM-CMSCs, both involved in 
vasculogenesis and angiogenesis. CXCL12 showed 10-fold and greater reduced expression 
in GDM-CMSCs vs H-CMSCs. The reduction of RSPO3 was not as significant as with 
microarray data, which had an average of 2-fold decrease in GDM-CMSCs as well as other 
vasculogenesis regulators; ras interacting protein 1 (RASIP1) and heme oxygenase 1 
(HMOX1) (Figure 5-12B).  
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Figure 5-12 Real-time PCR validated the genes involved in cardiovascular development 
Expression level of each gene was normalised to GAPDH expression. Results represent 
mean ± SEM. Statistical significance was determined by Student’s t-test, *p < 0.05, **p < 
0.01, ***p < 0.001. 
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5.4.4 Canonical pathway analysis  
Pathways mediating cardiac development and cell movement are both upregulated in 
GDM-CMSCs while the majority of downregulated pathways are involved in metabolic 
processes  
IPA canonical pathways analysis was used to evaluate pathways altered in GDM-CMSCs 
based on DEGs. The canonical pathways refer to the well-characterised cell signalling 
pathways that present common properties of a particular signalling module or pathway. 
Positively- and negatively- regulated pathways were identified by IPA with a p value 
indicating significance and the ratio of the number of DEGs that map to the all known genes 
in the pathway. 
Positively-regulated pathways included growth factors pathways (bone morphogenetic 
protein (BMP), Wnt/β-catenin, fibroblast growth factor (FGF), vascular endothelial growth 
factor (VEGF) signalling) and the transcription factor STAT3 pathway. These pathways are all 
involved in various growth and development processes. Moreover, Rac and Rho protein 
regulation signalling were also upregulated. Upregulated IL-1 mediated RXR function 
signalling was involved in the regulation of transport and metabolism of lipid, cholesterol, 
and bile acid (Figure 5-13A).  
Among the down-regulated pathways identified by IPA, most of them were associated with 
degradation processes, including ethanol degradation, oxidative ethanol degradation, fatty 
acid α–oxidation as well as the degradation of neurotransmitters (histamine, dopamine, 
noradrenaline, serotonin) and other molecules (putrescine, tryptophan) (Figure 5-13B). 
To elucidate the regulation of altered pathways and biological functions in GDM-CMSCs, we 
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built the gene regulatory networks of positively-/negatively- regulated pathways. DEGs 
were used as input nodes and the interaction network was generated according to literature 
findings and public database. 
The enriched biological functions in GDM-CMSCs were associated with upregulated 
pathways revealed by IPA analysis. STAT3 pathway was most significantly upregulated 
signalling in GDM-CMSCs, which is imperative for development, cellular homeostasis, and 
regulating genes in cell growth, proliferation, differentiation in several tissues441. The 
transcription factor STAT3 functions as a transducer of several cytokines and growth factors 
signalling. The upregulated growth factor pathways including BMP signalling, Wnt/β-
catenin signalling, and FGF signalling may also function through the activation of STAT3 
signalling and regulate various development processes as well as enriched cellular functions 
in GDM-CMSCs such as cell growth and survival. Hierarchical clustering map illustrated that 
multiple upregulated DEGs were involved in BMP, Wnt/β-catenin, FGF pathways and leading 
to increased activities (Figure 5-14A).  
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Figure 5-13. IPA canonical pathways analysis 
IPA canonical pathways analysis of positively- and negatively- regulated pathways in GDM-
CMSCs. The x-axis indicates the altered canonical pathways. The left y-axis indicates the 
statistical significance p value, calculated using the Fisher exact test. The right y-axis 
represents the ratio of the numbers of genes in our dataset that map to the all known genes 
in the canonical pathway. 
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Notably, BMP, Wnt/β-catenin, and FGF are key signalling pathways in heart development. 
As the cardiac-associated genes, NKX2.5 and NOG are regulated downstream to BMP, 
Wnt/β-catenin, and FGF pathways, the previously observed upregulation of NKX2.5 and 
NOG in GDM-CMSCs (Figure 5-12A) may contribute to enhanced cardiogenesis potential via 
the modulation of BMP, Wnt/β-catenin, and FGF pathways. Other important factors, such 
as WNT3/11, LEF1, FZD in the Wnt/β-catenin signalling pathway, and FGF1, MAPK, MET in 
the FGF signalling pathway also displayed higher expression in GDM-CMSCs than H-CMSCs 
(Figure 5-14A). 
Moreover, IPA pathway analysis identified increased activity of Rho family GTPase signalling 
in GDM-CMSCs, including Rac, RhoA, Cdc42 signalling. These GTP-binding proteins are 
activated by growth factors, cytokines and known to regulate cell migration, invasion, 
morphology, and cytoskeleton organisation442 which are all critical for tissue repair process. 
The key component genes of Rho family signalling were upregulated in GDM-CMSCs. 
Hierarchical clustering map showed increased expression of genes involved in Rho/Rac 
signalling at a magnitude of log2 fold changes in all 3 GDM-CMSCs samples normalised to 
H-CMSCs expression levels (Figure 5-14B). In agreement with IPA biological function 
analysis and functional validation performed in Figure 5-9 and 5-10, enhanced cell 
movement capacity in GDM-CMSCs may be associated with the activation through Rho 
family signalling.  
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Figure 5-14. Interaction network of positively-regulated pathways 
Interaction network was generated by Cytoscape visualization based on DEGs. Heat maps indicated the expression of genes involved in BMP, 
Wnt/β-catenin, FGF Signaling and Rho family signaling. Each gene is normalised to a mean expression of 3 Healthy-CMSCs samples. Blue shows 
the genes with below mean expression while red is above mean expression. Numbers indicate the log2 fold change in each sample. 
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Significantly reduced expression in ALDH family genes results in negative association with 
metabolic pathways in GDM-CMSCs 
Several pathways associated with degradation processes were significantly downregulated 
in GDM-CMSCs. Given the dysfunctional metabolic regulation in women with GDM, these 
pathways are of particular interest for investigating GDM-CMSCs behaviours. Figure 5-15 
illustrates the genes associated with these enriched downregulated pathways and showed 
that the decreased activities of degradation pathways were highly connected to the 
significant reduction in aldehyde dehydrogenase family gene expression, ALDH1, ALDH2, 
ALDH3 (Figure 5-15A). Aldehydes can be formed during the metabolism of amino acids, 
carbohydrates, lipids, vitamins as well as cytotoxic drugs and environmental chemicals. 
ALDH genes encode the key enzymes regulating cellular detoxification through oxidising 
endogenous and exogenous aldehydes, and play an important role in many degradation 
processes443.  
Notably, ALDH1A1 is one of the most downregulated genes in GDM-CMSCs (Table 5-1). 
Other genes including ALDH1A2, ALDH2, ALDH3B1 were also significant reduced in GDM 
microarray data comprising the core molecules in downregulated pathways network. The 
deficiency of ALDH family genes may lead to insufficient detoxification resulting in 
aldehydes accumulation and reactive oxygen species (ROS) imbalance. Additionally, a 
critical pathway for ROS regulation, the Nrf2-mediated oxidative stress response pathway, 
showed downregulated in GDM-CMSCs, owing to the low expression of important 
regulators, serine/threonine-protein kinase PRKC and antioxidant enzyme genes (HMOX1, 
SOD2, AOX1) (Figure 5-15B). 
Other down-regulated pathways, such as “IL-6 signalling” and “HGF signalling” regulate 
multiple molecules involved in angiogenesis (Figure 5-13B). For instance, CEBPB, FOS, ELK1, 
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CXCL8, which are the important regulators in IL-6 and HGF signalling displayed low 
expression in GDM-CMSCs. Moreover, the downregulation of “PI3K/AKT signalling” may 
affect the potent angiogenic factors, IL-6, IL-8, HGF and VEGF signalling transduction 
through mediating the PI3K/AKT pathway to promote angiogenesis444-446. Biological 
function analysis identified the downregulated genes in angiogenesis and vasculogenesis 
that were the downstream components of IL-6, IL-8, HGF pathways, suggesting the 
regulatory network of reduced angiogenic potential in GDM-CMSCs. Apart from its 
important role in angiogenesis, PI3K/AKT signalling is also only involved in cell proliferation, 
growth, and metabolism447.  
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Figure 5-15. Interaction network of negatively-regulated pathways.  
ALDH genes were the main molecules in the regulatory network. Networks were generated by Cytoscape visualization based on DEGs. 
Hierarchical clustering map showed significantly reduced in ALDH family genes expression in GDM-CMSCs and important regulators in Nrf2 
pathway.
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5.4.5 ALDH expression and function examination  
Given that the decreased ALDH family genes expression affected several metabolic 
pathways and the negative activation of Nrf2-mediated oxidative stress regulation, GDM-
CMSCs are likely to have imbalanced cellular ROS regulation. This may lead to increased 
oxidative stress, which are found in diabetic tissues448. The expression of ALDH1A1, ALDH2, 
ALDH3B1 in GDM-CMSCs and H-CMSCs was validated with real-time PCR, and 
demonstrated significantly reduced expression levels in GDM-CMSCs (Figure 5-16). In 
accordance with microarray data, ALDH1A1 was found to have a significantly decreased 
level of expression in GDM-CMSCs than in H-CMSCs (Figure 5-16A). Both ALDH2 and 
ALDH3B1 showed around 2-fold reduction in GDM-CMSCs with variation in individual 
samples (Figure 5-16B and C).  
 
Figure 5-16. Real-time PCR validation of ALDHs expression 
Validation of significantly decreased ALDH1A1, ALDH2, ALDH3B1 expression in GDM-
CMSCs. Expression level of each gene was normalised to GAPDH expression. Results 
represent mean ± SEM. Statistical significance was determined by Student’s t-test, *p < 
0.05, **p < 0.01, ***p < 0.001. 
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Low ALDH family genes expression in GDM-CMSCs may cause insufficient or impaired 
ALDH enzymatic function in detoxification of endogenous and exogenous aldehydes443. To 
evaluate ALDH enzymatic function, ALDH activity colorimetric assay was performed to 
measure the generation of nicotinamide adenine dinucleotide (NADH) during ALDH 
catalytic process for 30 minutes until the absorbance at 450 stop increasing. Acetaldehyde 
was used as a substrate to induce ALDH enzymatic activity.  
In the initial 5 minutes, there was no statistical difference in ALDH activity between H-
CMSCs and GDM-CMSCs. H-CMSCs and GDM-CMSCs increased ALDH activity from 0-15 
minutes with continually increased catalytic efficiency but gradually declined thereafter in 
both groups. Of note, significantly lower levels of ALDH activity in GDM-CMSCs were 
observed at 10, 15, 20, and 25 minutes and the highest level of ALDH activity was seen at 
15-min post-stimulation, showing significantly enhanced activity in H-CMSCs (Figure 5-17). 
The results confirmed that lower express of ALDH in GDM-CMSCs vs. H-CMSCs affected 
the enzymatic function of ALDH in detoxification. 
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Figure 5-17. ALDH enzymatic activity  
Reduced ALDH enzymatic function was detected in GDM-CMSCs by ALDH activity 
colorimetric assay measuring the absorbance at 450 nm. The results were obtained from 
6 H-CMSCs (Healthy03-08) and 6 G-CMSCs (GDM04-09) samples in duplicate represented 
as mean ± SEM. Statistical significance was determined by one-way ANOVA, *p < 0.05, **p 
< 0.01, ***p < 0.001 
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5.4.6 ROS and oxidative stress 
With impaired ALDH activity, accumulation of highly reactive and toxic aldehyde tends to 
induce ROS formation and increase oxidative stress. A significant reduction of 
antioxidative enzymes in GDM-CMSCs may lead to a deficiency in antioxidant defences. 
The detoxification enzymes NAD(P)H quinone dehydrogenase (NQO1) induced by Nrf2 
signaling was significantly reduced in GDM-CMSCs (Figure 5-17). Likewise, the expression 
of superoxide dismutase (SOD2) located in mitochondria regulating antioxidant defences 
was also significantly downregulated in GDM-CMSCs (Figure 5-17). Owing to the reduction 
in antioxidative enzyme expression, GDM-CMSCs is therefore likely to have elevated 
cellular oxidative stress. 
 
Figure 5-18. Real-time PCR validation of antioxidative enzyme expression 
The expression of NQO1 and SOD2 involved in Nrf2-mediated oxidative stress pathway 
were significantly reduced in GDM-CMSCs. Expression level of each gene was normalised 
to GAPDH expression. Results represent mean ± SEM. Statistical significance was 
determined by Student’s t-test, *p < 0.05, **p < 0.01 
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To examine the ROS production, H-CMSCs and GDM-CMSCs were treated with glucose to 
induce metabolic activity as hyperglycaemia is known to induce ROS levels in diabetes 
patients448. H2O2 treated-cells were used as positive control. ROS production was detected 
using the cell permeant reagent 2’,7’- dichlorofluorescin diacetate (DCFDA) which showed 
green fluorescence once being oxidised by cellular ROS. After treating with 25 mM glucose 
for 30 minutes, both H-CMSCs and GDM-CMSCs had increased ROS production without 
significant difference between two groups. However, higher level of cellular ROS was 
observed in GDM-CMSCs after 2-hour glucose treatment which showed increased 
intensity of fluorescence compared to H-CMSCs (Figure 5-19A).  
ROS production and changes over a period of time were quantified by measuring 
fluorescence via a plate reader. Observing the ROS production every 15 minutes, the ROS 
levels increased for first 45 minutes in both H-CMSCs and GDM-CMSCs following 
stimulating with glucose. The amount of ROS production was comparable in H-CMSCs and 
GDM-CMSCs. Between 45 to 90 minutes, ROS level showed significantly higher rates of 
increase in GDM-CMSCs than H-CMSCs. Notably, H-CMSCs did not produce increased 
amounts of ROS after 90 minutes and showed slightly reduced ROS generation whereas 
ROS level in GDM-CMSCs continued to increase and remained elevated from 90 minutes 
to the end of measured period (Figure 5-19B).  
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Figure 5-19. Detection of ROS production by DCFDA 
(A) ROS production was detected by DCFDA staining (green). Representative fluorescent 
images were shown from 5 H-CMSCs (Healthy03-07) and 5 G-CMSCs (GDM04-08) samples 
at different time point and imaged by confocal microscopy. Scale bar, 100 μm. H2O2-
treated H-/G- CMSCs were used as positive controls (B) Time-course measurement of ROS 
levels was determined by fluorescent intensity reading via a plate reader at the 
wavelengths of Ex/Em = 485/535 nm. The initial fluorescence intensity at 0 min was set at 
100%. Data are given as mean ± SEM from at least 6 samples in each group. Statistical 
significance was determined by one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001 
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To further elucidate the role of ALDH activity and ROS regulation, the enzymatic function 
of ALDHs was supressed by 100 μM of N, N-diethylaminobenzaldehyde (DEAB), a 
commonly used selective inhibitor of ALDHs. H-CMSCs and GDM-CMSCs were incubated 
with DEAB for 48 hours and ALDH activity was examined. In the presence of DEAB (ALDH 
inhibitor) the ALDH activity was significantly suppressed in both H-CMSCs and GDM-
CMSCs (Figure 5-20A). Moreover, when the ALDH function was suppressed, the ROS 
production was significantly increased during glucose-induced metabolic process (Figure 
5-20B). DEAB pre-treated H-/GDM- CMSCs produced higher levels of ROS than un-treated 
H-/GDM- CMSCs. This finding suggested the strong association between the ALDH 
function and cellular ROS regulation. 
Low levels of ROS are detectable in many metabolic processes; however, when ROS 
production is in excess of the cellular antioxidant capacity, it contributes to cellular 
damage. This can include DNA, protein, and lipid disruption. In GDM-CMSCs, 
downregulation of Nrf2-mediated oxidative stress regulation pathway and the impaired 
function of detoxifying enzymes ALDHs, suggests insufficient capacity to adapt to 
increased oxidative stress. 
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Figure 5-20. Inhibition of ALDH function by DEAB 
5 H-CMSCs (Healthy03-07) and 5 G-CMSCs (GDM04-08) samples were pre-incubated with 
100 mM DEAB for 48 hours. (A) ALDH enzymatic function was detected by ALDH activity 
colorimetric assay measuring the absorbance at 450 nm. (B) ROS generation was detected 
by DCFDA and the increasing level was determined by fluorescent intensity reading at the 
wavelengths of Ex/Em = 485/535 nm. The initial fluorescence intensity at 0 min was set at 
100%. Data are given as mean ± SEM. Statistical significance was determined by one-way 
ANOVA, ***p < 0.001 
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5.5 Discussion 
Overrepresented and underrepresented biological functions in GDM-CMSCs 
Microarray revealed that GDM had a number of upregulated genes involved in cell motility, 
cytoskeleton organization, survival, and together with epithelial development and skin 
formation. The ability of transplanted cells to mobilise and migrate to injury sites enables 
them to mediate tissue repair and regeneration449. According to IPA pathway analysis, the 
upregulation of Rho family GTPase signalling in GDM-CMSCs modulating actin cytoskeletal 
rearrangement is one of the fundamental migratory pathways450. Recently, a study 
showed that high glucose promoted human umbilical cord-derived MSCs migration ability 
and increased migration of transplanted MSCs into wound area in in vivo mouse models 
through the suppression of adhesion molecule, E-cadherin451. Hyperglycaemia induced 
human induced pluripotent stem cells to express cytoskeleton remodelling regulators and 
enhanced their migration452. Human umbilical endothelial cells isolated from GDM 
compared to healthy pregnancies showed increased migration ability although enhanced 
motility could be reflecting a proangiogenic state of GDM453.  
By contrast, the opposite findings such as reduced wound closure ability in perivascular 
stem cells from GDM women454 and impaired migration in GDM umbilical cord-derived 
endothelial cells were also reported455. The controversial effects of GDM on cell motility 
may due to different cell sources; for instance, in chapter 3 we demonstrated opposite 
growth patterns of GDM-AMSCs and GDM-CMSCs compared to their healthy counterparts. 
Although CMSCs and AMSCs were grown in the same GDM condition, they could show 
different response to the same environmental factor and have different biological 
characteristics. Likewise, GDM environment may have different impacts on migration 
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ability in different placenta-associated cell types. Our results based on microarray analysis 
of CMSCs demonstrated that AQP1, FLNB, CELSR1, and CD24 playing important roles in 
cell movement and cytoskeletal remodelling were significantly upregulated in GDM-
CMSCs. The finding was further verified by migration assays to confirm the enhanced 
motility of GDM-CMSCs.  
Despite of migration to the wound area, the ability of MSCs to differentiate and promote 
regeneration accelerates wound repair processes456. Several studies have indicated that 
the multi-lineage differentiation potential of perinatal tissue-derived MSCs enable them 
to develop into epithelium and promote skin regeneration457-459. Dehydrated placental 
membranes (amnion and chorion) have been used as skin substitute for burned and 
ulcerated surfaces for many years141, 460. Nowadays, cryopreservation technology is able 
to maintain the structural and cellular integrity of placental membranes and retain 
endogenous amniotic and chorionic MSCs vitalisation. The presence of MSCs in 
cryopreserved placental membranes improved wound-healing therapies461, 462. 
Microarray analysis identified increased skin regeneration potential in GDM-CMSCs 
characterised by the upregulation of epithelial development associated genes and 
regulators (EDN1, KRT14, HBEGF, TGFB2). The in vitro wound healing assays and activation 
of growth factors signalling (Wnt/β-catenin, BMP) may also contribute to enhanced 
capacity of GDM-CMSCs in wound repair. In line with a microarray study of BM-MSCs, the 
expression of genes associated with wound healing was upregulated in BM-MSCs from 
type 1 diabetes patients although the enhanced wound closure was not observed in their 
in vitro results463. 
In addition, activation of growth factors pathways, including Wnt/β-catenin, BMP, FGF, and 
STAT3 was also positively associated with cardiogenesis in GDM-CMSCs and significant 
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upregulation of heart development-related genes (NKX2.5, NOG, PDGFA). However, the 
increased activation of Wnt/β-catenin pathway may be associated with metformin 
treatment or the activation of insulin signal. One of Wnt pathway effectors is 
insulin/insulin-like growth factor receptor-dependent activation, which induces 
phosphorylation of various kinase protein in Wnt pathway464. Metformin were also 
reported to mediate Wnt/β-catenin signalling in hepatic cells and intestinal cells465, 466. FGF 
family proteins are involved in the regulation of energy metabolism and hyperglycaemic 
condition467. FGF-2 was significantly upregulated in diabetic nephropathy and high glucose 
environment increased FGF-2 mRNA as well as protein synthesis and secretion in human 
renal fibroblasts468. Thus, the enhanced activation of FGF pathway in G-CMSCs might also 
reflect the metabolic disorder condition in GDM women.  
Cardiovascular development was the most enriched function in GDM-CMSCs; however, 
the downregulation of angiogenic factors (RASIP1, CXCL12, RSPO3) and angiogenesis 
inducing pathways (IL-6, IL-8) resulted in reduced vasculogenesis and angiogenesis 
potential in GDM-CMSCs. The reduced expression of angiogenesis-related genes in GDM-
CMSCs might suggest that CMSCs did not contribute to frequently observed 
hypervascularisation in GDM placentas77. The vasculogenesis and angiogenesis in placenta 
are regulated by placental endothelial cells which are derived from mesoderm during 
embryogenesis469 while CMSCs arise from extraembryonic tissues. Different origins of 
placental CMSCs and endothelial cells may result in different biological properties and 
responses under hyperglycaemic environment. High glucose environment induced 
endothelial cell dysfunctions leading to abnormal angiogenesis in diabetes patients470, 471. 
However, enhanced angiogenesis was not found in CMSCs isolated from GDM women. In 
contrast, G-CMSCs showed reduced potential in angiogenesis. Our findings indicated that 
G-CMSCs were not directly involved in hyperglycaemia-induced angiogenesis. In line with 
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a recent study on placental chorionic villi-derived MSCs, the decreased tube formation 
ability and downregulation of VEGF were observed in GDM vs. healthy pregnancies472. 
 
ALDHs activity and ROS regulation 
Pathways associated with several degradation processes were altered in GDM-CMSCs due 
to the significantly reduced ALDHs expression. As a critical detoxification enzyme, ALDH is 
highly expressed in various embryonic tissues, stem cells, progenitor cells473, 474 and 
protect them against oxidative damages by detoxifying exogenous and endogenous 
aldehyde475. ALDH was also used as an indicator for purifying proangiogenic BM-MSC 
subset with an enhanced secretory function for vascular regeneration476. However, the 
role of ALDHs in GDM placenta-derived MSCs has yet to be examined. Significantly 
reduced ALDH family genes in GDM-CMSCs revealed by our microarray data emphasises 
the impact of pregnancy complication on cellular detoxification. GDM-CMSCs showed 
significantly lower ALDHs enzymatic activity than H-CMSCs and insufficient capacity to 
manage increased oxidative stress induced by environmental stimulation with glucose.  
The hyperglycaemic environment in GDM pregnancies tends to induce elevated ROS 
production and oxidative stress477. Although ROS can be induced by various molecules 
undergoing metabolic activities, glucose uptake is one of the major processes that 
stimulates instant ROS generation478, 479. In diabetes patients, hyperglycaemic condition 
led to ROS imbalance and resulted in ROS-induced cellular damage and cell death480. We 
demonstrated that glucose induced instant ROS production in both H-CMSCs and G-CMSCs 
whereas the reduction of ROS levels in H-CMSCs after 1.5 hours was not seen in G-CMSCs. 
It suggested that G-CMSCs showed less capability of adapting to the instant increase in 
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ROS production than H-CMSCs.   
In addition, impaired ALDH activity may exacerbate oxidative stress levels through causing 
ROS imbalance481. Some studies have reported an association between impaired ALDH 
function and oxidative stress production. For instance, inhibition of ALDH1A1 in human 
lens epithelial cells caused increased oxidative stress and induced mitochondrial 
damages482. In an in vivo study, ALDH2-deficient mice showed increased ROS production 
and enhanced oxidative stress leading to cardiovascular complications483. We found higher 
levels of ROS was induced in GDM-CMSCs vs. H-CMSCs upon glucose stimulation and 
increased ROS levels in GDM-CMSCs showed no sign of reduction in our observation 
period. It is likely that improving ALDH function may enhance detoxification, reduce ROS 
formation, and therefore protect GDM-CMSCs from oxidative cell damage484, 485. A recent 
study showed that treating decidual MSCs derived from preeclampsia women with 
ALDH1A1 activator restored ALDH1A1 activity and improved resistance to H2O2-induced 
oxidative stress in preeclampsia-derived MSCs486. Physiologically harmful environment of 
oxidative stress in GDM can be improved by antioxidants intake487, 488; however, restoring 
ALDH function in GDM women might be another therapeutic option and fundamentally 
improve biological properties of GDM-CMSCs. 
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5.6 Summary 
DNA microarray data provides an understanding of gene profile and biological functions 
altered in GDM-CMSCs which offers a valuable resource to the regenerative medicine 
development. To conclude from our findings, the uterine environment during pregnancy 
could impact on the stem cell biology derived from perinatal tissues. Enhanced migration 
ability of GDM-CMSCs may have clinical benefits for promoting systemically infused MSCs 
to migrate to the injured sites. However, detoxification enzyme ALDHs were significantly 
reduced in GDM-CMSCs leading to downregulation of several degradation pathways. 
Decreased ALDH activity in GDM-CMSCs was also associated with impaired ability to 
respond to oxidative stress with the evidence of elevated ROS production after glucose 
stimulation. The information based on microarray can be useful for exploring suitable 
clinical use of CMSCs from GDM and healthy pregnancies. 
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Discussion, Conclusion and Future Work 
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6.1 Summative discussion and conclusion 
6.1.1 Human placenta – an attractive source of MSCs 
Regenerative medicine based on MSCs is aimed at enhancing tissue regeneration, 
restoring and maintaining the normal function of tissues or organs and also intended to 
assist in the treatment of many life-threatening or chronic, lifelong disease. Although bone 
marrow MSCs are the most popular and widely studied MSCs for many years, concerns 
about BM-MSCs489, 490 such as decreased numbers and stemness with donor’s age, 
invasive isolation procedure, and allogeneic transplant rejection have encouraged 
researchers to explore new sources of MSCs. Nowadays, stem cells have been found in 
various adult tissues, neonatal-related tissues, and also induced pluripotent stem cells.  
Placenta, developing during pregnancy and playing a pivotal role in embryogenesis, 
contains plentiful undifferentiated stem cells491. As being a part of extra-embryonic tissues 
without the need for invasive procedures during cell extraction or ethical concerns, 
placenta has many advantages for MSCs therapy. The opportunity of storing perinatal stem 
cell in biobanks, including cord blood stem cells and placental stem cells, makes them 
rapidly available and become promising autologous sources for clinical applications492, 493. 
There is no doubt that placental MSCs hold a great therapeutic potential; however, these 
MSCs emerge during pregnancies and only accessible postpartum whether biological 
properties of placental MSCs altered by pregnancy complications is unclear. Little is known 
about the effects of GDM on placenta-derived amniotic and chorionic MSCs.  
In this study, cells were isolated from human placentas. To confirm their MSCs phenotype, 
firstly, cells derived from amniotic and chorionic membrane displayed attached fibroblast-
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like morphology, which is normally observed in MSCs culture. Secondly, cells were 
examined for surface markers expression by flow cytometry to meet the minimal 
definition criteria for MSCs according to the International Society for Cellular Therapy109. 
H-/G- CMSCs/AMSCs showed positive expression of CD73, CD90, CD105 and lacked the 
expression of CD14, CD19, CD34, CD45 and HLA-DR. Thirdly, these cells demonstrated 
differentiation ability towards mesenchymal lineage, such as osteogenesis, adipogenesis, 
and chondrogenesis. 
Characterisation of CMSCs and AMSCs from GDM and healthy placentas demonstrated 
significantly fundamental differences between CMSCs and AMSCs and evidenced the   
altered proliferative, adipogenic, immunomodulatory potential in CMSCs/AMSCs derived 
from GDM placentas. CMSCs and AMSCs were isolated from different layers of placental 
membrane - chorion and amnion. Two layers are connected together acting as a protective 
barrier during fetal development and MSCs derived from both chorion and amnion are 
thought to have the same origin; however, they were found displaying distinct 
characteristics in our study. CMSCs showed enhanced proliferation and tri-lineage 
differentiation potential compared with AMSCs regardless of deriving from GDM or 
healthy placenta. Secretome of both CMSCs and AMSCs displayed immunomodulatory 
capacity in regulating T-cell proliferation and macrophage polarisation but more profound 
effects were found in CMSCs.  
GDM is a temporary condition that usually disappears after pregnancy but it has long-term 
impacts on maternal health and fetal development. Embryonic stem cells and MSCs 
emerging during pregnancies are likely to be compromised by pregnancy complications. 
We found that GDM had distinct effect on CMSCs and AMSCs, for instance, altered 
proliferation ability was found in G-CMSCs and G-AMSCs vs. their healthy counterparts 
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while GDM affected CMSCs and AMSCs proliferation in an opposite manner. Likewise, 
adipogenic potential showed significantly enhanced in GDM-CMSC but not in GDM-AMSCs. 
Some studies have also demonstrated the influence of GDM on umbilical cord cell. 
Umbilical vein endothelial cells (HUVECs) and Wharton’s jelly derived MSCs (WJ-MSCs) 
from GDM pregnancies showed decreased glucose uptake and mitochondrial oxygen 
consumption, increased generation of ROS, reflecting a metabolic disorder state in GDM 
women494. These alterations might be associated with endothelial dysfunction leading to 
adverse vascular functions in infants495. A study indicated that mitochondrial transcription 
and biogenesis gene expressions were altered in GDM-WJ-MSCs which contributed to 
impaired mitochondrial functions496 and may play a role in impaired insulin release and 
glucose sensitivity497.  
Umbilical cord MSCs (UC-MSCs) isolated from obese pregnancies demonstrated greater 
adipogenesis tendency and less potential for myogenesis through the regulation of 
Wnt/glycogen synthase kinase (GSK)-3β/β-catenin pathway498. In correspondence to the 
clinical finding that fetuses development in obese women have higher infant adiposity499, 
500. In chapter 3, we also found that CMSCs derived from GDM placenta showed enhanced 
adipogenic commitment with higher basal level of adipogenic-related gene expression and 
more responsive to the stimulation of adipogenesis differentiation media leading to 
enhanced adipocytes generation. Obese and GDM pregnancies have similar intrauterine 
environment - high levels of glucose and placental hormones, and this environment is 
usually found to have increased amount of adipocytes501, 502. One of the hormones shows 
significantly increased in many obese and GDM pregnancies is insulin503, which is a 
common inducer for adipogenesis used in differentiation media504. High glucose condition 
was also reported to induce adipocyte-associated gene expression, such as proliferators 
activated receptor gamma (PPARγ), lipoprotein lipase (LPL), and adiponectin505, and might 
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be a potent inducer for adipogenic commitment506, 507.  
Immunosuppressive capacity of MSCs contributes to significant therapeutic outcomes of 
cell therapy. Little is known about the effects of GDM environment on immunomodulatory 
ability in either placenta-derived MSCs or umbilical cord-derived MSCs. A study examining 
UC-MSCs from obese/diabetic women indicated that the expression of genes involved in 
MSCs immunomodulatory ability, such as HLA-G was detected at passaged 2 and reduced 
in subsequent passages while the reduction was not observed in healthy UC-MSCs. 
However, except for HLA-G gene examination by PCR, there was insufficient evidence of 
the altered immunomodulatory function in MSCs derived from obese/diabetic samples508. 
Therefore, our study investigated the immunomodulation in both H-MSCs and GDM-MSCs 
through secretome regulation on T-cell proliferation and activation as well as macrophage 
polarisation by co-culture system. The findings suggested that GDM- and H- CMSCs 
provided an equivalent immunoregulatory effect on T-cells while GDM-CMSCs had a 
reduced effect on macrophage regulation. However, both H- and GDM- CMSCs displayed 
a superior immunomodulatory capacity in regulation of both T-cells and macrophages 
than AMSCs. 
Although some degrees of alterations were observed in GDM-CMSCs/AMSCs, the 
differentiation potential (osteogenesis, chondrogenesis), immunophenotype, and 
immunosuppressive ability were not significantly hampered by GDM environment. Most 
of the characteristics of GDM-CMSCs investigated in chapter 3 were comparable with H-
CMSCs and same as GDM-AMSCs vs. H-AMSCs. 
6.1.2 IPC generation – an application of autologous MSCs for diabetes therapy 
Women with GDM during pregnancy carry a lifetime risk of developing type 2 diabetes of 
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up to 50-60%509. Infants born to GDM pregnancy are also at risk of type 2 diabetes in early 
adulthood. Exploring the regenerative potential of placental MSCs from GDM women 
provides a promising possibility of using autologous MSCs in future diabetes therapy. 
Differentiating autologous stem cells in vitro and then transplanting to the patients 
themselves eliminates the complications of graft rejection or requirements of immune 
suppression regimen in transplantation510. A clinical study of diabetic patients on insulin 
injection receiving autologous bone-marrow stem cells transplantation showed an 
improvement of more than 50% reduction in insulin requirement511. However, in that 
study, the cell population used was a mixture of bone marrow HSCs and MSCs, and there 
was no complete follow-up study or the understanding of regulatory functions of 
transplanted cells in disease management. On the other hand, BM-MSCs from diabetic 
patients were generally thought to have been influenced under a prolonged diabetic 
environment. In diabetic mice models, a reduction in the numbers of endogenous BM-
MSCs, impaired proliferation, survival, differentiation ability of BM-MSCs were reported512, 
513.   
BM-MSCs from diabetic patients may be significantly influenced by prolonged exposure to 
hyperglycaemic and inflammatory environment for several years, while placental MSCs 
only emerge during pregnancy and could be more pluripotent than BM-MSCs. GDM 
environment affects some biological properties of CMSCs/AMSCs but does not entirely 
hamper their differentiation capacities. Through characterisation in chapter 3, we 
evidenced that GDM-CMSCs and AMSCs were able to demonstrate their stem cell 
functions via differentiation and immunomodulation; thus we sought to further 
investigate their therapeutic potential in diabetes cell therapy. 
MSCs are known to have potential in pancreatic islets regeneration and insulin resistance 
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amelioration202; however, transplanted MSCs were not found to spontaneously convert to 
beta-cells or secrete insulin514-516. There are also some concerns regarding teratoma 
formation and the promotion of tumour growth by transplanting undifferentiated 
MSCs517-519. Therefore, generating insulin-producing cells (IPCs) or engineered islet-like 
clusters from MSCs, progenitor cells, or genetically modified cells have offered an 
alternative approach for diabetes therapy. In order to induce IPC generation from MSCs, 
several growth factors and small molecules were used to mimic beta-cell development 
environment, while cell responses to these stimulations varies in different tissue-derived 
MSCs.  
We optimised a feasible approach for generating IPC from GDM-CMSCs and H-CMSCs with 
the ability to respond to glucose challenge and secrete insulin. GDM-CMSCs and H-CMSCs 
derived IPCs were functionally indistinguishable with similar morphology, comparable 
levels of beta-cell markers expression, and insulin secretion ability. However, IPCs 
differentiation method for GDM- and Healthy- AMSCs requires further optimisation. 
Although our study identified betacellulin as a potent inducer for insulin expression in 
AMSCs, insulin secretion function was not therefore improved. Insulin secretion is 
regulated by several internal or external factors, including insulin synthesis, insulin 
exocytosis, glucose sensing, functional structure formation, and environmental 
stimulation520-522. The insufficient insulin secretion of AMSC-IPCs in our study requires 
further investigation. Overall, our findings conclude that for the efficiency of autologous 
therapies for GDM women, endogenous CMSCs is a potential therapeutic target which 
could be clinically applicable to diabetes treatment in the future.  
While the advances of generating mature and glucose responsive IPCs from stem cells 
have brought a new strategy for diabetes treatment, the application in clinical practice 
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remains challenging. By stimulating with various compounds to induce IPC differentiation, 
the effective concentrations are inconsistent in different studies even though some studies 
used the same MSC source. Identifying specific cell surface markers for each stage of beta-
cell regeneration may improve current IPC generation protocols523. Additionally, the 
intensively laboratory process of IPC production has reduced the willingness of 
investments in clinical research. Moreover, although research has showed that MSC-
generated IPCs were able to secrete adequate amount of insulin in preclinical models, 
scientists are still struggling to find well-defined and reproducible condition of MSC-
derived IPCs and mass production of mature beta-cells to meet clinical needs517, 523-525. In 
present study, we evaluated the potential of using autologous CMSCs from GDM women 
for clinical application to diabetes treatment in the future. The IPC differentiation 
approach can be successfully applied to both H-CMSCs and GDM-CMSCs; however, 
differentiation method for AMSCs requires further optimisation and the long-term 
outcomes of using autologous MSC-derived IPCs needs to be investigated.  
6.1.3 Microarray – insights of gene profile to functional molecular levels 
Microarray technology allows scientists to study expression levels of a large number of 
genes at the same time. The large amount of data provided by microarrays requires 
computational analysis through bioinformatics approaches to explore biological 
meaningful hypothesis. We performed DNA microarray to further understand the 
characteristics of H-CMSCs and GDM-CSMCs. However, the limitation in present study was 
low sample sizes. In microarray data, gene profiles of 3 GDM-CMSCs samples showed 
variable expression with certain degrees of variability between each other while 3 H-
CMSCs samples were relatively consistent. The scatter plot shown in Figure 6-1 
demonstrated the relationship of expression patterns and variability in two experiments. 
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Gene with similar expression levels in two samples appeared a smooth linear curve while 
a non-linear indicates variation between two samples. An ideal experimental group with 
low variation should have a linear curve in the comparison of two independent samples 
within the same group. In Figure 6, three H-CMSCs samples showed high level of similarity 
while three G-CMSCs samples demonstrated some degrees of variation. Given that three 
G-CMSCs samples were collected from women received different treatments, it could have 
impact on their gene expression patterns and cause the variation. It is likely that increasing 
GDM sample sizes and analysing gene expression patterns based on different GDM 
treatments would provide more information regarding GDM-CMSCs transcriptional profile 
and reduce the variations.  
 
Figure 6-1. Scatter plot matrix of microarray data 
(A) Three GDM-CMSCs (GDM06, 07, 08) and (B) three H-CMSCs (H03, 07, 08) used for 
microarray experiment. A scatter plot is used to examine each microarray chip that has 
unusual/similar expression patterns compared to other microarray chips during 
fluorescent intensity detection. It can be used to visualise variations in gene expression 
between two arrays. Gene with similar expression levels in two samples appeared a 
smooth linear curve. In contrast, a non-linear curve indicates variations between two 
samples. The X and Y axes are the normalised intensity for the samples (log2 scaled), 
normalised to RNA control (poly A+ RNA with Spike-IN, Figure 5-1) and experimental 
control (healthy group), respectively. 
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Importantly, we validated gene expression by real-time PCR with 10 healthy and 11 GDM 
samples in order to verify the microarray results. The PCR is commonly used for microarray 
validation but some non-agreeing results of microarray and real-time PCR has been 
discussed, such as the difference in expression fold chages526, 527. In our study, although 
expression fold changes of some validated genes were found to have different expression 
levels between microarray and real-time PCR results, the up- or down- regulated states 
were all in agreement with microarray data.  
To gain insight into the biological characteristics of GDM-CMSCs, co-upregulated and co-
downregulated genes in all 3 GDM samples were identified and used for biological 
functions and pathways analysis. Furthermore, gene regulatory networks reveal the 
alterations in a set of genes and pathways that regulate biological processes instead of 
simple activation or inhibition of a single gene or signaling528. Following microarray 
analysis with IPA software, functional assays confirmed the overrepresented or 
underrepresented biological functions in GDM-CMSCs, including enhanced cell migration 
and spreading ability but an impairment in ALDHs enzymatic function and ROS regulation. 
The validation and investigation of the most represented biological functions in GDM-
CMSCs was discussed in chapter 5 while the information obtained from microarray data 
may also be useful in many other aspects529, 530. Microarray results, containing the 
expression of thousands of genes, can be used to study the drug target for GDM, 
association between GDM and the risk of type 2 diabetes, gene correlation with GDM 
progression, as well as transcriptional signature of GDM-CMSCs. For instance, PTAFR 
(platelet activating factor receptor), CMYA5 (cardiomyopathy associated 5), and CCR7 (C-
C Motif chemokine receptor 7) were detected in H-CMSCs but absent in GDM-CMSCs while 
PROM2 (prominin 2) and GDF6 (growth differentiation factor 6) were only detectable in 
GDM-CMSCs. The presence or absence of these genes could be meaningful in some 
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biological properties of H-CMSCs and GDM-CMSCs. Undoubtedly, there is still a lot 
remained to be explored in our microarray data.  
The main aim of this study is to determine the potential of GDM-MSCs in regenerative 
medicine. Through characterisation in chapter 3, we investigated stem cells properties and 
showed that both Healthy- and GDM- CMSCs/AMSCs were able to grow, proliferate, 
differentiate, and regulate immune cells in vitro. Moreover, GDM-CMSCs could be 
successfully differentiated into IPCs and display comparable functions with H-CMSCs 
derived IPCs, suggesting a promising potential for diabetes therapy in the future. Through 
microarray transcriptional profiling and bioinformatics, we were able to identify the 
enhanced and impaired biological functions in GDM-CMSCs based on their genome profile 
and this information would be valuable for developing potential application of GDM-MSCs 
in clinical practice.  
The increasing incidence of metabolic diseases during pregnancy affects the physiology of 
several maternal and fetal organ developments531. Maternal nutrients and metabolic 
activities significantly link to fetal programming and the later development of metabolic 
disorders in mothers and their children532, 533. GDM environment affected the epigenetic 
signature of cord blood534 and newborns exposed to GDM were more likely to have 
epigenetic differences in metabolic pathways535. We demonstrated that biological 
properties of CMSCs/AMSCs were altered in GDM pregnancy, including the increased 
adipogenic potential, immature senescence under high glucose culture, decreased 
metabolic enzyme (ALDHs) activities, and down regulation in metabolic pathways 
activation. These findings reflect the influence of GDM on cell biological properties and 
the altered features in GDM-CMSCs/AMSCs might be associated with the long-term risk of 
type 2 diabetes development. For instance, increased adipocyte formation and 
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accumulation were found in many obese diabetes patients536; senescence-associated 
secretory phenotypes (SASP) that secreted proinflammatory cytokines and exacerbated 
insulin resistance were frequently seen in type 2 diabetes patients537, 538. The study of 
GDM-CMSCs/AMSCs would provide further understanding of the fetal and maternal 
metabolic disorder development.  
The findings in our study were obtained by using H-CMSCs, H-AMSCs, G-CMSCs, and G-
AMSCs as a single experimental group. However, the individual differences within each 
group may cause variabilities in some results. For example, the severity of GDM and 
different treatment methods may have direct impact on biological characteristics in 
individual samples. At this stage, we were unable to collect more GDM placentas for 
further analysis, but in future study, treatment methods and blood glucose levels of each 
patient should be taken into account. Increasing sample size and experimental groups such 
as high-BMI GDM, low-BMI GDM, metformin-treated GDM, or insulin-treated GDM would 
reduce variabilities and provide further understating about GDM-MSCs.   
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6.2 Future work 
Our study has raised a number of considerations for future work. Frist, as autologous cell 
transplant is aimed at personalised medicine, variation in individual donor condition 
correlating to the CMSCs/AMSCs differentiation and characterisation result should be 
taken into account. For future study of GDM-MSCs, considering the individual differences 
during analysis, including glycaemic control and medical condition in each patient would 
provide more detailed understanding of GDM-MSC biological properties.  
In this study, all gene expressions were examined by SYBR-Green based real-time PCR, 
which is a highly specific, double-stranded DNA binding dye. However, genes with low 
expression levels are difficult to be detected by SYBR-Green dye and the small gene copy 
variations between samples are likely to be neglected. Thus, future study using TaqMan-
based PCR via a fluorogenic probe will allow the detection of small gene copy variations 
and provide more accurate gene expression results than SYBR-Green based method.    
To apply autologous MSC-generated IPCs in clinical practice the safety and efficacy of these 
IPCs for cell therapy need to be investigated. By using in vivo models, it would provide 
further understanding of the maturity, function, and survival of IPCs in a physically relevant 
situation. Although some functional features of IPCs were similar to beta-cells, the 
comprehensive comparison would require, such as the amount of insulin release and cell 
behaviours between lab-grown IPCs and mature beta-cells in human body. More 
importantly, whether islet-like clusters generated in our protocol are pure beta-cells or 
composed of heterogeneous population remains unknown.  
Microarray data also raises some questions and opportunities for future study. The 
pathways analysis revealed the upregulation of several growth factors pathways (BMP, 
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Wnt, FGF). Although these pathways have critical roles in regulating cardiac regeneration, 
they are also involved in many cellular functions. The exact relationship of upregulated 
pathways and cardiogenesis potential in GDM-CMSCs requires further elucidation. The 
potential of GDM-CMSCs in wound healing was identified by IPA analysis and the 
expression of genes associated with healing process as well as migration ability were 
validated through in vitro assays. However, wound healing assay is a simple experiment 
but the wound repair process is complicated. In vivo models would provide more 
convincing evidence for wound healing studies. In addition, there are many freely available 
and commercial platforms for microarray data processing. In present study, IPA software 
(Qiagen) was used to perform biological functions and pathways analysis based on 
Ingenuity Knowledge Base (Qiagen), while with other bioinformatics software based on 
different database, it might provide some undiscovered findings in our microarray data. 
However, IPA is a powerful software for microarray analysis that can also be used to predict 
upstream regulators, biomarkers, comparison and interaction networks which have not 
yet been discovered with our GDM and healthy CMSCs microarray data. 
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